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Abstract 
Abstract 
Primary screening of recent collections from the sea around New Zealand 
revealed a wide range of bioactivities, including antitumour, antiviral and 
anti.:.HIV activities. Seven marine organisms, including sponges and an 
ascidian, were examined to identify the active compounds responsible for 
these three type of biological activities. 
A chemical screening protocol was established for the dereplication and 
prioritization of antiviral natural product extracts, which was also applied 
to extracts with other bioactivities. A recent modification included HPLC 
analysis of the eluates from solid phase extraction cartridges, coupling the 
UV profiles of the corresponding peaks in the HPLC traces with MarinLit 
database. Extracts from two marine sponges which contained known 
cytotoxic compounds, pateamine and calyculins respectively, were used to 
test the efficiency of the modified protocol. These two types of active 
compounds were quickly identified by searching the UV data field in 
MarinLit. 
HIV -inhibitory activity was recognised in both aqueous and organlc 
extracts from a sponge Chondropsis kirkii. The aqueous extract was 
processed on a Sephadex-25 column. The positive results of a toluidine 
blue test on the resultant fractions suggested that sulphated 
polysaccharides may be responsible for the potent anti-HIV activity. The 
HIV -inhibitory components in the organic extract turned out to be a 
mixture of sterols. However, an increase of the cytotoxicity with 
increasing sample purity was also observed. 
Examination of a sponge Callyspongia irregularis resulted in the isolation 
of a known compound, mycalamide A, which is a potent antiviral agent. 
1 
Abstract 11 
Purification of the trace amount of compound obtained was mainly 
achieved by high speed countercurrent chromatography (HSCCC). 
Examination of another Callyspongia species has led to the discovery of a 
potently cytotoxic fraction (ICso 11 ng/mL). 
A New Zealand deep water sponge, Lamellomorpha strongylata, has 
turned out to be a rich source of bioactive compounds. Bioassay-guided 
analysis led to the separation of five new cytotoxic theonellapeptolides 
IlIa, lIIb, IIIc, HId and HIe (molecular-weight 1376-1453). These 
tridecapeptides were characterised by amino acid analysis using GC-MS, 
sequencing the ring-opened peptides with FABMS-MS, and ID (1 H, 13C, 
DEPT and decoupling experiment) and 2D (COSY, TOCSY, HMQC-
TOCSY, HMBC, HSMQC and ROESY) NMR, IR analysis and chemical 
reaction. Of these, the MS-MS technique played a very important role in 
sequencing. These compounds exhibited weak cytotoxicity. However, the 
other member of the theonellapeptolide family showed ion-transport 
properties. 
The absolute stereochemistry of lIIe was determined by X-ray crystal 
structure analysis in conjunction with a chiral HPLC method. The 
solution conformations of lIIb and IIIe were established mainly by 
correlations in the ROESY spectra. Six optically pure N-methyl amino 
acids were synthesised for a study of the stereochemistry of the 
component amino acids. The absolute stereochemistry of IlIa, IlIb, IIIe 
and IlId were determined by chiral LC-MS analysis. In addition, three 
minor components were isolated from the same sponge. 1 H NMR spectra 
showed that they all contained peptide components. 
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Chapter 1 
Introduction 
Chapter One-Introduction 2 
1.1 Marine Natural Product Chemistry 
One of the basic principles of ancient Chinese philosophy was "integrity 
of nature and human body". It implied that the human body is a part of 
nature, or that the life and function of the body are closely associated with 
nature. In the long history of the human race, nature has not only offered 
the food and clothes for man's survival, but has also provided medicine 
for man's health. Modern science has demonstrated that the chemical 
constituents from plants, animals and microbes (natural products) are 
responsible for the medicinal benefits observed. Scientists have been 
successful in the development of drugs from natural products. In the last 
decade, over 60% of approved drugs and pre-NDA (pre-New Drug 
Application) candidates (for the period 1989-1995) are of natural origin.1 
Natural products from marine organisms may have considerably greater 
potential than those from terrestrial habitats in terms of pharmacological 
uses. 2 The oceans cover about 71 % of the earth's surface, and have a 
wide biodiversity. An estimated range of total global biodiversity is 
between 3 million and 500 million different species. Approximately a 
half of these species live in the oceans.3 All but 2 of 28 major animal 
phyla are represented in aquatic environments, with 8 being exclusively 
aquatic, mainly marine.4 An equally important factor in terms of 
diversity of secondary metabolites is the unique biosynthetic conditions of 
the marine environment. Marine organisms live in a different ionic 
strength environment, with higher pressure and lower temperature 
conditions than their terrestrial counterparts. This combination of factors 
may produce some compounds which would be unstable under other 
conditions. S The marine world is a very competitive and hostile 
environment; thus many marine organisms have developed complex attack 
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and defence mechanisms, as well as symbiotic associations, to enhance 
their survival capability.6 However, despite successes in recognising 
bioactivity from marine resources and the belief that the marine 
environment is an exceptional reservoir of bioactive natural products, the 
research into the use of marine natural products as pharmacological 
agents can still be considered to be in its infancy.? 
In its early phase, the research on marine natural products was driven by 
chemical studies,?,8 which were serendipitous studies,9 although 
Bergmann's pioneering work in 1950 resulted in the development of two 
antiviral and anti tumour drugs. A realisation of the biomedical potential 
of marine natural products began with the first in a series of Symposia on 
Food and Drugs from the Sea in 1969.10 The first marine biomedical 
workshop was held in 1974 at the Smithsonian Institution in Washington. 
A variety of problems in marine biomedical research and their possible 
solutions were reviewed. This resulted in a paper identifying the major, 
future milestones and directions of research in the pharmacological-
biomedical exploration of the sea. 11 The first systematic investigations of 
biologically active marine organisms began in the 1970's.12 The RJV 
ALPHA HELIX Baja expedition in 1974 assayed 850 marine species for 
antimicobial and antifungal activities, and in 1978 an antiviral 
investigation of Caribbean marine organisms was carried out, which 
culminated in the first clinical trial of a marine natural product (didemnin 
B).13 In 1974, the Roche Research Institute of Marine Pharmacology 
(RRIMP) was established for the commercial development of 
pharmaceuticals from marine resources.1 4 In its seven year operational 
period, RRIMP identified more than 400 novel compounds from sponges, 
corals, echinoderms, molluscs, ascidians, sea grasses, microalgae, 
bacteria, algae, fish and other marine organisms. The RRIMP screens 
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included in vivo evaluation in gross observation, toxicity, effects on 
central nervous system, anti-inflammatory, anti-allergy, analgesia, 
cardiovascular effects, neurophysiology and biochemical pharmacology. 14 
Although the commercial exploitation of new drugs from the sea was up 
and down,IS interest in the development of marine natural products 
increased rapidly. Between the 1940's and 1950's, only a few dozen 
papers were published. The number of publications was in the hundreds 
in the 1960's, and jumped to the thousands in the 1970's. This increasing 
rate was maintained during 1980's, with more than 3,000 more papers 
published. 1 5 Meanwhile, the number of new compounds reported 
increased at the rate of 10% per year. 16 So far, more than 7,000 
compounds have been described. 17 The studies have been extended to all 
phyla of the marine organisms. However, the distribution of the 
compounds in the phyla is not even. The majority of the compounds have 
been isolated from sponges (33%), algae (25%) and coelenterates (18%), 
with the balance 24% coming from other invertebrate phyla, such as 
tunicates, molluscs, echinoderms and bryozoans. 16 
Since the 1970's, research in marine natural products has been focused on 
pharmacologically and biomedically significant compounds. A wide 
range of screening methods have been utilised. Looking at the literature, 
a profound portion of the secondary marine metabolites in the earlier 
studies showed antibacterial activity, while antitumour compounds have 
been dominant more recently 18. During the 1960's and 1970's, the 
antibacterial assay method was well established and most readily available 
to chemists. This can explain the high incidence of the observation of 
antibiotic activity. In the last two decades, the cytotoxicity bioassay 
method was widely adopted by chemistry laboratories due to its simplicity 
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and relatively low cost. At the same time, both government and industry 
have put more and more funding into cancer research. All these factors 
have contributed to the discovery of the large number of cytotoxic 
compounds. The high incidence of cytotoxicity of marine natural 
products may also be considered an outcome of the evolutionary history 
of the marine organisms.l6 Some of them, for example sponges, are at a 
very primitive stage. Other frequently used biological tests include 
screening for cardiovascular, antifungal, antiviral, anti-inflammatory, 
immunosuppressive, antihelminthic, central nervous system, hypothermic 
and analgesic activity. In recent years, increasing interest in mechanism-
based screening of natural products has been observed due to rapid 
development of biotechnology and a greater industrial involvement. 
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1.2 The Chemical Ecology of Marine 
Organisms 
In the course of developing biomedical compounds from marine sources, 
there are two important questions that have attracted the attention of both 
chemists and biologists for a long time. i) What is the true origin of the 
secondary marine metabolites? ii) What are the biological roles of these 
secondary metabolites in the marine organisms? 
To date, many suggestions have been made as to the sources of the 
biologically-active compounds.20 Accordingly, the bioactive natural 
products may come from micro-organisms associated with the marine 
macro-organisms, including symbiosis and epibiosis,21 or from the food 
chain by feeding. Recent studies have suggested that some bioactive 
compounds isolated from marine invertebrates, such as sponges, 
coelenterates, molluscs, or protochordates, are actually generated by 
microorganisms)2,23 For example, saxitoxin (1), a well-know shellfish 
poison, comes from dinoflagellates of the genus Gonyaulax and the blue-
green alga Aphanizomenon flos-aquae. 24 Tetrodotoxin (2), originally 
isolated from the pufferfish,25 has also been found in a red alga26 and a 
xanthid crab. 27 More typical examples are found with sponges. 
Structurally identical or similar metabolites have been isolated from 
different species of sponge; while in other cases, the same species 
contained totally different compounds.28 The association of microbes 
with sponges has been well documented)1 The microorganisms found in 
sponges are predominantly bacteria29 and cyanobacteria (blue-green 
algae), and to a less extent dinophycean Zooxanthellae and eucaryotic 
algae.3 0 More direct evidence for the symbiotic origin of sponge 
metabolites has been obtained for the sponge Tedania ignis, in which 
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several diketopiperazines were identified}l When several species of the 
genus Micrococcus bacteria were isolated from the sponge and cultured in 
the laboratory, the bacteria were found to produce the same 
diketopiperazines as those obtained from the sponge. This suggested that 
these compounds were most likely bacterial metabolites.32 
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When the microorganisms live on the surface of macro-organisms, such 
as sponges, corals and macroalgae, they are called epibionts. Epibionts 
fulfil important roles (eg. antifouling, antifungal, antibacterial and 
settlement aiding activities) for the host organisms. The embryos of the 
crustaceans Palaemon macrodactylus and Homarus americanus are 
covered with a unibacterial film. On fermentation, these bacteria yielded 
the antifungal compounds 2,3-indolinone-dione (3) and tyro sol (4), and it 
was demonstrated that these compounds prevented fungal infection of the 
embryos.33, 34 
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Faulkner20 has pointed out that unless a symbiont is observed, food-chain 
accumulation and convergent evolution must be considered as alternatives 
to explain the origin of compounds previously assigned to I!symbiosisl!.20 
A good example of food-chain origin of the biological metabolites is 
found with the nudibranchs, which are specialist sponge grazers. While 
feeding on sponges, the nudibranchs sequester the effective chemical 
armoury of their prey, which is subsequently employed for their own 
protection. 34 
The biological roles of secondary metabolites are normally related to 
antipredation, antifouling, competition for space, or species dominance 
etc.35 Marine natural products that have been related to chemical ecology 
include terpenes, steroids, phenolics and nitrogenous compounds.35 The 
high incidence of toxic, or deterrent sponge metabolites is found in 
habitats such as coral reefs, where the competition for space and feeding 
pressures are very high. Another piece of evidence for the adaptive 
significance of sponge constituents is the observation that sponges 
growing in exposed areas are usually more toxic than those found 
growing in less exposed situations. A striking example of such chemical 
defence is provided by a Red Sea sponge, Latrunculia magnifica. When 
the juice of this sponge was squeezed into an aquarium stocked with the 
fish Gambas afghanis, all the fish died within a few minutes.36 The 
occurrence of clean-surfaced animals that lack appendages, such as 
sponges, ascidians, soft corals, gorgonians and holothurians, suggests that 
antifouling allomones may be present. Marine organisms, in competing 
for space, may crowd, undercut, crush, overgrow, digest or poison their 
neighbours.37 Soft corals may move over hard corals and kill them to 
take space susceptible to secondary colonisation.38 Do all these biological 
functions have chemical bases? 
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A proper answer to the above questions is important for the study of the 
biosynthesis of active metabolites. Furthermore, the information might 
even be vital for the economic production of pharmaceuticals from 
marine sources.20 Moreover, it may provide guidance to allow natural 
product chemists to locate further marine organisms containing bioactive 
compounds. 
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1.3 
1.3.1 
Commercial Uses and Potential 
Applications of Marine Natural Products 
Drugs from the Sea 
Living a healthier and longer life has been the dream of human beings. 
Historically, natural products from terrestrial plants and micro-organisms 
have played vital roles in the development of new drugs.39 Thus, it is not 
surprising that marine natural product chemists focus their attention 
mainly on the biomedical applications of the secondary metabolites from 
marine sources. Although the potential of marine natural products as a 
new drug source was realised as early as 1969,10 no new drugs derived 
directly from marine organisms have been marketed to date. However, 
the enthusiasm for biologically active compounds from the sea has not 
faded. With more in-depth studies, even more potential in this field can 
be recognised since a higher incidence of bioactive compounds has been 
recognised from marine organisms than those encountered from 
terrestrial sources.40 (A marketable new drug is probably on the verge 
of breakthrough.) 
Currently, there are several marine related compounds at a clinical, or 
preclinical testing stage. The first marine natural product which 
progressed to clinical trials was didemnin B (5). This depsipeptide was 
isolated from a Caribbean ascidian Trididemnin solidum by Rinehart et 
al.41 This compound exhibited a wide range of biological activities, such 
as antiviral, immunosuppressive, and cytotoxic activity. It is clinically 
tested only as an anticancer drug due to its highly cytotoxic properties. 
Another early marine compound that proceeded towards clinical trials 
was girolline15 (6), but testing was stopped due to blood-pressure 
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problems in the patients. Another anticancer compound in clinical 
evaluation is bryostatin 1 (7).42 Dolastatin 10 (8), a peptide isolated from 
the sea hare Dolabella auricularia,43 is in phase I clinical trials. 
Ecteinascidins (9), alkaloids isolated from the tunicate Ecteinascidia 
turbinata,44 are nearing phase II clinical trials)1 Another two cytotoxic 
compounds, halomon (10) and halichondrin B (11), are in preclinical 
evaluation. The former from the red alga Portieria hornemannii exhibits 
promising differential cytotoxicity against several tumour celllines.45 
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The latter was first isolated from a Okinawan sponge,46 and later 
obtained from a New Zealand deep water sponge Lissodendoryx sp.47 
An Eastern Indian Ocean sponge in the genus Spongia produced a 
structurally unprecedented marocyc1ic lactone, spongistatin 1 (12), with 
extremely potent cytotoxicity against human tumour cell lines.48 
Spongistatin 1 exhibited 0150 values of 2.5-3.5 x 10-12 M against several 
highly chemoresistant tumour types, ego HL-60, SR leukemias, NCI-H226, 
NCI H23, NCI H460, NCI H522 non-small cell lung, DMS 273 non-small 
cell lung, HCT-116, HT 29, KM 12, KM 20L2 SW-620, SF-539, U-251 
brain, SK-MEL-5 melanoma, OVCAR-3 ovarian and RXF-393. 
Spongistatin 1 can effectively inhibit the cell lines derived from human 
melanoma and lung, colon and brain cancer. 
There are two anti-inflammatory compounds, which have progressed to 
clinical trial stage. Manoalide (13), isolated from the sponge Luffariella 
variabilis,49 exhibited inhibiting activity against phospholipase A2 
(IC50=0.05 IJ,M) and phospholipase C (IC50=1.5 IJ,M), resulting in 
reduced arachidonic acid release. This compound was also applied to the 
study of the role of calcium-channel blocking agents and signal 
transduction pathways due to its calcium-channel blocking activity. A 
series of derivatives of manoalide have been synthesised, some of which 
have been clinically evaluated. 50 
Anti-inflammatory depsipeptides, salinamides (14) A and B, were found 
from a marine Streptomycete. These two peptides have non-amino acid 
fragment containing an epoxide and chlorohydrin respectively. The most 
potent in vitro activity is against Streptococcus pneumoniae and S. 
pyrogenes. Importantly, they exhibited potent topical anti-inflammatory 
activity against the phorbol ester-induced mouse ear edema assay.51 
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Since ara-A and ara-C, the first antiviral agents, derived from marine 
ara-nucleosides were developed, discovery of antiviral drugs from the sea 
has been one of the main targets of marine natural product chemists. The 
results are very encouraging. A wide range of marine secondary 
metabolites showed antiviral activity. Examples include reiswigins (15) 
from Epipolasis reswigi, isospongiadiol from a Spongia sp., topsentins 
(16) from a Mediterranean Topsentia genetris and a Caribbean 
Halichondria sp., and sulfolipids, anti-HIV compounds from a 
cyanophyte. 15 
Modern medicinal studies have revealed that disorders of the immune 
system may cause a variety of diseases, such as diabetes, arthritis, 
psoriasis, multiple sclerosis, as well as the rejection problems in organ 
and tissue transplantations. Immunoregulating drugs have a great 
potential for clinical application. Marine natural products tum out to be a 
very promising source of immunoregulating agents, although only a very 
small portion of marine organisms have been tested for this kind of 
activity. Of them, discodermolide (17) and microcolin A (18) exhibited 
very promising immunosuppressive properties. Discodermolide, obtained 
OH 
HO 
Spongistatin 1 (12) Manoalide (13) 
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from Discodermia sp., is a polyhydroxylated lactone.52 It has a different 
mechanism of action from the currently used immunoregulating drug, 
cyclosporine A. The former showed suppressive activity in the murine 
two-way MLR and conconavalin A stimulation of splenocyte cultures, and 
the proliferation of human peripheral blood leukocytes at relevant 
concentrations «80.6 J-LM). 
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As well as the therapeutic targets mentioned, a series of other 
pharmacological models are also applied in screening bioactive marine 
natural products. A wide diversity of biological activities, such as 
antibacterial, antifungal, cardiovascular, antihelminthics, antithrombic 
and multidrug-resistance reversing activity, have been explored. In an 
attempt to find new drugs against antibiotic-resistant pathogens, the 
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bacterium Pseudomonas fluorescens was isolated from a tunicate. After 
cultivation on solid media, two potent antibacterial compounds, andrimid 
(19) and moiramide B (20), were identified.53 The former was 
previously obtained from an Enterobacter sp .. During chemotherapy, a 
frequently encountered problem is that cancer cells become resistant to 
anticancer drugs when a drug is used for long term treatment. A cyclic 
depsipeptide, hapalosin (21), isolated from a blue-green alga 
(cyanobacteria) Hapalosiphon welwitschii, exhibited multidrug-resistance 
reversing activity.54 This compound can potentiate the cytotoxicity of 
common antitumour drugs like vinblastine and adriamycin toward drug-
resistant cells. A Fijian Jaspidae sponge was found, containing 
anthelminthic components, the bengamides (22).55 Cyclotheonamides 
(23), isolated from a sponge Theonella sp., are potent thrombin-
inhibiting cyclic peptides.56 Moore et al.57 discovered a cyclic peptide, 
puwainaphycin C (24), from a blue-green alga Anabaena BQ-16-1. This 
peptide elicits a strong, positive inotropic effect in isolated mouse atria. 
Gambieric acids A-D (25) were obtained from the cultured marine 
dinoflagellate Gambierdiscus toxicus. These polyether metabolites are the 
most potent in vitro antifungal agents reported to date. Only moderate 
toxicity against mice or cultured mammalian cells was observed for these 
compounds.58 They will possibly be developed into new antifungal 
drugs. 
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1.3.2 Biomedical Tools 
Tetrodotoxin (2) was originally isolated from the liver and gonads of a 
certain puffer fish (Tetraodon group).59 The toxin was also found in the 
porcupine fish (Diodontidal), the ocean sunfish (Molidae), newts 
(Taricha), atelopia, the blue ringed octopus, several species of biota and 
bacteria, as well as some South American frogs. It is about 160,000 times 
more potent in blocking axonal conduction than cocaine.60 The main 
action of tetrodotoxin is paralysis of the peripheral nerves. It is widely 
used as an inhibitor in neurophysiological research since it inhibits 
specifically the sodium ion permeability of the membrane.61 
Lophotoxin (26), a paralytic pyran aldehyde derivative, was isolated 
from several species of the genus Lophogorgia. In receptor studies with 
lophotoxin, it was found to irreversibly inactivate the nicotinic 
acetylcholine receptor on intact BC3H-l cells in culture. Since the 
binding is irreversible, it differs from all known ganglion blockers. This 
toxin has been used as an important neuropharmacological probe in 
studying complex neural pathways.62 
Palytoxin (27) is an extremely poisonous, water soluble substance from 
marine cnidarians (Palythoa).63,64 It influences calcium- and potassium-
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ion transport in nerve cells and heart tissue. Animals undergo paralysis 
and heart failure. Palytoxin has become a tool in ion transport studies. 
Ciguatoxin (28) is a group of structurally similar, lipid-soluble 
compounds. It was originally recognised from human disease caused by 
the ingestion of any of a wide variety of coral reef fishes containing 
toxins. However, the true origin of the compound turned out to be a 
photosynthetic benthic dinoflagellate, Gambierdiscus toxicus. The toxins 
increase permeability of excitable membranes to sodium, causing 
depolarisation. 
Okadaic acid (29) and related compounds are polyether toxins, which 
were first obtained from Halichondria okadai and H. lnelanodocia.65 
Later on they were also isolated from several dinoflagellates66 and most 
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recently from aNew Zealand sponge Raspailia agminata.67 Okadaic acid 
and its congeners showed protein inhibiting, smooth muscle contraction 
affecting, and tumour promoting activities. 68 
1.3.3 Healthcare and Health-food 
Translcis- ~-carotene can be obtained from a variety of species of the 
genus Dunaliella dunaliella predominates in many aquatic marine habitats 
and in salt water bodies which contain more than 10% salt. Dunalie lla is 
probably the most halotolerant eukaryotic organism known, showing a 
remarkable adaptation to a variety of salt concentrations from as low as 
0.2% to about 35%,69 It is believed that ~-carotene possesses an 
antioxidant function and the ability to quench various radical species, 
which in tum may reduce the incidence of several types of cancer. As a 
food-colouring agent and as provitamin A, ~-carotene is added to 
commercial products, such as cosmetics, health-foods, vitamin 
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preparations and pharmaceuticals. These products are marketed 
worldwide.70 
A recently developed skin-care cosmetic contains the diterpene glycoside 
pseudopterosin C (30),71 isolated from the gorgonian coral 
Pseudopterogorgia elisabethae collected in the Bahamas. This product is 
now marketed under the name Resilience by Estee Lauder in New 
York.72 
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Eicosapentaenoate and docosahexaenoate, obtained from fish oil, exhibited 
activities in the prevention and cure of thrombosis and lowering of blood 
cholesterol. 73 Health food containing these compounds has been 
successfully marketed in United States, Japan and China. 
1.3.4 Other Industrial Applications 
Tyrian purple, the vibrantly coloured dye extracted from Murex sp. and 
related molluscs about 1600 BC, was probably the first commercial 
marine natural product.74 The modern industrial applications of the 
materials derived from marine sources are mainly the polysaccharides. 
Agars, carrageenans and alginates are the best known and most widely 
used products of seaweeds. Agar is mainly prepared from several species 
of the genus Gelidium. It is frequently used in the pharmaceutical 
industry, such as the culture base for bacteria and a binding for tablets. It 
is also a laxative.2 Carrageenan, another red seaweed polysaccharide 
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originally obtained from Irish Moss and Chondrus crzspus, can be 
produced from several other genera now. A refined extractive is used 
for emulsions, ego in a cough syrup and in tooth pastes. Its potassium salt 
is utilised in shaving soaps and haircreams, and as a binding agent for 
tablets.?5 It was also found to be valuable in the control of ulcers through 
action with the mucous lining of the stomach.?6 Sodium alginate, an 
excellent suspensory agent, has had extensive applications in both the 
pharmaceutical and food industries. Algin capsules are usually used to 
deliver the drugs that must be liberated intestinally, because the alginates 
are only hydrolysed in the intestine. There are a number of dental uses, 
ego in moulds and the control of bleeding. 
A successful commercial development of a marine natural product is the 
insecticide derived from nereistoxin (31). This toxin was first isolated 
from Lumbrinereis brevicirra in 1934. Once its structure was 
established, cartap hydrochloride, one of its derivatives, was synthesised. 
It is active against the rice stem borer and other insect pests, and does not 
appear to be toxic to warm-blooded animals.?7 This product has been 
widely used in agriculture since 1966. 
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1.4 Problems and Challenges in Marine 
Natural Product Studies 
The collection of marine organisms is a difficult task. It requires both 
wide biological knowledge and special equipment. The usual approach is 
by SCUBA diving. It is hard for the divers to determine exactly where 
they should collect the specimens, because visibility is often poor under 
water. It is impossible to know the abundance and variety of animals in a 
particular habitat before the divers get to the bottom. As a result of the 
wind and waves, the collection sites are frequently obscured. Recollection 
of the biologically active organisms is even more difficult, because the 
record for original collection is less accurate, or the bioactive components 
vary with seasonal and geographical factors. Marine natural product 
chemists often have trouble in actually identifying the specimens due to 
the worldwide shortage of taxonomists. 
Usually, the biologically active components exist In very low 
concentration in the marine organisms. It is often a challenge for the 
natural product chemist to obtain enough of the pure compounds for 
chemical and biological study. Some of the marine natural products are 
sensitive to light, moisture, or oxygen, especially as they become purer 
during the isolation process. Separation of these subtle compounds is 
frustrating work. In the extreme situation, several years of hard work 
may be required to obtain enough of the pure compound to establish the 
structure.78 
The good old days of 'grind and find', when nearly every orgamsm 
contained new and interesting molecules, are fast disappearing. The most 
bioactive extracts now mainly contain only known compounds. 16 
Avoiding the duplication of work on known active compounds is 
Chapter One-Introduction 24 
important both for saving funding and time, and for patent application. 
Development of rapid methods to gain insight into the properties of the 
active compounds before initiation of the purification procedures has 
become apriority. 
Another challenge is supplying enough pure material for pharmacological 
study and commercial development of the new drugs. Naturally growing 
marine organisms may either have limited biomass available, or contain 
very low concentrations of the active components. The structures of the 
biologically active compounds sometimes are too complex to be 
synthesised economically. This problem may hinder the further 
development of a new drug. Some solutions have been proposed for these 
problems.1 5 These include collection in large quantities but without 
damage to the environment from the collection, organic synthesis, 
aquaculture, tissue culture and gene engineering techniques. Of these 
options, aquaculture shows the most promise. Two recent examples give 
very encouraging results. One is aquaculture of a colonising bryozoan, 
Bugula neritina, for the large scale production of the anticancer agent 
bryostatin 1. CalBioMarine Technologies has successfully cultured this 
animal offshore of La Jolla, CA, and partially purified bryostatins from 
both wild and aquacultured materials.79 Another example is culturing 
Lissodendoryx sp. for the anticancer compound, halichondrin B. To 
obtain enough pure material for pharmacological and preclinical studies, 
both a large-scale recollection and aquaculture were considered. The 
University of Canterbury group and NIWA, with National Cancer 
Institute support, has successfully transported sponge samples from depths 
of 70-100 m to 10-30 m depth, while maintaining production of 
halichondrins.2 These results demonstrated the feasibility of commercial 
production of bioactive compounds by aquaculture. 
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1.5 Marine Pep tides 
1.5.1 Introduction 
The peptides are an important group of compounds. They are widely 
distributed in the human body, terrestrial plants, miroorganisms and 
marine organisms. Most of the peptides playa vital role in various life-
processes, and many show remarkable biological activities. The peptides 
can act as chemical messengers, neurotransmitters, hormones, pain-
killers, poisons, antibiotics, or food additives. 80 Among a variety of 
applications of the peptides, their utilisation for medical purposes has 
gained most importance. A well known example is penicillin (a modified 
tripeptide), a lifesaving antibiotic. Since penicillin was discovered in the 
1940's, it has saved thousands and thousands of lives. Another peptide, 
angiotensin II, can cause an increase of blood pressure in the human body. 
A series of antagonists of this peptide have been synthesised to treat high 
blood pressure. 
Normally, molecules composed of less than 50 amino acid residues are 
classified as peptides. Although the building blocks of the peptide 
molecules are relatively simple (the amino acids), the structures of 
peptides can be constructed in nearly countless wa)'s due to the varied 
arrangements of the regular amino acids as well as the incorporation of 
abnormal amino acids and non-amino acids. The linkages between 
individual residues within peptides is the amide bond. A typical amide 
bond is shown below: 
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The amide bond does not exhibit the properties of the normal amino 
group or carbonyl group, as the nitrogen lone pair conjugates with the 
carbonyl group, influencing the bond lengths of C-O and C-N. The 
amide bond is best described by the following resonance forms: 
H 
R~~" 
_II \) R' • Co 
The amide group is planar as the conjugation requues the nitrogen, 
carbon and oxygen p-orbitals all to lie in same plane. The peptide bond is 
relatively inert to most chemical reactions, with the carbonyl group only 
attacked under forcing conditions. The nitrogen does not usually exhibit 
nucleophilic tendencies. 
As a prerequisite to completely understanding the biological properties or 
synthesis of the peptide, the structure of the peptide must be established. 
Normally, the natural peptides exist as a complex mixture in which the 
peptides are varied by a few residues, or by a change in the order of the 
residues. So, once pure the isolation and purification procedures are 
necessary to obtain a single congener for further study. The sequence of 
the constituent amino acids can be determined to establish the primary 
structure. Finally, the stereochemistry of the peptide can be addressed by 
various chemical and spectral methods. 
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1.5.2 Isolation and Purification of Pep tides 
Peptide molecules can be separated based on their size, charge at a given 
pH and polarity. 
Like their component amino acids, the pepddes possess an amino group at 
one end, a carboxylic group at the other end, and a series of sidechains 
separated by amide bonds. The peptide molecules can have a net charge 
at any pH, and the net charge is greatly affected by the nature of the side 
chains. The charged peptides can be absorbed by ion exchange resins, and 
their migration rate on the resins varies with pH and polarity of the 
eluant. Usually the peptides move on a column faster at their isoelectric 
point. One can take advantage of these properties to separate quite 
similar molecules. Another separation technique utilising the charge 
properties of a peptide is electrophoresis. In this method, a mixture of 
the peptides is loaded onto a solid support at a defined pH (either a sheet 
of filter paper, or a polyacrylamide gel). When a voltage potential is 
applied, the positively charged peptides move towards the cathode, while 
the negatively charged peptides migrate towards the anode. Alternatively, 
an isoelectric focusing technique can be used for difficult separation 
problems. In this technique, peptides which differ only slightly in their 
net charge at a given pH are required to migrate across a pH gradient. 
The longer the electrophoretogram is run, the sharper the bands become. 
A peptide mixture can also be separated by gel chromatography based on 
either their size, or both size and polarity. The former principle is 
applied to gel filtration, and the latter to gel permeation. The large 
molecules can not migrate into the pores of the gel, so they are eluted 
first. In contrast, small molecules can diffuse into the pores and interact 
with the inner surface, thus causing selective absorption of polar 
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substances with low molecular weight.81 The sizes of the peptide 
molecules in a mixture varies with the number and side chain type of the 
constituent amino acids. Gel filtration chromatography is suitable for 
mixtures containing a range of peptides of different molecular weight 
(size). However, it is very rare to obtain a pure peptide using this 
technique.80 It is more practical to use gel filtration for the separation of 
peptides from proteins, polysaccharides and low molecular weight non-
peptidic components. In the natural products field, the gel permeation 
technique, based on LH-20, is frequently used for separation of 
compounds in the molecular mass range <4000. Sephadex LH-20 has dual 
lipophilic and hydrophilic properties. Its lipophilic properties come from 
the isopropyl groups introduced by hydroxypropylation of Sephadex G-
25, while the hydrophilicity is due to the numerous hydroxyl functions 
present. Depending on the polarity of the mobile phase, and the 
compounds to be separated, it is possible to perform normal phase, 
reversed phase and selective adsorption chromatography on LH-20.82 
The peptides may be separated based on both molecular size and polarity 
with a carefully selected single solvent, or solvent mixture. This is a very 
useful technique for elimination of other secondary metabolites to yield a 
'pure' peptide mixture. Usually a pure peptide can be obtained 
subsequently by using high performance liquid chromatography (HPLC). 
The excellent resolving power of the reversed-phase (RP) mode of HPLC 
has resulted in this technique becoming the predominant method for 
peptide separations,83,84 although other modes are encountered in the 
literature. Solid phases for RPHPLC are mainly chemically-bonded 
phases of silica gel, for example, C-18, C-8, C-4, CN and phenyl. The 
fully end-capped C-18 or C-8 coated silica gel beads are widely used. 
However, a comparison study on different reversed-phase packings 
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revealed that the CN phase is very potent in separation of peptides and 
proteins.84 The CN column showed excellent selectivity for peptides with 
varied hydrophobicity and peptide chain length. Peptides which could not 
be resolved easily on the C8 column were readily separated on a CN 
column. 84 River et ai. 85 also pointed out the importance of the pore size 
of the beads, which played an important role in the chromatographic 
o 0 
process. A pore size of 300A versus 80-l20A was recommended for both 
good recovery and peak symmetry. Among various solvent systems, 
methanol-water and acetonitrile-water systems are most widely used. 
Incorporation of trifluoroacetic acid (TFA) in the mobile phase as a polar 
modifier can provide excellent conditions for the separation and 
purification of peptides. TF A has a significant effect on both peak shape 
and retention time in the concentration range 0.01-0.25%.86 
1.5.3 Amino Acid Analysis 
In order to identify the amino acids present, complete hydrolysis of the 
peptide to yield the free amino acids is necessary. The standard 
conditions include dissolving the peptide in 6M HCl and heating the acid 
solution at 110°C for 24 hours. However, caution must be taken because 
some amino acids can be destroyed, or modified under these conditions. 
For instance, tryptophan is completely destroyed during acid hydrolysis, 
amide side chains (eg., asparagine and glutamine) will be hydrolysed to 
the corresponding acids and threonine and serine can be slowly 
dehydrated to give corresponding alkenes. Some problems are also 
encountered with aliphatic amino acids, as there is steric hindrance due to 
the bulky side-chains. When Val-Val, Val-He, He-Valor He-He sequences 
exist in the peptide, careful interpretation of the data is necessary, because 
the cleavages of these bonds are incomplete under standard conditions. 
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The dansyl method (see Section 1.3.4) can help to identify such dipeptide 
sequences. In the case of uncertainty about the correct composition of a 
peptide, a second hydrolysis of the peptide for 72 hours should be 
performed. Methionine and carboxymethylcysteine are partially oxidised 
during the isolation of small quantities of peptides. The addition of 
mercaptoethanol (0.05% (v/v» will give better results for some amino 
acids. 
Alternatively, the peptides can be hydrolysed with 2M NaOH (aq) at 
100°C. Alkaline hydrolysis does not affect tryptophan, but will destroy 
senne, threonine, cystine and arginine. This method also causes 
racemisation of the amino acids. Thus, acid hydrolysis is the preferred 
method. 87 
Characterisation of the released ammo acids can be achieved by 
chromatographic techniques. Of the various possibilities, such as paper 
chromatography (PC), thin-layer chromatography (TLC), gas 
chromatography (GC), high performance liquid chromatography (HPLC) 
and ion-exchange chromatography (IEC), the last technique has been the 
most widely used since the classic work of Moore and co-workers. 88-90 
The technique was soon automated with slight modification, and routinely 
used in biochemistry laboratories. Today it is still one of the most 
reliable methods for amino acid analysis. In comparison with GC, 
however, the main drawback of the ion exchange technique is the low 
sensitivity and relatively long operating time. These drawbacks remained 
even when ninhydrin was replaced by fluorescamine,91 pyridoxal,92 or 
radioactive reagents93 for detection. 
The advantages of the GC method are obviously the low cost and the 
much greater versatility of the instrument compared with a specialised 
Chapter One-Introduction 31 
ammo acid analyser. When GC is coupled with mass spectrometry 
(GC/MS) , it offers a more powerful method for identifying unknown 
amino acids, or non-amino acid components (see Section 4.3). 
A disadvantage, however, is the necessity to derive the hydrolysate to 
produce volatile, less polar compounds that are suitable for GC analysis. 
Successful analysis of amino acids with GC is dependent on the synthesis 
of derivatives that are stable and reasonably volatile. Among the 
derivatization methods, the most preferred are those that require at least 
two derivatization steps, eg., esterification of the carboxyl group followed 
by acylation of the a-amino and remaining functional groups. A variety 
of alcohols have been used for the esterification step. These include 
methanol, propanol, isopropanol, butanol, isobutanol and isoamyl alcohol. 
The resultant amino acid esters are next acylated by the addition of acetic 
anhydride, trifluoroacetic anhydride (TFAA), pentafluoropropionic 
anhydride (PFP A), or heptafluorobutyric anhydrides (HFBA) along with 
an appropriate solvent, ego CH2C12 or ethyl acetate. However, the only 
acyl derivatives that permit quantitative GC amino acid determinations 
are trifluoroacetic (TFA) and heptafluorobutyric (HFB), and with some 
restrictions, acetic anhydride.94 Taking account of the difficulty of 
preparation, the resolution on the GC columns, and the losses of the more 
volatile derivatives during evaporation of the solvents, it is the N(O,S)-
HFB isobutyl esters, the N(O,S)-HFB n-propyl esters, and N(O,S)-TFA n-
butyl esters that have been used most extensively.97 
In the early studies, amino acid analysis by GC was mainly performed on 
a conventional packed GC column. The polyester phases occupied a 
predominant position. Other types of stationary phases, such as 
polyglycols and silicones, were employed less as they were not able to 
Chapter One-Introduction 32 
separate the isomers.94 In the last decade, with the introduction of fused 
silica capillary columns and the development of immobilised stationary 
phases, the capillary column showed more potential in amino acid 
analysis. 96 The application of RPHPLC, utilising phenylisothiocyanate 
derivatives, has shown a dramatic increase recently.97 
1.5.4 Sequence Determination 
Sequencing is a key procedure for the structural analysis of the peptides. 
The choice of the method for peptide sequence analysis will govern to a 
large extent the whole approach to cleavage and separation of the 
resultant amino acids. The procedures include determination of the 
amino, or carboxy-terminal residues, and sequencing of the peptides by 
removal of one residue at a time. 
For N-terminal determination, the dansyl chloride method and Dabitic 
method are frequently used due to their high sensitivity, without the 
requirement for expensive analytical equipment. The N-terminal amino 
acid of the p€ptides are reacted with dansyl chloride in NaHC03 solution. 
This is followed by acid hydrolysis (6M HCI). The hydrolysate is 
chromatographed along with a standard mixture of dansyl amino acids, on 
a polyamide layer plate. The dansyl amino acids can be identified by 
inspection of the spots under the UV lamp.98 The Dabitic method uses 4-
N,N-dimethylaminoazobenzene-4'-isothiocyanate as the coupling reagent. 
The advantages of this method over the dansyl method are that asparagine 
and glutamine are distinguished from aspartic and glutamic acids 
respectively, and that tryptophan may be determined. However, the 
determination of serine, threonine and lysine is less satisfactory. 
Alternatively, reverse-phase HPLC may be used for the detection. 
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The identification of the carboxy terminus is generally less easy than the 
N-terminus. One approach employs hydrazine, which reacts with 
peptides to cleave the amide bonds. Eventually, all of the constituent 
amino acids in the peptide are converted to hydrazides, except for the C-
terminal residue, which will be present as the carboxylate. This can then 
be identified by amino acid analysis. 
The most common method of sequencing peptides is the Edman 
degradation, which was developed by Edman in 1950.99 The degradation 
is a cyclic procedure, by which the amino acid residues are cleaved one at 
a time from the N-terminus of the peptide and identified as 
phenylthiohydantoin derivatives. However, the overlap caused by 
incomplete coupling and cleavage reactions at each cycle together with a 
gradually increasing background resulting from small amounts of non-
specific peptide bond cleavage during the degradation limit the application 
of the Edman degradation to, at the most, about 70 residues using 
automated sequencers, or about 30 residues using manual techniques. 
Thus, the polypeptides are normally chopped down with either enzyme 
cleavage, or partial acid hydrolysis.! 00 After separation procedures, the 
individual peptide fragments are subjected to Edman analysis. The whole 
sequence can be established by the overlaps between these fragments. 
There are several other factors which may interfere the Edman method. 
For instance, blockage of the Edman degradation may occur when 
peptides contain asparagIne, glutamine, tryptophan, S-
carboxymethy1cysteine and a-acetyl serine, when the N-terminus is 
blocked with formyl, acetate, methoxyacetate etc., when an abnormal 
amino acid (eg. ~-alanine) or novel amino acids exist in the peptide 
molecules, or when the peptides possess a cyclic structure. The last three 
situations are frequently encountered in the study of peptides from micro-
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organisms and marine organisms. The use of FAB mass spectrometry is a 
technique well suited to by-passing this SOli of problem. This technique is 
not limited by N-terminal blocking, or the preserice of rare residues, or 
even cyclic peptides.1 01 Meanwhile, it provides very rich information 
about the structures of the amino acids. So, it is extremely useful when 
new amino acids or non-amino acids are present in the peptide chain (cf. 
Section 4.5). When the MS/MS mode is applied, it can even analyse 
peptide mixtures.102 Recently, the development of an Edman method 
coupled with reversed-phase high performance chromatography 
(RPHPLC), together with the powerful computer-based quantitation and 
interpretation of chromatograms, has made automated sequencing 
extremely reliable. 1 03 Furthermore, with the development of 2D NMR 
techniques, such as 2D TOCSY, HMQC and HMBC, more and more 
sequencing work can be accomplished by NMR analysis (see Chapters 4-6 
and related references). 
1.5.5 Stereochemistry of Peptides 
X~ray crystallography is the most straightforward method to study the 
structure and stereochemistry of the peptides. As soon as the relative 
configuration is established by X-ray analysis, the absolute 
stereochemistry of a peptide can be elucidated by determination of the 
configuration of one or two constituent amino acids. However, crystals 
suitable for X-ray analysis are not readily obtainable in most situations. 
The stereochemistry of peptides is usually first attempted using other 
techniques. 
The typical techniques in the study of the stereochemistry of peptides 
include GC or HPLC analysis of either free amino acids, or their 
derivatives. The original procedures for resolution of the enantiomers of 
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amino acids involved the introduction of a chiral auxiliary to the carboxyl 
or amine functional groups of the amino acids. The resultant 
diastereoisomers could be resolved on optically inactive GC stationary 
phases. 104, 105 However, since a chiral stationary phase for capillary 
column GC was developed by Gil-Av,106 this type of stationary phase has 
become predominant in the studies of amino acid enantiomers. Of 
various chiral GC columns, Chirasil-Val, which consists of N-propional-
L-valine tert-butylamide coupled to a co-polymer of 
carboxyalkylmethylsiloxane and dimethylsiloxane, is most widely used. A 
very good resolution can be achieved when the amino acid enantiomers 
are converted into N(O,S)-isopropyl esters. Recently, a rapid 
derivatization method was developed by Abe et ai., in which the amino 
acids were converted into N(O)-2,2,2-trifluoroethoxycarbonyl 2',2',2'-
trifluoroethyl esters. I07 With this type of derivative, 18 pairs of protein 
amino acid enantiomers were resolved on a Chirasil-Val column. It is 
noteworthy that two pairs of enantiomers of isoleucine and alio-isoleucine 
were well separated in one run. 
Another efficient technique is RPHPLC. The resolution of enantiomers 
can be accomplished for either the free amino acids on a chiral column, 
or by separating derivatives of the amino acids on a non-chiral column. 
Generally, the latter method gives better results. This latter approach can 
be achieved in two ways: one uses dansylated amino acids (Dns-Am) with 
a chiral additive to the mobile phase; 108 the other employs diastereomers 
produced from the reaction between amino acids and I-fluoro-2,4-
dinitrophenyl-5-L-alanine amide using the normal HPLC solvent 
(Marfey's method).109 Marfey's method has been successfully used in the 
study of several peptides from marine organisms. A new trend is the 
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coupling of HPLC with mass spectrometry (LCIMS), which provides 
more information for structural studies. 
NMR techniques, particularly the NOE, NOESY and ROESY techniques, 
are very powerful in the study of conformations of the intact peptide. 
This has led to a better understanding of the relationship between the 
conformations and the biological activities of the peptides.110 
1.5.6 Pep tides from Marine Sources 
The study of marine natural products started to boom in the 1970's, but 
the early literature was dominated by reports of non-nitrogenous 
metabolites. I I I It is only recently that marine peptides have become one 
of the most rapidly growing groups of marine natural products. Since 
Fusetani et al. isolated the first bioactive peptide, discodermin A, from 
marine sponge Discodermia kiiensis,112 more than 400 peptides have been 
reported from marine organisms. It is interesting to note that 80% of 
them possess a cyclic structure. A high incidence of unusual amino acids 
or fatty acids have also been observed in marine peptides. 111 These 
marine peptides exhibit a wide range of bioactivities, such as cytotoxic, 
antimicrobial, antifungal, anti-viral and immunomodulating activity. This 
group of natural products has great potential in the search for new drugs 
and the development of pharmaceuticals. 
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1.6 Aims of This Project 
As a part of the continuing search for bioacti ve natural products from 
marine organisms in the Marine Group of the University of Canterbury, 
this project includes: 
A. Chemical screening study. This part of the work involved testing a 
modified protocol for chemical screening and searching for suitable 
organIsms for further chemical study by screening a wide range of 
samples. 
B. Investigation of anti-HIV components from a sponge and an 
ascidian. The primary tests indicated some HIV -inhibitory activity from 
a Chondropsis kirkii (sponge) and a Styela sp. (ascidian). Further 
separation was necessary to reveal the chemical properties and biological 
profile of the active compounds. 
C. Studies of antiviral and cytotoxic constituents in a CaUyspongia sp. 
D. Separation and structural studies on the antitumour cyclic 
peptolides from Lamellomorpha strongylata. This sponge contains 
several classes of bioactive compounds. This project will focus on the 
peptolide fraction. 
Chapter 2 
Chemical Screening 
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2.1 Introduction to Chemical Screening 
Marine natural products is a rapidly growing field. Over the last two 
decades, more than 7,000 compounds have been identified. I7 These 
discoveries have made a great contribution to both chemistry and biology. 
However, it has also caused problems for chemists because known 
compounds are being encountered with increasing frequency as the 
number of publications rise. This creates problems for chemists trying to 
find unique compounds for both publication and patenting. For those 
chemists using bioassay-guided separation techniques in searching for 
biological compounds, the presence of recurring compound classes is also 
a troublesome factor because it diverts the researcher's attention from 
other extracts with potential. Another problem in the day-to-day work of 
marine natural product chemists is that some of the bioactive components 
in the crude extract are sensitive to most separation media, especially as 
they are purified. To solve these problems the chemist requires an insight 
into the general properties of the interesting (bioactive) components 
before initiating a formal separation procedure on a large scale. A 
technique developed for this particular purpose has been called "chemical 
screening" . 
The concept of "chemical screening" has been in use for a while, but in 
the chemical sense the meaning has varied. In the work done by 
Grabley113 and Noltemeyer et al114 the term chemical screening meant 
screening for secondary metabolites by means of functional group- or 
compound-class-specific TLC detection reagents. Their methods were not 
related to the biological activity of the targeted organisms, but to chiral 
synthons for synthesis. These approaches turned out to be very effective 
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for the discovery of new natural products, and have been successfully 
used by many natural product chemists. 
With a greater emphasis being placed on the discovery of the bioactive 
secondary metabolites, another chemical screening protocol was 
developed and successfully applied to the dereplication and prioritization 
of the crude aqueous extracts from terrestrial plants and lichens, cultured 
cyanobacteria, and marine invertebrates and algae as part of an anti-HIV 
study 115. Later, the protocol was further modified by Blunt et al l16 and 
its application was extended to organic extracts with cytotoxic, anti-HIV, 
anti-viral, anti-bacterial and anti-fungal activities. It turned out to be a 
quick, simple and cheap method for optimising the isolation procedure 
for both aqueous and organic extracts. It is now a routine screening 
technique used by Marine Group at the University of Canterbury. 
The general procedure adopted in this project includes the extraction of 
samples using suitable solvents, the rapid separation of the crude extracts 
with solid phase extraction cartridges, bioactivity testing of the eluates 
from the individual cartridges, interpretation of the bioassay results and 
decision making. Different types of solid phase extraction cartridges 
were carefully selected in order to obtain the information about polarity, 
neutral or ionic character, and molecular weight range. All cartridges 
were pre-equilibrated with an appropriate solvent. Then an aliquot of an 
extract (-5 mg) was either dissolved in a suitable solvent, or coated onto 
the celite before loading onto each cartridge. Generally, three fractions 
from each column were collected, but a fourth is an option. Each of the 
derived fractions were then tested along with a primary standard in the 
bioassay system. 
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For organic extracts, C18, CBA and LH-20 are frequently used, while the 
Diol, amino or PEl cartridges are chosen as alternative phases. Usually, 
MeOHIH20 (1:1), MeOH and MeOHlCH2Ch (1:1) solvent systems are 
used for the C18 cartridge; MeOH/O.05M aqueous NH4Ac (4:1), 
MeOH/2% aqueous ammonia (4:1) and MeOH/O.05% aqueous TFA (4:1) 
for CBA phase; while MeOH was used for LH-20. The C18 and CBA 
column can be run either under gravity or vacuum, but the LH-20 
cartridge should only be operated under gravity. 
Normally, the aqueous extracts are processed with CI8, CBA and amino 
phases. Wide-pore C4 and Sephadex 0-25 are also useful. The C18 
cartridges are eluted with H20, MeOH/H20 (1:1) and MeOH in tum, 
while the latter two cartridges are run with the following solvent systems: 
CBA, 0.05M of aqueous NH4Ac, 2% aqueous ammonia and MeOHlO.05% 
aqueous TFA (1:1); amino, 0.05M of aqueous NH4Ac, aqueous 0.05% 
TFA and MeOHlO.05% aqueous TFA (1:1) respectively. 
The formal separation of the bioactive compounds on a large scale can 
then be initiated based on the interpretation of the screening results. The 
information from such a chemical screening exercise is illustrated by a 
typical model as below. 
+ 
II + + 
III 
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This profile implied that the bioactive compound(s) was of medium 
polarity, relatively large size (MW>750) and cationic. An optimised 
separation procedure can be readily established from the analysis. 
When the above method is coupled with HPLC using photo-diode array 
(PDA) UV detection and a taxonomy-oriented database (MarinLit),17 the 
approach becomes even more productive. The peaks in common in the 
HPLC traces of the bioacti ve fractions are likely candidates for the 
bioactive components. Comparison of the UV data for these peaks against 
that stored in MarinLit may result in the recognition of known structures 
or structural types. The current work has been carried out both to make 
some contribution to the modified chemical screening protocol, and to 
search for suitable candidates for further investigation. 
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2.2. Testing of the Modified Protocol 
Like the development of any other method, the chemical screening 
approach has been improved step-by-step. A recent modification of the 
protocol included coupling of the results with HPLC and the MarinLit 
database. In order to test the efficacy and validity of the modified 
method, two sponges, Mycale sp.1 17 and Lamellomorpha strongylata, 118 
containing known bioactive compounds were chosen for detailed 
examination. They contain the cytotoxic compounds pateamine (31) and 
calyculin E (32) respectively. 
An organic extract of the Mycale sp. was chromatographed on C-18, 
Diol, PEl and LH-20 cartridges using the procedure described in Section 
2.1. The bioassay results indicated that the activity appeared in the second 
fraction of C 18, the third fraction of Diol, the second fraction of PEl and 
the second fraction of LH-20. 
o 
Pateamine (31) 
The structural conclusions from the data were medium polarity, cationic 
and medium sized. Then each of the active fractions was analysed by 
reverse phase HPLC, using an acetonitrile/H20 gradient. The common 
peak (Rt=3 min) was observed in all HPLC traces. A UV spectrum 
corresponding to this peak indicated that the related compound( s) have 
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OH 
OH OH 6CH3 
Calyculin E (32) 
maximum absorptions at 274 and 285 nm, which was consistent with the 
UV data of pateamine. Obviously the active compound can be quickly 
located by the new screening procedure. 
The organic extract of L. strongylata was passed through C-18, Diol, 
PEl, CBA and LH-20 cartridges respectively. Fractions 2 and 3 from 
C18, and all three collections from Diol showed strong cytotoxicity. 
These data can be interpreted as active compounds of different polarity or 
the compounds eluting over a wide range of polarities. It turned out to be 
" .. 
the latter. The activity in the first and the second fractions from the PEl 
and CBA respectively suggested that the active compounds were cationic. 
The activity was observed in the first two fractions of LH-20, indicating 
large to medium sized molecules. The active fractions were each analysed 
by RPHPLC and the results summarised in Figure 2.2.1. Searching of 
MarinLit with the UV data (A,max 321, 227 nm) of the common peaks 
(320 and 580 sec.) indicated that one of the active components probably 
had a calyculin type skeleton. 119 This assumption subsequently proved 
correct, and four known calyculins and two new compounds, 
calyculinamides, were identified. lI8 It is noteworthy that further 
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processmg of another fraction with end absorption only in the UV 
spectrum resulted in the identification of a different group of cytotoxic 
compounds. This was the theonellapeptolides. A detailed discussion 
about their isolation and structure study will be given in Chapters 4, 5 and 
6. 
-
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Fig. 2.2.1 HPLC analysis of the active fractions from L. strongylata. (a) Isoplots of 
the HPLC traces of the bioactive fractions from chemical screening (left); (b) 
normal HPLC presentation summed from A 220-390 nm for the active LH-20 
fraction(right top); (c) UV profile of the active components at 320 and 580 sec. 
These experiments clearly demonstrated that the modified approach was 
very powerful for gaining insight into the properties of the bioactive 
components in the early stage of a study. 
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2.3 Screening for Anti-HIV Components from 
the Sponge Chondropsis kirkii 
The primary bioactivity screening of the extract from C. kirkii showed 
medium to intense anti-HIV activity. But, there was no obvious 
cytotoxicity in P388 assay. The chemical screening was carried out using 
C4 wide pore, and Sephadex G-25 cartridges for the 'aqueous extract, and 
with C18, Diol and PEl phases for the organic extract. 
Strong anti-HIV activity was found in the first fraction off the C4 
cartridge, and in the first and second fractions off G-25. There was mild 
cytotoxicity in the former, but no cytotoxicity in the latter. This kind of 
chromatographic behaviour implied a high molecular weight for the 
active compounds. On the other hand, a medium anti-HIV (51-54%, 
inhibition) activity accompanied by mild cytotoxicity (31-34%, 
cytotoxicity) eluted in the third fraction off the C18 cartridge, and the 
first fraction off the Diol column. These data were interpreted as another 
group of less polar active components. No activity was observed in any 
fractions off the PEl column which suggested that the active molecules 
were polyanionic. 
Because recurring compound classes are frequently responsible for the 
anti-HIV activity of marine aqueous extracts,120 it was necessary to 
examine and dereplicate for these classes of compounds before embarking 
on a major effort in this project. 
Sulphated polysaccharides are often responsible for the anti-HIV activity 
of aqueous fractions. It is necessary to remove this type of component in 
order to focus on other classes of active compounds. A 50% EtOH in 
water solution can precipitate the polysaccharides and protein, and reduce 
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interference from these compounds. Albano and Mourao 121, 122 
demonstrated the cationic dye toluidine blue bonded to polyanionic 
molecules in aqueous solution and induced a metachromatic shift in 
wavelength. This resulted in a decrease in absorbance with increasing 
concentration of the poly anionic molecules. They successfully applied 
this method to the determination of sulphated polysaccharides in sea 
cucumbers and tunicates. To find out whether sulphated polysaccharides 
existed in the supernatant of the aqueous extract of C. kirkii, the solution 
was run through a Sephadex G-25 column. Each fraction was analysed 
for sulphated polysaccharides at three different concentrations (see 
Experimental, Table 7.2.1). A decrease in absorbance with increasing 
sample concentration was observed for the two active fractions, but there 
was no obvious absorption change with concentration for the inactive 
fractions. This suggested that sulphated polysaccharides were present in 
the supernatant. However, Beutler et al120 had noticed that colour 
interference from the crude extracts gave erroneous results in a 
significant number of cases. To obtain more evidence, the ethanol 
precipitate was redispersed into water and analysed in same way as for the 
supernatant after filtration. All seven fractions exhibited strong anti-HIV 
activity. The toluidine blue test indicated a positive response for the 
presence sulphated polysaccharides to all seven fractions as a function of 
different concentrations (cf. Table 7.2.1). These data gave more 
supporting evidences for the above assumption. The activity in the 
supernatant can probably therefore be attributed to the presence of trace 
amount of sulphated polysaccharides. Because this class of compounds 
was not a target of this project, no further study on them was carried out. 
Chemical screening also indicated that the organic extract contained anti-
HIVactivity. The organic extract from Chondropsis sp. was loaded onto 
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a C-18 column, which was eluted with an increasing proportion of MeOH 
in water, MeOH/CH2Cl2 and CH2Cl2. The anti-HIV activity was found 
in the fractions eluted with MeOH and MeOH/CH2Cl2 (1:1). All the 
active fractions were combined on the basis of their TLC behaviour, and 
re-chromatographed on a Diol column. The anti-HIV activity was 
concentrated in just three fractions, accompanied by weak cytotoxicity. 
After LH-20 chromatography, the individual fractions were examined by 
1 H, or 13C NMR spectroscopy. The spectra indicated that the components 
were a sterol mixture. Reverse phase HPLC analysis indicated at least six 
partially resolved peaks, although only one spot was observed by TLC. 
An attempt to purify the steroid fraction by HPLC (CN column in a 
reverse phase mode) did not result in any pure compounds. Bioassay 
results on the fractions from the HPLC chromatography indicated that the 
level of anti-HIV activity had not varied much during the purification, but 
that the cytotoxicity had increased most notably (see Table 2.3.1). The 
HPLC of the most active fraction showed that this was still a mixture of 
up to six compounds, but with one compound predominant. The 1 H NMR 
spectrum (Fig. 2.3.1) of this fraction confirmed that one sterol was 
predominant, but difficulties were encountered in the interpretation of the 
data. The multiplet at 8 3.54 was typical of an H3 resonance for a sterol. 
A doublet at 8 4.68 (2H, J=15 Hz) was assigned to two olefinic protons 
with trans-geometry, and must therefore be located in side chain. 
However, a doublet at 8 5.38 (J=3 Hz) normally attributable to the H6 
resonance of a 5( 6)-double bond corresponded to two, rather than one 
proton, suggesting the presence of a third trisubstituted olelfin in a very 
similar chemical and magnetic environment to the 5(6) olefin. The l3C 
NMR spectrum showed six unsaturated carbon signals between 8 121.7 
and 140.7. Four methine carbons were recognised by the DEPT 
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experiment. The resonances at 0 140.7 and 121.7 were assigned to C5 
and C6 respectively. These data implied that the major sterol had one 
hydroxyl group, and three double bonds in its structure. The acetylated 
derivatives of the sterols were also prepared and subjected to analysis on a 
variety of HPLC columns. No significant improvement was obtained in 
this way. As the samples were cytotoxic steroid in character and not 
strong inhibitors of HIV, it was decided not to proceed further with this 
sample. 
Table 2.3.1. Anti-HIV activity and cytotoxicity of the fractions from 
Chondropsis kirkii 
Sample Code Antiviral % Inhibition CEMCells% 
cytotoxicity 
Crude Fraction 89 21 
SL235.4 59 49 
SL236.1 50 22 
SL236.3 47 26 
SL240.7 63 45 
SL241.2 72 44 
SL242.3 87 47 
Chapter Two-Chemical Screening 50 
o 
Fig. 2.3.1 1 H NMR spectrum of SL242.3 
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2.4 Extraction and Chemical Screening of the 
Ascidian Styela sp. 
The ascidian Styela sp. was extracted with MeOH, MeOH/CH2Ch (1:1) 
and CH2Ch in tum, followed by partition of the extracts between water 
and ethyl acetate to yield aqueous and organic extracts. An equal volume 
of EtOH was added to the aqueous fraction which was then filtered 
through celite to remove the precipitate and give a supernatant solution. 
The supernatant and organic extracts were each tested for anti-HIV 
activity. The former exhibited a 28% inhibition against the infected cells, 
while the latter only showed cytotoxicity in the assay. To further evaluate 
the anti-HIV activity, the aqueous extract was screened with C4 wide pore 
and the Sephadex G-25 cartridges. The second fraction from the C-4 
cartridge showed good HIV-inhibitory activity (106% inhibition), and the 
first and fourth fractions from the same column had a weak activity. All 
four fractions from Sephadex G-25 cartridge were negative. Since the 
separation mechanism of G-25 is molecular size selection, the retained 
molecules must be of low molecular weight. Absorption of the bioactive 
material was also a possibility. The anti-HIV active compounds were 
considered most likely to be polar molecules with low molecular weight. 
Furthermore, their separation should rely mainly on reverse phase 
chromatography. 
The aqueous extract was chromatographed on a C-18 column, eluted 
initially with water, then different proportions of MeOH in H20 up to 
100% MeOH. The first three fractions showed weak HIV-inhibitory 
activity. The signals between () 7.9-8.8 in IH NMR spectrum (Fig. 2.4.1) 
of fraction 1 are related to either the amide protons of peptides, or the 
aromatic protons of nuc1eotides. The resonances between () 4.0-5.0 could 
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be accounted for by the a-protons of amino acids~ while the peaks 
between 8 3.1 and 3.9 suggested the presence of a sugar moiety. So~ the 
existence of small peptides~ or nucleotides in the active fraction were 
deduced. The above analysis also excluded any activity related to 
sulphated polysaccharides. 
For the organic extract, C18, Diol and PEl cartridges were used for 
chemical screening. The cytotoxic activity was found in the second and 
third fractions off C18, the first and second fractions off Dial, and the 
third fraction off PEI. This chromatographic behaviour suggested that 
the active compounds were of medium-polarity to non-polar~ and 
probably anionic. 
Unfortunately, the limited amount of sample prevented further 
processmg. Despite repeated attempts, it proved impossible to recollect 
this animal. The ascidian Styela sp remains a candidate for further study. 
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Fig. 2.4.1 IH NMR spectrum of fraction 1 from C18 column 
(Styela sp.) 
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2.5 Chemical Screening of an Unidentified 
Sponge (Code No. 94FLOI-Ol) 
Weak anti-HIV activity was observed in the crude extract from this 
unidentified sponge species. In order to obtain more information about 
the active compound(s), the frozen sponge (550g) was extracted by the 
same procedure as used for C. kirkii. (see experimental), Both the 
aqueous and organic extracts were analysed by the chemical screening 
protocol. The resultant fractions were sent to the USA for anti-HIV 
bioassay. The bioassay results revealed no remarkable anti-HIV activity 
in any fraction. This is a indication of the unstable bioactive components. 
No further work was carried out on this sample. 
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2.6 Chemical Screening for Anti-viral Activity 
of the Extract from Cally S p 0 n g i a 
irregularis 
The primary bioassay for the organic extract from C. irregularis revealed 
very potent anti-viral activity with weak cytotoxicity (inhibition zones 
were 4+ against both Herpes simplex and Polio virus, while zone of 
cytotoxicity was +). Chemical screening of the organic extract was on 
C18, Diol and LH-20 phases. The anti-viral activity was found in the 
second fraction from the C i 8 column and in all three fractions from Diol, 
while only weak activity was observed from the last fraction from the 
LH-20 column. These data implied that the active components have 
medium polarity accompanied with some less polar compound, or there 
was strong tailing on the Diol phase, and medium to low molecular 
weight. The processing of this sample will be discussed in Chapter 3. 
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2.7 Chemical Screening of an Unidentified 
Sponge (Code No. 95CR4 .. 18) 
The organic extract from the unidentified sponge 95CR4-18 was screened 
on C18, Diol, PEl, CBA and LH-20 phases. Fraction 3 from C18, 
fraction 3 from Diol and fraction 2 from LH-20 exhibited potent 
cytotoxicity, while fractions from PEl and CBA showed only very weak 
activity. These observations suggested that the active compound(s) were 
polar to medium polarity. Meanwhile, a decrease in the bioactivity in all 
fractions, except those from LH-20, was noticed. The dilution, which is 
equivalent to the ICso for the two most active fractions from the C18 and 
Diol phases, had risen to 526 and 233. This compared with the initial 
dilution of <97.5 for the fraction from LH-20 and standard. This 
resulted from either an experimental error, or by loss of the bioactive 
compound(s). The most likely scenario is loss of bioactivity on the C18 
and Diol phases. 
To find out the effect of the solid phases on the bioactivity, an active 
fraction was run through a C18 column. All collections were then tested 
for cytotoxicity. This time the most active fraction, corresponding to a 
MeOH eluate, showed a dilution value of 5541. An obvious decay in the 
bioactivity had been observed. In order to gain insight into the nature of 
the bioactive compounds, the HPLC with PDA detector was used for 
further study. Unfortunately, no common peaks among the various active 
fractions could be recognised. This was attributed to either UV inactive 
components, or a very low concentration of the active compounds. No 
further work was undertaken on this sample due to the instability of the 
active component(s). 
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2.8 Chemical Screening of an Unidentified 
Sponge (Code No. 95CR2-10) 
An aqueous extract of this sponge exhibited very potent cytotoxicity 
(ICso<97.5). The chemical screening was carried out using C4 wide 
pore, PEl, CBA and 0-25 cartridges. Bioactivity testing of all 11 
fractions revealed that only the first fraction from the CBA column was 
active, and then only weakly cytotoxic. The activity nearly disappeared 
after chromatography. However, the standard solution of the extract 
remained active (dilution <97.5). It was assumed that the active 
components were sensitive to all the normally used solid phases. 
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2.9 Conclusion 
In the current work, a total of eight marine organisms were processed in 
a search for suitable candidates for further study. The results indicated 
that chemical screening is a very efficient tool for both dereplication and 
optimisation purposes in studying bioactive marine natural products. At 
the same time, the above experiments also explored limitations related to 
the approach. When the bioactive components exist in trace amount, or 
are UV inactive, the interpretation of the results is not straightforward. 
Of course, these shortfalls can be supplemented by "secondary chemical 
screening" 123 and coupling this protocol with other analytical means, for 
example, LC/MS or IR spectrometry. As a direct result from the current 
chemical screening, the sponges Callyspongia irregularis and 
Lmnellomorpha strongylata were chosen for further chemical 
investigation. This work resulted in the identification of several anti-viral 
and cytotoxic compounds (see Chapters 3,4, 5 and 6). 
Chapter 3 
Antiviral and Cytotoxic 
Compounds from 
Callyspongia sp. 
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3.1 Introduction 
Callyspongia irregularis was chosen for further study because both very 
promising antiviral activity (HSV 4+ and PV 4+) and cytotoxicity against 
P388 cell line (177 x 10-6 dilution) had been observed in the primary 
bioassay. However, the NMR spectra of the active fractions from 
chemical screening indicated that the active components probably existed 
in very low concentration. Considering the available amount of the 
sponge sample (380 g of fresh animal), great care needed be taken in the 
separation procedure to minimise the loss of the active compounds. With 
this in mind, high speed countercurrent chromatography (HSCCC), and 
gel permeation techniques were adopted as the main separation means, 
while Diol column chromatography and RPHPLC were reserved for the 
final purification stages. By this strategy, a trace amount of the known, 
strongly antiviral compound, mycalamide A,124 was identified. At the 
same time, several other cytotoxic fractions were located. In order to 
further explore the biological activity of this sponge, a recollection was 
carried out in 1995. In fact, another species of CaUyspongia with similar 
characteristics to C. irregularis was collected. This species was named 
Callyspongia sp.2. Multistep bioassay-directed separation of the organic 
extract from C. sp.2 did not result in the isolation of mycalamide 
compounds, but rather two very cytotoxic fractions with ICso 11 ng/mL 
and <97.5 ng/roL, were obtained. 
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3.2 Compounds 
Callyspongia 
Isolated from Genus 
A number of compounds with a variety of bioactivities have been isolated 
from species of sponges from the genus Callyspongia. To date, not many 
species from this genus have been targeted by chemists. The typical 
biological activities of the components found in this genus include 
cytotoxicity,125,126 inhibition of the epidermal growth factor (EGF),127 
inhibition of the fertilisation of starfish gametes, inhibition of 
phosphatidylinositol-specific phospholipase C (PI-PLC),128 and anti-
microfouling effect. 129 A feature of earlier work in this genus has been 
the isolation problems encountered.127 
3.2.1 Cytotoxic Compounds from Callyspongia sp. 
A number of straight-chain and branched fatty acids containing cyclic 
peroxides, and steroidal peroxides have been isolated from sponges of this 
genus. Many of the cyclic-peroxide-containing acids exhibited cytotoxic 
or other types of biological activity. Two branched-chain acidic 
compounds, (33) and (34), containing a cyclic peroxide moiety were 
isolated from a Callyspongia sp,125 Their structures were elucidated by 
spectral methods. The peroxide partial structure was deduced from 
unsaturation elements in cooperation with NMR analysis. Acids (33) and 
0, 
o 
Peroxide (33) 
'". r.OOH 1,,/-
Peroxide (34) 
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(34) inhibited murine leukaemia cell growth (EDso (P388) 5.5 and 2.6 
).1g/mL respectively.) 
Another cytotoxic compound, callystatin A (35), was identified from 
Callyspongia truncata. 126 It was characterised as a polyketide with a 
terminal a,~-unsaturated 8-lactone and exhibited cytotoxicity against KB 
cells (ICso 0.01 ng/mL). The absolute stereochemistry at C-19 in 
callystatin A (35) was established by Mosher's method130. Since 35 was 
also found in another marine sponge, Stelleta sp, and is related to the 
antitumour antibiotics, eg., leptomycin,127 kazusamycin 128 and 
leptofuranin,129 isolated from the cultured broth of several strains of 
Streptomyces sp., it was hypothesised that symbiotic microorganisms 
participated in the biosynthesis of callystatin A. 
o 
o OH 
Callystatin A (35) 
3.2.2 Other Bioactive Compounds from CaUyspongia sp. 
Davies-Coleman et ai. reported isolation of EGF-active polymeric 
pyridinium alkaloid from the sponge Callyspongia fibrosa. 13 1 This 
compound is illustrative of the complexity and difficult factors sometimes 
encountered in the structural elucidation of polymeric compounds. The 
structure of the EGF-active compound was first proposed, on the basis of 
ion-spray mass spectrometry, to be the cyclic dimer 36 (n=2), but further 
comparison with synthesised 36 and its derivatives revealed that 
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hypothesis was incorrect. The mass spectrum from ion-spray mass 
spectrometry showed a predominant peak at mlz 379, which was 
interpreted as arising from a dimer structure (36). The molecular 
formula of the salt of 36 was therefore thought to be C26H40N2Cb. 
n 
Dimeric pyridinium alkaloid (36) (n=2) 
However, when 36 and several other derivatives were synthesised, and 
compared with the authentic natural product, the differences were 
obvious. Firstly, the natural product exhibited a different Rf value from 
the synthesised compounds by TLC. Secondly, the larger the molecule, 
the less abundant the parent ion observed in the ion-spray mass spectrum, 
while the natural product did not show the (M2+ + A-) peak in its MS 
spectrum. Finally, the bioactivity of the synthesised compounds did not 
match that observed for the natural product. The difference in potency 
was at least 17-fold. Thus, the authors suggested the active natural 
product was a high molecular weight oligomer or polymer. 
Several polyacetylene compounds have been isolated from CaZZyspongia 
species, but only two polyacetylene sulfates, callyspongins A (37) and B 
(38),132 were reported showing starfish gamete fertilisation-inhibitory 
activity. In this experiment, the oocytes were induced to maturity by 
treatment with 1 ~M I-methyladenine. Maturing oocytes were fertilised 
40 min after the start of the I-methyladenine treatment. The oocytes 
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were examined for the presence of the germinal vesicle and the 
fertilisation envelope at 5 min after insemination. Compounds 37 and 38 
inhibited the fertilisation of starfish gametes at minimum inhibitory 
concentrations of 6.3 and 50 11M respectively. 
Cally spongin A (37), Rl=R2=S03Na 
Callyspongin B (38), Rl=S03Na, R2=H 
Fukami et al133 isolated an enzyme inhibitor, akaterpin (39) from an 
unidentified Callyspongia species. The structure was characterised by 
spectral methods. This new triterpene exhibited inhibitory activity 
against phosphatidylinositol-specific phospholipase C (PI-PLC) with an 
ICSO of 0.5 Ilg/mL. It also inhibited neutral sphingomyelinase with an 
ICso of 30 Ilg/mL. Akaterpin was also a potent PI-PLC inhibitor. 
~\~ 
O ..... s'ONa 
Hl~ gJ:. o,J? : ""'" ~:::.::o ONa 
H S 
E ~ 
Akaterpin (39) 
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Wang et al134 found three anti-microfouling nitroalkyl pyridine alkaloids, 
untenines A (40), B (41) and C (42), from the Okinawan sponge, 
CaUyspongia sp. This was the first isolation of a nitro alkyl metabolite 
from a marine organism. Compounds 40,41 and 42 showed anti-
microfouling activity with IC100 values of 3.0, 6.1 and 5.8 J.lg/cm2 
respectively. It is suggested that these rare nitro alkyl metabolites are the 
precursors of nitroso, hydroxylamine and amine derivatives, considered 
to be transient intermediates from nitro groups reduced by reductase in 
the presence of NADPH. Niphatynes135 isolated from sponge, Niphates 
sp., provide more evidence for the assumption. 
Untenine A (40) 
Untenine B (41) 
Untenine C (42) 
Niphatynes A and B 
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3.3 Studies on Anti-viral Components from 
Callyspongia irregularis 
C. irregularis possesses a tubular body fonn with a purple colour in sea 
water. The animals used in this study were collected at Moeraki (South 
Island, New Zealand, 15 m depth) by SCUBA. 
3.3.1 Extraction and Separation of Compounds from C. 
irregularis 
The frozen sponge was blended and extracted with MeOH, MeOH/CH2Ch 
and H20 respectively. After precipitation of the higher molecular weight 
species with ethanol, the aqueous portion was freeze-dried to produce an 
aqueous extract. This extract did not show any activity in a cytotoxicity 
test. However, the organic extract exhibited strong activity against 
Herpes simplex and Polio virus, and cytotoxicity in both the anti-viral 
bioassay and P388 assay. 
The organic extract was chromatographed on C-18 eluted initially 
with H20, followed by increasing concentration of MeOH in water, 
MeOH and MeOH/CH2Ch. The main activity was found in the fractions 
that eluted with MeOHIH20 (7:3). The fractions from MeOH/CH2Ch 
(1:1) and CH2Ch also gave a mild cytotoxicity response. From these 
results it was concluded that the major active compound was polar , but 
that the less polar fractions also contained some activity. The eluant was 
combined into six fractions according to the bioactivity, and with 
reference to TLC characteristics. A further purification of the most 
active fraction was effected by high-speed countercurrent 
chromatography (HSCCC). The solvent system, petroleum etherl ethyl 
acetatel methanol/water (6:11:6:4) with the upper phase as the mobile 
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phase, was employed. This procedure successfully concentrated the 
bioactivity into just two fractions. The 1 H NMR of the active fractions 
displayed many resonances in 0 3.0-4.5 region. This suggested that a 
polyhydroxy or polyether compound was present in the mixture. The 
two active fractions were combined and the separation by repeated 
HSCCC. The resultant fractions were combined into five portions based 
on their biological activity. Of these, II.2 displayed significant anti-viral 
and cytotoxic activity, while II.5 showed only cytotoxicity (see Scheme 
3.3.1). 
The anti-viral fraction was chromatographed on a Diol column. A 
compound, which showed whole-well inhibition against both Herpes 
simplex virus type I (a DNA virus) and Poliovirus type I (an RNA virus) 
at a concentration of 0.01 ~g/mL, was isolated. The bioactivity profile of 
this compound was very similar to that of the antiviral compound, 
mycalamide A (43), previously isolated by the Marine group from a 
Mycale sponge. 124 After a careful examination of the spectral data for 
both the active compound and those of authentic mycalamide A, it was 
concluded that the compound isolated from C. irregularis was 
mycalamide A. The mycalamide A was present at a very low 
concentration in the sponge. Only about 200 Jlg was obtained in this 
work. 
OH 
Mycalamide A (43) 
Chapter Three-Antiviral and Cytotoxic Compounds from Callyspongia sp. 68 
To accumulate more sample for further characterisation, the less active, 
but related fraction II. 1 , was purified by RPHPLC using MeOH/H20 
containing 0.05% TFA (trifiuoroacetic acid) as eluent. However, neither 
the antiviral, nor the antitumour activity was observed in any fractions 
from HPLC. In a similar way, a cytotoxic fraction (II.5) was submitted 
to RPHPLC for purification. Again, no bioactivity was found in any 
collections from the column. At this point a re-examination of the 
literature for the chemical properties of mycalamide compounds was 
made. In his thesis work," Dr. Andrew M. Thompson had pointed out 
that mycalamide samples had no detectable activity after standing in 10% 
MeOH/aqueous hydrochloric acid (0.1M) for three days. So, it is most 
likely that the presence of the trace amount of TF A in the HPLC solvent 
contributed to the decomposition of mycalamide A during concentration 
and loss of the bioactivity. 
* Thompson, A. M. Synthetic Studies on a Potential Antitumour compound 
(PhD. thesis), 1991, pp.145-146. 
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Scheme 3.3.1 Bioassay-guided separation of the extract from C. 
irregularis 
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3.3.2 Identification of Mycalamide A 
Since mycalamide A displayed significant in vivo anti-viral and 
antitumour activity, it has attracted wide attention from both chemists and 
biologists. Before the separation of mycalamide A from C. irregularis, it 
had been obtained only from a species of the genus Mycale (family 
Mycalidae Lundbeck, order Poecilosc1erida).1 24 This new discovery 
offers an additional source as well as raises very interesting questions as 
to the origins of the mycalamides. Is it a sponge metabolite, or it formed 
by a symbiont? 
As a limited amount of the sample was available, the structural 
information could only be extracted from the IH-NNIR spectrum and by 
MS analysis. In order to obtain more evidence to confirm the structure 
of the active compound, the sample was sent to the National Institutes of 
Health for high resolution mass spectroscopy (HRMS). The molecular 
ion could not be detected due to its very low intensity. Fortunately, a 
major ion at mlz 472, corresponding to the loss of CH30H from the 
molecular ion at mlz 503, was recognised both in the FABMS spectrum of 
the sample and the standard mycalamide A. An ion at mlz 472.2528 (6 
-1.9) in the former and mlz 472.2533 (6 -1.3) in the latter were observed 
respectively, which correspond to a molecular formula of C23H3809N. A 
comparison of the link scan from mlz 503 for the Callyspongia sample 
with that obtained for mycalamide A revealed that both of them yielded a 
reasonably intense ion at mlz 472, and that nearly all other major 
daughter ions from mlz 503 are the same, although the ratios of the 
daughter ions varied between the two spectra (Fig. 3.3.1 and 3.3.2). This 
deviation can be attributed to the co-existence of impurities in the 
CaUyspongia sample, that affected ionisation conditions. The major ions, 
Chapter Three-Antiviral and Cytotoxic Compounds from CaUyspongia sp. 71 
58).2. 
•• 
,. 
z. 
'0 
H3.a 2:4.9.0 
_ m m ~ _ ~ m ~ ~ m ~ _ m ~ _ _ _ ~ _ - -
.v, 
Fig. 3.3.1 Link Scan at mlz 502 for Mycalamide A 
'a9£!978 500.1" 
29 
352.9 
" 
2< 
" 
z. 
,. 
,. 
I< 
" 
,. 
"?Z.ll' 
32~.1 391.1 
.. 353. t 
.ld<all • 157.1 311.21 ild., Jl .. JdJ l'·· l ~I 
'00 3l' ". , .. '0' , .. ". ". ". <B. "" .,." 
Fig. 3.3.2 Link Scan at mlz 502 for Fraction 111.2 from C. irregularis 
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Scheme 3.3.2 EI Mass Spectroscopy Fragmentation of Mycalamide A 
(43) 
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such as m/z 471, 440, 421, 408, 396 (see Scheme 3.3.2) as well as 215, 
197, 181, 195 and 87, were recognised as the common peaks in their 
ElMS spectra (refer to Scheme 3.3.2). 
These observations provided supporting evidence for the assignment of 
identity. The assignment of the IH NMR spectrum (Fig. 3.3.3) was based 
on a comparison with that of authentic myca1amide A. Both the chemical 
shifts and the coupling constants of compound III.2 were consistent with 
those observed in the IH-NMR spectrum of mycalamide A.135 Identical 
retention times for the mycalamide from the Callyspongia sample and 
authentic mycalamide on RPHPLC also supported the assignment. 
3.3.3 Isolation of Cytotoxic Components 
In addition to the antiviral components, the chromatography on the flash 
C-18 column yielded two cytotoxic portions, 1.4 and 1.6 (see Fig. 3.2.1). 
Partitioning of fraction 1.6 with the HSCCC method concentrated the 
cytotoxicity into a few fractions, which were combined to give fraction 
V.1. Further purification of V. r by LH -20 chromatography produced 
two active fractions. But, the specific cytotoxicity (mass (mg)IIC50 
(ng/mL) x 104) had decreased from 714 units (V.1) to 23 units 
(VI.4+ VI.5). After passing through a Diol column, the specific activity 
dropped to just 5 units (see Scheme 3.3.1). This was a significant loss of 
bioactivity in the course of the column chromatography. Because no acid 
was used in the above procedures, decomposition, or irreversible 
absorption of the active components on the stationary phase must have 
been responsible for the loss. 
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N 
Fig. 3.3.3 IH NMR (300 MHz) spectrum of fraction 111.2 from C. 
irregularis 
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The other cytotoxic fraction (104) was also explored for location of 
possible anti tumour compounds. Again the HSCCC method gave a good 
concentration of the bioactivity. However, a total loss of cytotoxicity 
resulted when a further purification was attempted by RPHPLC. This 
fraction did not contain mycalamide-like compounds as there was no 
antiviral activity in 104. The observed cytotoxicity must be due to another 
class of compound, that was sensitive either to acid or to the RPHPLC 
conditions. 
These attempted isolations confirmed that HSCCC is a good separation 
means, especially for dealing with trace amounts of bioactive components 
which are also unstable. Besides the antiviral compound, mycalamide A, 
the existence of some other class of cytotoxic components was implied. 
But, the latter group of compounds are sensitive to the regular isolation 
conditions. Any future studies on the Callyspongia sp. should bear these 
observations in mind. 
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3.4 Extraction and Separation of Compounds from 
Callyspongia sp.2 
The sponge was collected on the Chatham Rise at a depth of 40-150 
m by trawling. The shape and colour of the sponge are similar to C. 
irregularis. However, the initial bioassay exhibited only cytotoxic, but 
not anti-viral activity. A modified extraction and separation strategy was 
applied in dealing with this sample. 
The frozen sponge was blended and extracted with MeOH, MeOH/CH2Cb 
and CH2C12 in turn. The combined organic extract was dissolved in 
MeOH/H20 and partitioned against hexane. After removal of the 
methanol, the aqueous portion was partitioned against ethyl acetate. 
These three fractions were then each tested for cytotoxicity against the 
P388 cell line. The bioassay results (IC50 was 431 ng/mL) indicated that 
the activity was concentrated into the ethyl acetate extract, and no 
significant bioactivity was present in the aqueous or the hexane fractions. 
The ethyl acetate extract was chromatographed on a C18 column. The 
active fractions were combined for further study (see Fig. 3.4.1), The 
most active fraction displayed an IC50 of just 31 ng/mL. But, an HPLC 
analysis indicated that it was still a complex mixture. It was also found 
that the cytotoxic components were very "sticky" on the C-18 column, 
because not much activity was observed in any fractions until the column 
was stripped with MeOH. After passing through an LH-20 column, the 
IC50 of the most active fraction dropped further down to just 11 ng/mL. 
When a further purification of this fraction was attempted on a Diol 
column, most of the bioactivity was lost. The IH NMR spectrum of VI.3 
(see Scheme 3.4.1) showed three pairs of aromatic signals at 8 7.52, 7.68 
and 8.16, and several peaks between 8 3.2-4.4 as well as multiplets at 8 
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2.10 and 2.38. The active fraction probably contained structures related 
to polymeric pyridinium alkaloids. 
When another of the initial cytotoxic fractions (1.3) was separated on Diol 
followed by a C-18 column, a loss of bioactivity was again observed. It 
appears that decomposition of the active compounds accounted for the 
loss, because the decrease was found from both normal and reverse phase 
chromatographic procedures. 
However, in complete contrast when the Diol was used for the separation 
of one of the less active fractions (1.5), it worked well, since the specific 
cytotoxicity increased from 445 units to 5384. But, subsequent 
chromatography on a Lobar Diol column again resulted in the loss of 
cytotoxicity (specific unit = 636). This problem was probably caused by 
irreversible absorption by some contaminants in the stationary phase 
because the IC50 values were similar for fractions VII1.3 and IX.2 (see 
Scheme 3.4.1). Further purification of IX.2 yielded a cytotoxic fraction 
with an IC50<97.5 (X.1, in Scheme 3.4.1). In the IH NMR spectrum of 
X.l (Fig. 3.4.1), a singlet at (5 8.03, a doublet at (5 6.76, a doublet of 
doublets at (5 4.23 and a triplet at (5 3.77 were readily recognised. In 
addition, the 1 H NMR spectrum also showed other aromatic signals 
between (5 7.06 and 7.63, while the resonances between (5 3.40 and 4.20 
indicated the existence of hydroxyl, ether or amino groups. A broad 
triplet at (5 5.19 can be attributed to a vinyl proton. From these data, an 
aromatic moiety with polar functional groups (0 or N) was a possibility. 
The NMR spectrum also implied that this fraction was still a complex 
mixture. Due to limited amount of material available, this work was 
stopped. 
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Scheme 3.4.1 Bioassay-guided separation of the extract from 
CaUyspongia. sp.2 
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Fig. 3.4.1 IH NMR (300 MHz) spectrum of fraction X.1 from 
Callyspongia. sp. 2 
N 
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4.1 Introduction 
In studies on marine natural products it is rare to encounter several 
classes of compounds in one species with both interesting structures and 
biological activities. Theonella swinhoei (Theonellidae) and 
Lame llomorpha strongylata are two examples of this rare type of marine 
sponge. They both contain the cytotoxic compounds the swinholides and 
the theonellapeptolides, although these two organisms are classified into 
different sponge orders. 
Since the first paper in 1986, Kitagawa's group in Japan has isolated 
swinholide A and theonellapeptolides la, lb, Ie136, Id137, le l38 and IId139 
(44-49) from the Okinawan marine sponge Theonella swinhoei. 
Swinholide A is a potent cytotoxic dimer macrolide. Compounds 44-49 
were found to inhibit development of the fertilised eggs of the sea urchin 
Hemicentrotus pulcherrimus at 2, 2, 2, 50, 10 and 25 ~g/mL 
concentrations respectively.1 40 Later, another report indicated that 
theonellapeptolides lb, Ie, ld and Ie exhibited cytotoxicity against the 
L1210 cell line with IC50 values of 1.6, 1.3, 2.4 and 1.4 ~g/mL.136 In 
addition, theonellapeptolides ld and Ie showed ion-transporting activity 
for either Na+, K+, Ca2+, or Na+ and K+ ions.1 37 ,140,141 These 
peptolides are comprised of 1;3 amino acids. A high ratio of N-methyl 
amino acids and D-amino acids in the structures are characteristic of this 
group of compounds. Furthermore, the C-terminus in each of the 
theonellapeptolides forms an ester bond with the hydroxyl group of 
threonine, which results in a 37 membered-ring. Because the N-terminus 
of the peptolides is blocked by a methoxyacetyl group, and also because of 
the presence of p-alanine, the Edman method was not suitable for 
sequencing these peptolides. Of necessity, the sequences of the peptolides 
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were determined by multi-stepped partial hydrolyses. The absolute 
configurations of the chiral amino acids were determined via reverse 
phase HPLC chromatography, coupled with CD analysis. 
Previous research in bioactive marine natural products undertaken by the 
Marine Chemistry Group at the University of Canterbury had revealed 
that deep-water marine organisms are a very promising source of 
bioactive compounds.147 ,124,42 A well-known example is Lissodendoryx 
sp., which was collected using benthic dredging at a depth of 100m. This 
sponge yielded a series of very potent antineoplastic compounds, the 
halichondrins. To further explore the potential pharmaceutical resources 
of deep-water marine organisms, an expedition to the Chatham Rise, 200 
km off the East Coast of the South Island, was carried out in early 1995. 
Bioactivity screening of small scale (2g) extractions on 85 specimens 
yielded an incidence of cytotoxic and antimicrobial activity almost twice 
as high (37%) than average of the previous collections. These 
preliminary assays results confirmed that deep water organisms are a rich 
source of bioactive compounds.I 37 A sponge, Lamellomorpha 
strongylata, showing very potent cytotoxicity in the extracts was chosen 
for further chemical study. 
Dr Eric Dumdei carried out a bioassay-guided separation of 
Lamellomorpha strongylata from the Chatham Rise collection and isolated 
three distinct classes of cytotoxic compounds. The characterisation of 
calyculins A, B, E, and F, calyculinamides A and B, and swinholide H, 
which comprise two of the classes of cytotoxins from this sponge, have 
been previously reported. 118 This project focused on the purification and 
structure elucidation of the third class of cytotoxic compounds, the 
theonellapeptolides. 
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The frozen sponge was homogenised, extracted with NleOH:DCM (1:1) 
and subjected to chromatography on a variety of phases. A fraction from 
LH-20 chromatography showed weak P388 activity (ICso=25 l-lg/mL). 
Purification, by repeated RPHPLC, yielded five new active compounds, 
theonellapeptolides IlIa, IIIb, IIIe, IHd and HIe, in order of elution (see 
Section 4.2). 
This chapter deals with the structural elucidation of the major peptolide, 
theonellapeptolide IIIe (50). The remaining peptolides will be discussed 
in Chapter 5 and 6. 
N ~o~ I~O 
~ Me 
o 
o 
Theonellapeptolide lIIe (50) 
A new structural elucidation strategy, different from that reported 
previously, was adopted. It was chosen because it proved to be more 
efficient, less time consuming and more reliable. 
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The amino acid content of the peptolide was established by GCIMS, 
following the complete acid hydrolysis of the peptolide and derivatization 
of the hydrolysate. Next, the cyclic peptolide was methanolysed to yield a 
ring-opened peptide as the methyl ester, which was sequenced using FAB 
MSIMS analysis. Concurrently, a series of 1D and 2D NMR spectra were 
obtained. The NMR techniques, especially 2D TOCSY and HMBC, 
helped to distinguish between the isobaric amino acids, and constructed 
the sequence of the peptide. The ROESY spectrum offered more 
connectivity information, which was used to confirm the entire structure. 
Finally, the absolute configuration of the constituent amino acids were 
defined by X-ray crystallography, coupled with a chiral reverse phase 
HPLC method. 
Theonellapeptolide HIe (50), exhibited an MH+ ion at mJz 1419 in the 
LRFAB mass spectrum. The molecular formula C71H127N 13016 was 
determined by HRFABMS (m/z 1550.8577, [M+Cs]+, L1 -0.1). The 
peptidic nature of the fraction was indicated by both the 1 H NMR 
(doublets between 0 7.18-9.0) and the 13C NMR (resonances between 0 
169-176) spectra. A negative result against ninhydrin suggested that the 
N-terminus was blocked or part of a cyclic peptide, while the observation 
of a lactone carbonyl stretch (1734 cm- 1) in the IR spectrum, coupled 
with the unsaturation requirements of the molecular formula, indicated 
that 50 was most likely a peptolide rather than a peptide. As a result of 
searching the MarinLit17 database, the structural similarity of this new 
compound to the known theonellapeptolides was revealed. 136-140 
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4.2 Isolation of Theonellapeptolides from 
Lamellomorpha strongylata 
The P388 cytotoxic assay on the extract from this sponge showed an off-
scale activity [<97.5 x 10-6 dilution] in a preliminary assay. Chemical 
screening carried out by Dr Dumdei on the extract offered some useful 
information about the properties of the active components. Results from 
the Diol and C18 cartridges indicated a moderate polarity, while the PEl 
and CBA cartridges indicated weak anionic properties, and the LH-20 
column indicated a relatively large molecular size. 
To obtain sufficient material for chemical studies, a larger scale (1 kg) 
extraction was carried out using MeOH:DCM (1:1). After removal of the 
organic solvent, the aqueous fraction was acidified to pH 3 and extracted 
with EtOAc. The combined organic extracts were chromatographed on a 
C18 column. The activity was concentrated in the fractions eluting off 
the column between 80% and 100% MeOH. These active fractions were 
combined and subsequently loaded onto a Diol column, which was eluted 
in a step-gradient ranging from petroleum ether to methanol. The 
activity was found in the three bands that eluted with 50-30% petroleum 
ether in DCM. These three active fractions were each chromatographed 
on LH-20 using MeOH:DCM (1:1) as eluant to yield three distinct classes 
of cytotoxic compounds. Most of the biological activity was attributed to 
calyculins A, B, E, and F, calyculinamides A and B, and swinholide H, 
which comprised two of the classes of cytotoxins from this sponge. The 
structures of these compounds were characterised by Dr Dumdei. The 
third fraction, with weaker P388 activity (ICSO=25 ~g/mL), eluted just 
prior to the calyculinamides A and B, and comprised the peptolide 
fraction. 
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The active fractions from the LH-20 column on the crude peptolide 
mixture were combined. Final purification, by repeated RPHPLC of this 
combined fraction, yielded six cytotoxic compounds, named 
theonellapeptolides IIIa, IIIb, HIe, HId, IIIe and IIIf (Figure 4.2.1). IIIe 
was the major component, and comprised about 60% of the total peptide 
mixture. 
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4.3 Amino Acid Analysis by GelMS 
4.3.1 General Method 
Because the 1 H NMR spectrum indicated that theonellapeptolide lIle 
contained a high ratio of N-methyl amino acids, these amino acids needed 
to be identified with more care than the regular amino acids. For the past 
four decades, various chromatographic techniques, including paper 
chromatography (PC), thin-layer chromatography (TLC), 
electrophoresis, high performance liquid chromatography (HPLC), ion-
exchange chromatography (IEC) and gas chromatography (GC) have been 
developed for this purpose. The amino acids were identified in each of 
these methods through the retention data. The latter three techniques 
have been the most widely used. However, chromatographic methods 
alone are not suitable for identification of unusual or unknown amino 
acids in biological and extraterrestrial materials. This is because there is 
an absence of structural information. The combination of gas 
chromatography-mass spectrome,try (GC/MS) takes advantage of both the 
high separation efficiency of GC and the rich structural information from 
MS, and hence provides assurance on identification of any unexpected or 
novel amino acids. 
The free amino acids themselves are not volatile enough for GC/MS 
analysis. To increase the volatility of the amino acids, either one or both 
of the functional groups of the amino acids needs to be derivatised. 
Previous work has explored a wide range of derivatization methods. 
Typically, the amino groups can be acylated by CI-CS perfluorinated or 
non-fluorinated acid anhydrides. The carbonyl group can be derivatised 
as an ester by CI-CS alcohols, with or without a branch.94 Of the 
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possible combinations, N-trifluoroacetyl-n-butyl esters have been most 
widely used for GC/MS amino acid analysis. Based on both volatility and 
stability, the N-trifluoroacetyl-n-butyl ester (TAB) derivatives were 
chosen in this project. 
The fragmentation patterns for the TAB derivatives of all protein amino 
acids and two non-protein amino acids have been established. 143,144 The 
basic fragmentation pathways for these amino acid are depicted in Fig. 
4.3.1. 
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Fig. 4.3.1 Mass spectral fragmentation pathways of TAB a-amino acids 
For the aliphatic amino acids, such as glycine, alanine, valine, leucine, 
isoleucine, norleucine, a-aminobutyric acid, a-aminoisobutyric acid, 
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sarcosine and related N-methyl variants, cleavage C(. to the carbonyl group 
generates either the base peak or the second strongest peak (ion I). Other 
important fragmentations include cleavage of the bonds between the 
carbonyl carbon and ester oxygen (ion VII), Nand C(.-C in fragment I 
(ion IV), C(.-C and ~-C (ion IX and XI), ~-C and y-C (side chain of 
leucine), and loss of CF3 (ion II) and C4H9 from the side chain. 
In this group, leucine, isoleucine and norleucine have the same molecular 
weight. However, they can be distinguished by different fragmentation 
pathways of the side chain. For example, the loss of C3H 7 from the side 
chain of leucine and C4H9 from the side chain of isoleucine respectively 
are favoured, because secondary radicals are more stable than primary 
ones. Isoleucine eliminates a butoxy or butene group in conjunction with 
the cleavage between C2-C3 carbons, yielding higher intensities for the 
mlz 153 and 171 ions than do either leucine or norleucine. Similarly, the 
cleavage between the C3 and the C4 of leucine is preferred. This 
generates peaks at mlz 140 and 166 in conjunction with the loss of a 
butoxycarbonyl group or butanol. No major fragments, besides the M-
101 (M-COOC4H9), were found for norleucine. 
For hydroxy amino acids, both the amino and hydroxy groups were 
converted to trifluoroacetyl. The peaks at mlz 139 and 153 were 
observed as the major peaks in the mass spectra of serine and threonine 
respectively143. Also reported were intense mlz 138 and 152 peaks. 
These ions correspond to the loss of the hydroxycarbonyl group plus 
trifluoroacetic acid. For serine, a M-72 peak rather than a M-73 peak145 
was observed. This ion arises from a double hydrogen rearrangement 
from the ester portion of the molecule, resulting in elimination of a 
neutral fragment with the elemental composition of C4HgO.143 
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The important fragmentation pathways for ~-amino acids are summarised 
in Fig. 4.3.2. 
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Fig. 4.3.2 Mass spectral fragmentation pathways of TAB ~-amino acids 
~-amino acids usually give more intense molecular ions than a-amino 
acids. In contrast to a-amino acids, the fragmentation pathway yielding 
M-101 (M-COOC4H9, ion I) is not significant in ~-amino acids due to the 
additional methylene group between the carbonyl and the amide nitrogen. 
In fact, ~-amino acids give a relatively strong M-102 signal resulting 
from the loss of butoxycarbonyl and a hydrogen. The stability of this ion 
can be explained as: 
o 0 
II +. II + . 
CFa-C-N-C-CH ........ ~----,....,.. CFa-C-N=C-CH 
I I-I I I I 
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Comparing with a-amino acids, p-amino acids also show a more intense 
M-73 (M-OC4H9, ion VII). The intensity observed with p-amino acids 
can be attributed to the contribution of the following resonance 
structures: 
+ 
,.0: R-CH-C~ 
I 
R'-CH-N-C-CF3 
~" ~ 
.. 
... 0: 
R-CH-C'" 
I +1 
R'-CH-N-C-CF3 
I II 
R" 0 
For all N-methylated a- and p-amino acids, the peak at m/z 110 was 
considered a diagnostic signal due to its absence from the spectra of all 
non-N-methylated amino acids. This peak has an elemental composition 
C3H3NF3, but its origin is still unknown. 
4.3.2 Amino Acid Analysis of Theonellapeptolide HIe 
Theonellapeptolide IIIe was submitted to complete acid hydrolysis. The 
hydrolysate was converted to N-trifluoroacetyl n-butyl esters using a 
similar method to that reported.96 After a preliminary analysis by 
capillary GC, the derivatives were analysed by GCIMS using the same 
type of column. A total of ten main GC peaks were recognised (Fig. 
4.4.3). They were labelled in order of increasing retention time. 
Peak 1 exhibited a low intensity molecular ion at m/z 255. The peak at 
m/z 110 is characteristic of an N-methyl amino acid. Signals at m/z 154 
and 182 corresponded to the loss of butoxycarbonyl and a butyl group 
respectively. Thus, peak 1 was identified as N-methylalanine. 
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Fig.4.3.4 Mass spectral fragmentation of N-TFA-n-butyl ester of N-
methylalanine 
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In the mass spectrum of peak 2, the base peak was at mlz 140. This is a 
characteristic peak for alanine, sarcosine and N-methyl-~-alanine. The 
low intensity ion at mlz 110, co-occuring with the mlz 154 ion, implied 
contamination from N-methylalanine. This suggested that peak 2 is 
alanine, rather than sarcosine and N-methyl-~-a1anine. The ions at mlz 
168 and 186 arise from M-73 (C4H90) and M-55 (C4H7). The peak at 
mlz 126 can be attributed to ion III (Fig. 4.3.1). 
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Fig. 4.3.5 Mass spectral fragmentation of N-TFA-n-butyl ester of 
alanine 
Peak 3 was identified as valine by comparison of MS data with that 
reported by Leimer et al.1 43 In the spectra of both peak 3 and valine, the 
base peak at mlz 168 (I in Fig. 4.3.1), corresponding to cleavage a to the 
carbonyl carbon, was quite distinctive. The relatively strong mlz 153 ion 
was attributed to the elimination of an isopropyl grpup from mlz 196, 
which corresponded to the loss of butoxy (M-73). The ion at mlz 227 
arises from the loss of C3H6 from the side chain of the amino acid. 
However, the fragmentation mechanisms were not clear. 
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The major fragmentation patterns for peak 4, shown in Fig. 4.3.7, 
showed all the characteristics of an a-amino acid. The strong signal at 
m/z 182 corresponded to M-101 (ion I in Fig. 4.3.1), which then 
eliminated C4H8 from the side chain of the amino acid to yield the 
equivalent of structure III at m/z 126. The peak at m/z 171 was formed 
by loss of C4H8 from m/z 227, (cf. ion V in Fig. 4.3.1). Further 
examination led to the conclusion that the amino acid in question was 
isoleucine because of a relatively strong mlz 153. This ion corresponds to 
further elimination of a stable isobutyl group from the ion equivalent to 
VII. 
All the major signals in the spectrum of peak 5 (see Fig. 4.3.8) were 14 
mass units more than the corresponding fragments of isoleucine (Fig. 
4.3.7). 
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However, an m/z 110 ion was also observed. These data suggest that peak 
5 is N-methylisoleucine. The ion at m/z 224, which can be explained by 
structure (VII), lends support to this assignment. 
The mass spectrum of peak 6 (Fig. 4.3.9) displayed a similar 
fragmentation pattern to that for the N-TFA-n-butyl ester of N-
methylisoleucine, suggesting another N-methyl amino acid with the same 
molecular mass as peak 5. A relatively strong m/z 154 vs 140 ion implied 
an N-methylleucine structure. The strong m/z 154 ion can be explained 
by the loss of the isopropyl group from the ion I through cleavage of the 
bond between the C3 and C4 carbons, while the relatively low intensity of 
the m/z 140 ion is due to the loss of an unstable primary butyl group 
from ion I by cleavage of the bond between carbons 2 and 3 (see Fig. 
4.3.1). In this way, peak 6 was assigned to N-methylleucine. 
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Fig. 4.3.9 Mass spectral fragmentation of N-TFA-n-butyl ester of N-
methylleucine 
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The spectrum of peak 7 shows a molecular ion at mlz 255. The 
molecular mass was the same as that of N-methylalanine, but the 
fragmentation patterns are different. The base peak was observed at mlz 
154 in the former, but was at mlz 140 in the latter, a 14 mass unit 
difference. Apparently the most favoured cleavage was shifted by a CH2 
unit. This was consistent with the characteristic fragmentation pathway of 
p-amino acids. A strong M-102 at mlz 153 rather than 154, and the 
observation of an ion at mlz 110 confirmed this thinking. This amino 
acid was assigned as N-methyl-p-alanine. 
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Fig. 4.3.10 Mass spectral fragmentation of N-TFA-n-butyl ester of N-
me thy 1-p-alanine 
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Peak 8 was identified as the N-TFA-n-butyl ester of leucine based on the 
following analysis of the dominant fragmentation ions (see Fig. 4.3.11). 
The second strongest peak at m/z 182 in the spectrum was formed by 
cleavage a to the carbonyl carbon. The peak at M-101, due to the loss of 
C4H8, yielded the m/z 140 ion. Successive loss of C4H9, C3H7 and CF3 
from the molecular ion resulted in m/z 114. Ions at m/z 126, 153, 171 
and 227 can be explained by the structures III, VI, X and IX respectively 
(Fig. 4.3.1). 
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Fig. 4.3 .11 Mass spectral fragmentation of N-TFA-n-butyl ester of 
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A comparison of the mass spectrum with published MS data led to the 
identification of peak 9. There was a high correlation between published 
data for ~-alanine and peak 9 (Fig. 4.3.12), except for the ion at mlz 207. 
(Because this ion appeared in all spectra of the derivatives of the 
hydrolysate components, it was possibly a contaminant.) The major 
fragments, ions at mlz 116, 126, 139, 168 and 186, can be reasonably 
explained as M-CF3-CO-N=CH2, ~-cleavage of the amide nitrogen, M-
102, M-C4H90 and M-55. 
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Fig. 4.3.12 Mass spectral fragmentation of N-TFA-n-butyl ester of~­
alanine 
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The GC behaviour of the last amino acid derivative indicates that its 
polarity was much higher than others in the hydrolysate. Although a 
molecular ion could not be detected, the ions at m/z 281, 266 and 227 can 
potentially be assigned as arising from M-72, M-101 and M-140. This 
evidence, coupled with the very strong signal at m/z 153 and 152 
suggested that this peak corresponded to threonine. The cleavage between 
C2 and C3 accompanied by a hydrogen transfer to the carbonyl group 
would yield the ion m/z 227. Elimination of a stable secondary CF3-CO-
O-CH-CH3 radical in conjunction with the loss of C4H90 (m/z 73) 
accounts for the intense m/z 153. Ions at m/z 141, 179 and 198 can be 
attributed to cleavage ~ to the carbonyl carbon with the charge retained 
on the CF3-CO-O-CH-CH3 fragment, elimination of trifluoroacetic acid 
from M+ followed by the loss of butanol, and C4H7 respectively. 
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Fig. 4.3.13 Mass spectral fragmentation of N-TFA-n-butyl ester of 
threonine 
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Examination of the relative integral areas in the GC trace revealed that 
peaks 3, 5 and 6 each comprised two moles of amino acids. This result, 
coupled with the above mass spectral analysis, indicates that 
theonellapeptolide lIIe was comprised of 13 amino acids, which included 
alanine, N-methylalanine, ~-alanine, N-methyl-~-alanine, isoleucine, N-
methylisoleucine (x2), leucine, N-methylleucine (x2), threonine and 
valine (x2). 
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4.4 Sequencing the Ring-opened Peptide 
The amino-acid sequence plays a vital role in the structural studies of 
peptides. Sequencing methods, such as the Edman degradation, enzyme 
or acid partial hydrolysis, GC/MS and MS, have been developed. Of 
these, the Edman method is the best known and most widely applied. 
Several automated sequencers based on the Edman sequence are 
commercially available. However, some limitations of the method itself 
can result in the failure of sequential Edman degradation. This method 
can not be used when the N-terminus of the peptide is blocked or 
modified, or unusual amino acids are present. 
Because the theonellapeptolides contain ~-alanine moieties and have their 
N-termini blocked, they can not be sequenced by the Edman degradation. 
However, Kitagawa's group successfully sequenced six theonellapeptolides 
using partial hydrolysis in conjunction with MS and HPLC analysis. 
Their strategy was to separate fragments from partial acid hydrolysis by 
HPLC, and then to elucidate the structures of the fragments by MS and 
NMR. The larger fragments were submitted to repeated partial 
hydrolysis and spectral analysis, until the whole sequence was established. 
To sequence theonellapeptolide lIIe, the same method was tried. The 
peptide was hydrolysed with 30% trifluoroacetic acid (TFA) at 110°C for 
40 minutes. The hydrolysate was then analysed by both column 
chromatography and TLC. It transpired that only a very small 
proportion of the peptolide had been hydrolysed. To find better reaction 
conditions a series of experiments using different concentrations of HCI 
with varied reaction temperatures or reaction times were carried out. All 
hydrolysates were analysed by HPLC. It was found that most of the 
reactions produced more than ten fragments, but the starting material was 
Chapter Four-Theonellapeptolide IlIe 104 
the largest fraction. In order to clarify the situation, the fragments from 
one such reaction were analysed by FABMS. The spectra did not provide 
much information on the sequence, as the expected cleavages were not 
observed. The spectra were obscured by complex fragmentation. 
Considering both the time component (structural elucidation for one 
typical peptolide required separation and characterisation of 19 
fragments) and the sample cost, a different strategy was undertaken. 
Over the past decade, FABMSIMS has emerged as a powerful sequencing 
technique. This has gained more and more attention from both biologists 
and chemists. The advantage of FABMS over conventional techniques is 
that unusual and modified amino acid residues are readily identified. 
Mixtures containing several peptides are amenable to analysis, and since 
there is no requirement for a free N-terminus, cyclic peptides and N-
terminally blocked materials can also be characterised. The working 
principle of FABMS can be simply described. The sample molecule is 
dispersed in a matrix, and bombarded with either fast atoms or ions to 
cleave the molecular ion (or [M+H]+) and produce daughter ions, which 
are recorded by a detector. However, a number of steps may occur 
between those two types of ions. A daughter ion can possibly have more 
than one origin. The peptide can not be sequenced unambiguously by a 
single FABMS spectrum, because it offers little structurally significant 
information. This disadvantage can be remedied by tandem mass 
spectrometry (MS/MS). The MS/MS technique not only gives clues as to 
the relationship between precursor (parent) and product (daughter) ions, 
but also increases fragmentation abundance and eliminates the 
interferences from matrix fragmentation. 
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The possible fragmentation pathways of a peptide in F ABMS are outlined 
in Fig. 4.4.1. The nomenclature utilised in this manuscript for the amino 
acid sequence-determining fragment ions follows that proposed by 
Roepstorff and Fohlman 146. The three possible cleavage points of the 
peptide backbone are labelled A, Band C when the charge is retained on 
the N-terminus of the peptide, and X, Y and Z when the charge is 
retained on the C-terminus. The numbering (subscript i) indicates the 
peptide bond cleaved, counting from the N- or C-terminus respectively. 
The number of hydrogens transferred to or lost from the noted fragment 
are indicated by a corresponding number of primes placed to the right or 
left of the letter respectively. 
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Fig. 4.4.1 Nomenclature used for the amino acid sequence-determining 
fragment ions 
The peptolide lIIe, as such, was not directly suitable for FABMS/MS 
analysis. To make a suitable form for sequencing, the lactone bond of 
theonellapeptolide lIIe was hydrolysed with KOH. After purification on 
reverse phase HPLC, the major product, corresponding to a linear 
peptide, was submitted to FABMS analysis. Unfortunately, neither the 
(M + H)+ nor intense signals in the high mass range (mass value>600) 
could be recognised. There was not much information that could be 
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extracted. These problems probably resulted from a strong competition 
for ionisation or inhibition from salts 147,148. Because the linear peptide 
was generated from basic hydrolysis, a carboxylate anion probably 
existed. The anion would suppress the protonation of the molecule, hence 
causing a very low intensity of (M+H)+ to be observed. This assumption 
has been supported by observations from other researchers. 149,150,151 In 
the positive mode of F ABMS, basic peptides generally give good signals, 
whereas the acidic peptides sometimes can not be detected. 152 
To ascertain whether blocking the carboxylate group would improve the 
quality of the spectrum, the methyl ester of the ring-opened peptide was 
prepared by methanolysis of the peptolide with NaOCH3/CH30H. The 
hydrolysate was separated by RPHPLC and produced four fractions. 1 H 
NMR were obtained for all fractions. The major product (51) showed 
peptidic character. An NMR comparison with the starting material 
revealed that all amide protons and N-methyl protons had obvious shifts, 
and that a new methyl signal had appeared at (5 3.55, attributable to a 
methyl ester. HRFABMS gave the molecular formula C72H131017N13. 
This molecular mass was.3~ amu higher than theonellapeptolide lIIe, 
corresponding to addition of a CH30H to the parent. This result further 
confirmed the formation of the methyl ester. 
The low resolution FABMS spectrum ( Fig. 4.4.2) of the linear methyl 
ester provided much more information than that of the KOH hydrolysate. 
The highest-mass peak in the FAB spectrum, using glycerol as the matrix, 
was mlz 1451. This was assumed to be (M+H)+. In a spectrum using 
NOBA as the matrix, ions at mlz 1603, 1489 and 1473, which 
corresponded to M+23 (Na+), M+39 (K+) and M+153 (NOBA), were also 
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These ions helped to confirm that the IOn at mlz 1451 was indeed 
(M+H)+. 
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Fig. 4.4.2 FABMS spectrum of compound 51 
The first reasonably strong peak below rnJz 1451 (Fig. 4.4.2) appeared at 
mlz 1107, with a mass gap of 343 amu from the (M+H)+. This mass 
difference can be considered as loss of a fragment comprising three 
amino acids. From mlz 1107, the ions at mlz 1022, 895, 711, 584, 400, 
299 and 172 can be viewed as the loss of amino acid residues one by one 
or possibly two at a time, from mlz 1107. Similarly, the signals at mlz 
966, 867, 740, 669, 556, 429 and 344 can be attributed to the successive 
loss of one residue from the ion at mlz 1051. In the spectrum, the masses 
at mlz 184, 172, 127, 113, 101,85 and 71 implied the amino acid residues 
valine+N-methylalanine (or N-methyl-~-alanine) or leucine (or 
isoleucine)+alanine (or ~-alanine), valine+methoxyacetate (73 mu), N-
Chapter F our-Theonellapeptolide III e 108 
methylleucine (or N-methylisoleucine), threonine, N-methylalanine (or 
N-methyl-~-a1anine) and alanine (or ~-alanine) respectively. Combining 
these two sets of information with the amino acid analysis result, the 
peptide fragment 51a can be mapped out. This assumes that these 
fragments were formed by the loss of individual amino acid residues one 
by one from the (M+H)+ ion. 
(Melle) (MeA/a) 
CH30CH 2CO -- Va/ -- MeLeu -.- Thr --- Me-f3-Ala 
MeAla --- Melle -- lie -- f3Ala -- Melle -- Val 
(Mef3Ala) (MeLeu) (Leu) (Ala) (MeLeu) 
Fragment 51a of the ring-opened peptide (51) 
N.B. The amino acids in the parenthesis () may exchange with their isobaric residues. 
This temporary assignment needed further confirmation. The observed 
ions could have been generated from internal fragmentation or from 
different precursor ions. Furthermore, interfering peaks could have 
arisen from the matrix. In addition, some of the signals were very weak, 
which added more uncertainties to the assignments. To circumvent the 
uncertainties presented by the direct analysis of the FABMS spectrum, 
MS/MS techniques were used to obtain more information. A series of 
carefully selected fragments were scanned to establish the relationships 
between the precursor (parent ion) and the product (daughter ion) ions. 
Initially, the (M+H)+ at m/z 1451 was selected for tandem mass 
spectrometric analysis (Fig. 4.4.3). The fragmentation was anticipated to 
occur from both ends of the peptide. From one direction (N-terminus), 
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the ions at mlz 1451, 1279, 1152, 1051, 867, 740 and 556 were 
recognised. A second series of fragments including mlz 1451, 1291, 
1178,1107,1022,895,711 and 584 were traced from the C-terminus of 
the peptide chain. The peptide fragments Slb and Slc were mapped out 
based on these data. 
(Melle) (MeAla) 
CH 30CH 2 CO --- Val -- MeLeu -- Thr -- (Me(3Ala+Val] 
(3Ala Melle 
(Ala) (Me Leu) 
Peptide fragment 5Ib 
(CH30Ile) (lie) (!3Ala) (MeJ3Ala) (MeLeu) 
CH 3 0Leu---- Leu --- Ala --- MeAla -- Melle 
Melle ---- [lIe+J3Ala] 
(Me Leu) (Leu+Ala) 
Peptide fragment 5Ic 
N.B. The residues in parentheses [] were calculated from the difference of amu. 
The link scans yielded rich structural information on fragmentations in 
the high mass range, which was where the intensity of the signals from a 
normal scan are usually too low to be distinguished. Comparison of the 
peptide fragments Slb and Slc showed that the whole sequence of Slb 
and a part of Slc was overlapped with sequence Sla. There was a 
tripeptide segment with a mass of 342 in Slc which was missed in Sla. 
This tripeptide fitted the "mass gap" between Sla and the entire linear 
peptide. 
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Fig. 4.4.3 Link: scan for m/z 1451 
The ion at m/z 1107, one amu less than the ion generated by subtracting 
342 from the (M+H)+ ion, was attributed to either a cleavage 
accompanied by a one hydrogen transfer to the tripeptide part, or the C-
terminus carrying an additional H+ for protonation of the peptide 
molecule. Re-examination of Fig. 4.4.3 revealed that the mass gap 
corresponding to the loss of the first amino acid residue from the C-
terminus was 159, rather than 158. This corresponded to the fragment 
from N-methylleucine methyl ester. Since signals from the transfer of 
one or two hydrogens to the charged fragment are normally more 
abundant, the above observation strongly suggested that the N-
methylleucine at C-terminus carried one additional H. 
The verification of the composition of the tripeptide was accomplished by 
a link for the ion at m/z 344 (Fig. 4.4.4). The resultant daughter ions 
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included m/z 312, 284, 185 and 72, which can be reasonably explained by 
344-CH30H, followed by loss of CO, then 344-N-methylleucine methyl 
ester-leucine to release an alanine residue (mlz 72). The signals at mlz 
44, 86 and 100 (Fig. 4.4.4) corresponded to the immonium ions (R-
CH=NH+) of alanine, leucine and N-methylleucine. This offered more 
evidence for the existence of these amino acids. The ions at mlz 159 and 
160 can be assigned to Y I! and YIlt ions (cf. Fig 4.4.1), while the mlz 216 
ion probably arose from eliminating COOCH3 at the C-terminus and an 
alanine residue at the other end of the tripeptide accompanied by a two 
hydrogen transfer. 
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Fig. 4.4.4 Link scan for mlz 344 
A link scan for mlz 429 (Fig. 4.4.5) gave only a weak signal at mlz 344, 
but successive losses of N-methylleucine methyl ester (mlz 270), leucine 
(mlz 157) and alanine residues were observed to yield methylalanine (mlz 
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86) that can be recognised along with all the other immonium ions. 
Therefore, a tetrapeptide fragment was drawn out from the above 
assignments. The tetrapeptide structure not only makes up the missed C-
terminus in 51a, but also shows one residue overlapping with it. 
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The sequence at the N-terminus was confirmed by the following link 
scans. A link scan for the ion at mlz 299 (Fig. 4.4.6) gave rise to 
daughter ions at mlz 172 (strong) and 100. The ion at mlz 172 was 
assignable to Bl +COCH20CH3 (cf. Fig. 4.4.1), which loses the N-
terminal blocking group (COCH20CH3) to release a valine residue (plus 
one hydrogen) at mlz 100. The elimination of the N-terminal blocking 
group (72 mu) from mlz 299 was also rationalised by observation of a 
peak at mlz 227. The peaks at mlz 255 and 144 can be accounted for by 
mlz 299-C2H60 (from methoxy acetate) and 172-CO respectively. The 
fragment mlz 299 was also recognised as a daughter ion in a link from 
mlz 400 (Fig. 4.4.7). The peaks at mlz 270 and 229, found in the same 
spectrum, were assignable to A2 (cf. Fig 4.4.1) and Thr-MeLeu (or Thr-
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Melle) fragments. These each confinned that the threonine was the third 
residue from the N-terminus. Considering that the threonine was the only 
hydroxy amino acid in the component amino acids of HIe, it must fonn 
an ester bond with the carboxyl group of MeLeu at the C-terminus to 
produce a cyclic structure. From this, one can conclude that the side 
chain for the cyclic depsipeptide can be figured as MeLeu(Melle)-Val-
COCH20CH3. 
The remaining sequence between the threonine and N-methylalanine was 
clarified by the link experiments described below. A link for m/z 1107 
showed that the fragments m/z 1022, 895, 711, 584, 400 and 299 were 
formed from it, but other important peaks at m/z 782, 485 and 172, 
expected in structure of Sla, were of low abundance. Fortunately, a link 
for m/z 1022 picked up m/z 895, 782 and 711 ions at a reasonable 
intensity, although the intensity of m/z 485 was still very low. However, 
a link from m/z 711 gave a reasonably intense peak at m/z 485. Other 
daughter ions at m/z 584, 400, 299, 172 and 100 in this link confinned 
the existence of the major fragment, MeLeu-Val-Me~Ala-Thr-MeLeu­
Val-CO-CH20CH3, in the structure of Sla. 
Fragmentations from the other end of the big fragment were also 
observed. 
-171 -127 
711 "" 540 ,. 413 
Val·OAcOMe MeLeu 
·101 
Thr 
.127 ·85 
... 312 ----')10)10- 185 ... 100 
Melle p-MeAla 
These fragmentations corresponded to the loss of Val-COCH20CH3, 
MeLeu and Thr from the above fragment, then loss of Melle from the 
other end. A link from m/z 584 produced ions at m/z 485 (weak), 400, 
299, 185 and 100, which verified that m/z 485 was the daughter ion from 
m/z 584. 
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The same sequence was obtained by interpretation of the MSIMS spectra 
originating from the C-terminus fragmentations. Peaks at m/z 966 and 
669, which were expected in the fragmentation of 5Ib, did not show up 
in the spectrum of (M+H)+. However, m/z 966 was recognised as a 
daughter ion of 1051 in a link scan from m/z 1051. Other important 
daughter ions of 1051, such as 867,740 and 556 corresponding to Y8, Y7 
and Y 5 respectively (cf. Fig. 4.4.1), were also found in the same link. 
Again, there was no peak at m/z 669. In order to find the sequence of the 
dipeptide that comprised the sixth and seventh amino acids from C-
terminus, the ions at m/z 867 and 740 were scanned. Only a weak peak 
at m/z 669 was found in the spectrum of m/z 740. However, an ion at 
m/z 556 was readily recognised as the daughter for m/z 867, 740 and 669. 
These results provided indirect evidence for the assignment of leucine or 
isoleucine in the sixth and alanine or ~-alanine in the seventh position of 
the linear peptide (from the C-terminus). A strong peak at m/z 397, 
which arose from the loss of a tripeptide from the C-terminus, was 
observed in the spectrum of the ion at m/z 740. This implied that 
cleavage of the bond of Ile (or Leu)-~-Ala (or Ala) was not favourable. 
The same phenomenon was also observed when the peptide chain was 
sequenced from the N-terminus end. The ion at m/z 429 was clearly 
identified as a daughter ion of m/z 556 in the link scan for m/z 556. This 
suggested the loss of an N-methylleucine or N-methylisoleucine. The 
sequencing from m/z 1051, corresponding to the fourth residue in from 
the N-terminus, was accomplished. 
The entire sequence of the linear peptide can be assigned by putting all the 
above information together (see Fig. 4.4.8). The numbers on the 
structure represent the Bi and Yi (i= 1-13) ions, corresponding to 
sequencing from the C- and N-termini respectively. 
Chapter Four-Theonellapeptolide lIIe 
I 172----, : \r: o I I I I I 
MeoJi--N !..- N 
I H I 
, I 
I 0 I 
299----' 
I 
I 
I 
I 
I 
01 
I 
I :--~ 
I 
I 
I 
400--. 
, 
OHi 584---' 
I 
I 485-; 0: I I H ;/N~!N ,/ 
0 : I I : 
116 
~1152 
378 
0: 
t....-.1051 
i N~ 
: '- 86 711 
L-,.. 966 r-9--- ________ .1 
'---->- 1279 
m/z 160 -----; 
I 
o 
MeO 
556 ---, 
I 
I 
I 
NH 
740 
10 
I ~782 
I 
~1107 I I ~1022 
895 
Fig. 4.4.8 FABMSIMS fragmentation ions from both N- and 
C-terminus of the ring-opened peptide 
The cyclic structure of the peptolide was established by joining the 
hydroxy group of threonine with the carboxyl of the C-terminal N-
methylleucine, leading to the assignment of the peptolide as 50. 
However, the positions of the N-methylleucines, N-methylisoleucines, 
leucine, isoleucine, alanine, ~-alanine, N-methylalanine and N-methyl-~­
alanine may be replaced by their isobaric isomers respectively. To solve 
this problem, it was necessary to utilise NMR techniques 
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N-MeLeu---
Thr N-Mej3Ala Val N-Melle j3Ala 
I 
N-MeLeu 
I 
Leu Ala N-MeAla N-Melle lie 
The entire structure of theonellapeptolide lITe (50) 
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4.5 Structural Elucidation by NMR 
4.5.1 Strategy for Structure Elucidation by N~IR 
At this juncture, a tentative structure had been proposed for 
theonellapeptolide HIe. This was based on both amino acid analysis and 
sequencing of the ring-opened peptide. However, the position of some 
residues was still uncertain. This problem was solved by a detailed 
analysis of the various NNIR spectra. Extensive NMR techniques, 
including IH, IH-IH decoupling, l3C, DEPT, COSY, TOCSY, HSMQC, 
HMBC and ROESY, using different deuterium NMR solvents, were 
utilised to determine this complex structure. 
The assignment of the individual signals in the NMR spectra were assisted 
by the COSY and TOCSY data. Considering the relatively large number 
of carbon atoms and the complexity of the structure, overlaps were 
expected in 13 C NMR spectrum. In the end, carbon spectra were 
acquired in different solvents and the spectra were then compared in 
order to resolve the ambiguities. The DEPT (both 90° and 135°) spectra 
also provided useful information for this purpose, as well as determining 
the multiplicity of the carbons. The individual spin systems were 
recognised based on careful interpretation of COSY, TOCSY, HSMQC, 
HNIBC, ROESY as well as IH-IH decoupling spectra. This allowed the 
assignment of most proton signals. The linkages between the individual 
residues were established through two and three bond H-C correlations 
observed in the HMBC spectra, while observation of the nOe between 
protons in adjacent residues in the ROESY spectra provided more 
connectivity data. 
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4.5.2 Optimising the Conditions for NMR lVleasurement 
The molecular formula, determined by HRFABMS, indicated that 
theonellapeptolide HIe contained 127 hydrogen atoms and 71 carbons. 
So, heavily crowded 1 Hand 13C NMR spectra were expected. Therefore, 
high quality 1 Hand 13C NMR spectra were necessary for the 
unambiguous assignment of the structure. To achieve the best result, the 
optimisation of the NMR solvent was carried out by either changing the 
type of the deuterium solvent, or varying the ratio of the component 
solvents where solvent mixtures were used. Temperature effects on the 
overlap problem were also examined. 
Initially, deuterochloroform was used to acquire the 1 H NMR spectrum. 
Seven peaks between 8 6.7-8.8 were recognised, although a pair of peaks 
exhibited partial overlap due to line broadening. Five sharp singlets were 
found between 8 2.6-3.4. A 13C spectrum was acquired at 23°C, and 11 
signals were detected in the carbonyl carbon area (8 168-176) with two 
split peaks. The split peaks were presumed to arise as a consequence of 
the slow interchange between different conformations. When the probe 
temperature was increased to 45°C, the splitting either collapsed or 
decreased. Most of the peaks became sharper. This observation 
supported the assumption of slow interchanging between conformations. 
However, only 11 carbonyl resonances were distinguished rather than the 
expected 14. 
When 13% CD30D in CDC13 was used as the NMR solvent, the resolution 
in the N- and O-methyl regions was improved and a further methyl 
singlet was recognised. This improvement suggested that CD30D was a 
good modifier for this compound. Next, 100% CD30D was tested. As 
expected, the resultant spectrum was much better than those obtained 
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previously. In the downfield portion of the spectrum, all seven signals 
were well resolved as doublets. Seven methyl groups between 0 2.6 and 
3.4 were observed as very sharp singlets. At least seven pairs of doublets 
in the upfield range (0 0.78-1.44), as well as several other groups of 
isolated signals, were clearly defined. CD30D was an excellent solvent 
for the proton spectrum. A similar improvement was observed in the 13C 
spectra using this solvent. Fourteen signals were found between 0 170-
177. Sixty seven out of the total 71 carbons were distinguishable. Most 
of them were also quite sharp .. Unfortunately, slow exchange occurred 
between some of the exchangeable protons in the low field area and 
CD30D over a period of less than 90 minutes. Even after adding 10%-
20% of CDCb, the intensity of the exchangeable proton peaks still 
decreased quite obviously within two hours. This established that CD30D 
was not a suitable solvent for running more complex experiments, such as 
HMBC and ROESY, which usually require longer acquisition times. 
However, these spectra were still worthwhile as references to sort out 
overlaps in the spectra acquired in other solvents. 
To avoid the exchangeable proton problem, DMSO and d6-pyridine were 
examined as alternative solvents. In the DMSO spectrum, the peak 
patterns at low field became more complex. At the same time, peak-
broadening was remarkable in the other parts of the spectral range. 
These observations implied that the interchange among the conformations 
of the cyclic peptide was slowed in DMSO. For this reason, DMSO was 
not a good solvent to use. In contrast, the signals in most parts of the 
spectrum in pyridine-d6 were much sharper than those in DMSO. Three 
drops of H20 was used as a modifier in the pyridine. The resultant 
spectrum showed an improvement in the low field portion, but the 
Chapter Four-Theonellapeptolide fIle 121 
modification caused line broadening in other parts of the spectrum. It 
was concluded that this solvent was not worth modifying further. 
A review of the literature resulted in a reconsideration of the use of <4-
methanol. A low percentage of H20 in CD30D had frequently been used 
to acquire NMR spectra for proteins and polypeptides.153 In the case of 
theonellapeptolide lIIe, 10% H20 was used to suppress the deuterium 
exchange. The spectrum was then re-measured at six hour intervals. It 
was found that the peaks corresponding to the exchangeable protons were 
still distinguishable in the spectrum obtained after twelve hours at room 
temperature, and that the resolution of the spectrum was comparable to 
that obtained in CD30D. The drawback with this choice of solvent was 
the strong H20 peak that appeared at 8 4.7. This resonance disturbed 
other important resonances around it. These resonances corresponded to 
the a-protons of the amino acids. 
The last group of solvents tested for optimisation purposes was a mixture 
of d6-benzene and CD30D. This pair was selected on the assumption that 
methanol could improve the resolution of the signals, while addition of 
C6D6 would dilute the concentration of the exchangeable deuterium atoms 
in the solvent, effectively reducing the rate of exchange. With a 1: 1 
mixture of CD30D/C6D6, the results looked very encouraging. The 
resolution was still very satisfactory, especially in the low field portion, 
and the methyl resonance area. A series of spectra were next obtained 3, 
6, 12 and 72 hours after the sample had been prepared in this solvent 
system. The probe temperature was maintained at room temperature. 
There was no obvious decrease in the intensity of the active proton signals 
in the spectrum after three hours. The intensity of the peaks at 8 7.3 and 
7.5 decreased gradually after six hours. These two signals had 
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disappeared after 72 hours. When the ratio of CD30D was reduced to 
40%, the signal at 8 8.78 had diminished discernibly after four hours 
standing. A decrease in the rate of exchange was observed when the ratio 
was changed to 30% CD30D/C6D6. At this ratio, the resolution was still 
good, except that the two methyl signals around 8 3.2 were less well 
resolved. A further decrease in the percentage of methanol to 20% 
resulted in a further improvement of the methyl resonances, but caused a 
partial overlap for two signals at about 8 3.8 which had been well 
resolved previously in other solvent mixtures. The spectra were 
measured in this solvent at 0, 5 and 18 hours after sample preparation. 
The exchangeable protons lasted for 18 hours without obvious collapse. 
Reducing the ratio to just 10% CD30D/C6D6 caused greater overlap for 
the signals, while pure C6D6 turned out to be worse than the mixed 
solvent. After assessment of the data, a mixture containing 20% CD30D 
and 80% C6D6 was chosen as the NMR solvent for further spectral 
studies. This represented a balance between resolution and the lifetime of 
the exchangeable protons. However, if the sample stayed in the NMR 
tube for more than ten hours, it needed to be re-converted to the fully 
protonated form. This was accomplished by standing the sample in 
CH30H for more than six hours. 
4.5.3 Characteristics of the IH NMR Spectrum 
There were seven doublets in the down-field region of the IH NMR 
spectrum (see Fig. 4.5.1), The peak at 8 9.0 was broadened, but was 
clearly a doublet in the spectra with CD30D or 10% H20/CD30D as the 
solvent. These signals were assigned to seven amide protons. Between 8 
4.9 and 8 5.5, several multiplets heavily overlapped each other. From the 
integral values this group of peaks consisted of ten protons. They were 
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attributed to the a-protons of the· amino acid residues or the p-proton of 
threonine. The multiplicity can be accounted for by coupling from either 
the p-protons on the side chain or both the p- and amide protons. The 
resonances at 8 4.0-5.0 were due to the a-H in a-amino acids or the P-H 
in p-amino acids. A two proton singlet at 8 3.86 (which appeared as a 
doublet in the CD30D spectrum) indicated the existence of an isolated 
methylene group. This is a characteristic peak for methoxyacetate. The 
broad peaks at 8 3.53 and 8 3.73 were assigned to either a- or p-amino 
acids. The most distinctive characteristic features of this spectrum were 
the seven sharp singlets at 8 3.33, 3.30, 3.24, 3.19, 3.16, 2.75 and 2.69. 
These signals are typical of methyl groups attached to nitrogen or oxygen 
atoms. Since only six N-methyl amino acids were identified from the 
amino acid analysis, the seventh must be a methoxy group. At higher 
field in the spectrum, six pairs of doublets stand above complex 
multiplets. Normally, this is the aliphatic methyl area. The side chains of 
alanine, N-methylalanine, valine, leucine, N-methylleucine, isoleucine, N-
methylisoleucine and threonine are responsible for these doublets. The 
remaining 65 hydrogen atoms were crowded into the 80.8 to 2.6 range. 
The 13C NMR spectrum obtained in 20% CD30D/C6D6 showed 13 
signals between 8 169 and 176, while 14 were visible in CD30D. A 
comparison of these two spectra revealed that the peak at 8 172.5 was 
comprised of two carbon signals. These peaks arose from the carbonyl 
groups of the peptide bonds. The 14 carbonyl signals can be assigned to 
the 13 amino acids, and a methoxyacetate. Fifty two of the remaining 61 
carbons lay between 8 9-72. Of these, the resonances at 8 72.1 and 71.2 
were assigned to the carbons attached to oxygen. The DEPT data further 
distinguished the former resonance as CH2-0 and the latter as being due 
to CH-O. Since only one CH2 and one CH group were directly connected 
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to an ether and an ester oxygen respectively, the 8 72.1 signal was 
assigned to the ~-carbon of methoxyacetate, while 8 71.2 was assigned to 
the ~-carbon of threonine. Ten resonances, the a-carbons of a-amino 
acids or the methoxyl carbon, were found between 8 52 and 63. 
However, the spectrum measured in 10% H20/CD30D yielded 11 signals 
in that region, so at least two carbons were overlapped in 20% 
CD30D/C6D6. The DEPT spectrum confirmed that the resonance at 8 
59.0 arose from a methyl group which was assigned to the methoxyl of 
methoxyacetate. Furthermore, the signals at 8 45.4, 40.8, 38.8, 38.3, 
26.9,25.6 and 25.3 arose from the resonances of CH2 groups. The other 
resonances could not be readily assigned at this stage. 
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Fig. 4.5.1 IH NMR spectrum of theonellapeptolide HIe (50) 
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4.5.4 Assignment of the Spin Systems 
Theonellapeptolide lIIe consisted of 13 amino acids. Therefore, there 
should be at least the same number of spin systems present in the IH NMR 
spectrum. The spin systems of the seven amino acid residues with an 
amide hydrogen were traced from the amide proton, through the 
corresponding residue, by 2D TOCSY. Those with N-methyl groups 
turned out to be troublesome. It was necessary to examine all possible 
correlations and make careful comparisons with each spin system. 
In the 1 H NMR spectrum of lIIe, the most distinctive signal was a well 
isolated sharp singlet at 8 3.86. Unambiguous assignment of this signal 
was used as a firm base for further extension of the structure through the 
spectral analysis. Fortunately, the signal of its attached carbon (8c 72.1) 
was also readily recognisable in the HSMQC spectrum. Similarly, the 
methoxy proton signal (8 3.16) was located by looking at the cross peak 
from the carbon signal at 8 59.0. The HMBC spectrum revealed 
correlations from the methoxy protons to a methylene carbon, and from 
the methylene protons to the methoxy carbon, as well as to a carbonyl 
carbon (8 170.4). Thus, the methoxyacetate moiety was confirmed. 
Because the methylene proton showed cross peaks to the methoxy and an 
amide resonance at 8 7.45 in the ROESY spectrum, this partial structure 
was verified. 
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Fig. 4.5.2 HMBC and ROESY correlations of threonine residue 
The 2D TOCSY spectrum indicated that the amide proton at (5 9.0 was 
coupled to the signals at (5 5.47, 5.0 and 1.31. In turn, the HSMQC 
spectrum revealed that the proton at (5 5.47 was attached to the carbon at 
(5 71.2, assigned to the ~-carbon of threonine by the DEPT spectrum. 
Hence, the ~-H of the threonine was located. The proton at (5 5.0, 
attached to the carbon at (5 53.7 (HSMQC), can be placed in the (1.-
position. The resonance at (5 1.31 was also observed as a sharp doublet, 
and exhibited correlations to both of the (1.- and ~-carbons in the HMBC. 
The above data suggested a threonine residue (see Fig. 4.5.2). This 
segment was confirmed from the following correlations observed in the 
ROESY spectrum: NHlH2, NHlH3, H4IH3 and H4IH2. 
Chapter Four-Theonellapeptolide lIfe 
G :HMBC 
(-~"~ : ROESY 
Fig. 4.5.3 HMBC and ROESY correlations of allo-isoleucine residue 
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The amide proton at 8 8.76 was coupled to the resonances at 8 5.38, 1.75, 
1.38, 1.04 and 0.98 (2D TOCSY). Further examination of the TOCSY 
spectrum resulted in the observation of correlation peaks at 8 8.76, 1.75, 
1.55 (weak), 1.30, 1.18 and 0.98 from the 8 5.38 signal. In the COSY 
spectrum, the proton at 8 8.76 was coupled to a proton at 8 5.38, then that 
at 8 5.38 to 8 1.75, and then that at 8 1.75 to 8 1.22. The HSMQC 
spectrum showed that the 8 5.38 and 1.75 signals were methine protons, 
while the two protons at 8 1.55 and 1.22 attached to the same carbon at 8 
26.9. The HlVIBC spectrum showed the following cross peaks: H2/C3 and 
C4, H3/C2, C4, C5 and C6, H5/C3, C4 and C6 (see Fig. 4.5.3). 
Combining the above evidence yielded an isoleucine moiety. 
This partial structure was further defined by the ROESY spectrum 
(Figure 4.5.3). Observation of the correlation between NH and the 
methyl group at 8 0.98 implied that these two groups were close to each 
other in space. The correlations from H3 (8 1.75) to H2, H4 and H6 are 
indicative of its location at the ~-position of isoleucine. The two 
methylene protons, correlated to each other, showed correlations to H2. 
So, the second residue was identified as isoleucine. 
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Fig. 4.5.4 HMBC and ROESY correlations of leucine residue 
The TOCSY spectrum showed that the third amide signal (b 8.43) was 
coupled with resonances at b 5.15, 1.87, 1.34 and 0.99, while the proton 
at b 1.87 correlated with b 8.43, 5.15, 1.34, 1.04 and 0.98. The latter set 
confirmed that these signals all belonged to the same spin system. The 
HSMQC experiment revealed that the protons at b 1.87 and 1.34 both 
correlated to a carbon at b 40.8. This was confirmed as a secondary 
carbon by the DEPT spectrum. 
The HSMQC and DEPT spectrum identified two methine groups, b 
1.86/25.4 and 5.15/48.8. The latter was assigned as the a CH. Coupling 
observed between the protons at b 5.15 and 1.87, and 1.87 and 1.34 iIi the 
COSY spectrum suggested that b 1.87, and by implication the b 1.34 H, 
were related ~-protons. 
An HMBC experiment provided more correlations between NH and C 1, 
H2 and C3, H3 (bH 1.87) and C2, H3 and C4 (bC 25.4), as well as from 
both H5 (bH 1.04) and H6 (bH 0.98) of the terminal methyl groups to C3 
and C4 respectively. These data supported the assignment of the methine 
at b 1.86/25.4 to the y position of the amino acid. H2 exhibited a two 
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bond correlation to C3 at b 40.8. By gathering the information from 
these analyses together, a leucine fragment could be defined (Fig. 4.5.4). 
A ROESY experiment, which displayed a correlation between H4 and H5 
at b 1.86, added more assurance to the above assignment. Other 
con-elations observed in the ROESY spectrum included NHlH2, H21H3a, 
NH/H3b, H3a (b 1.87)/H3b (b 1.34) and H3/H6. All these observations 
are consistent with the structure of leucine. 
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Fig. 4.5.5 HMBC and ROESY correlations of valine (2) residue 
Correlation peaks from the NH at b 8.19 to protons at b 5.06, 2.06 and 
0.99 were observed in the 2D TOCSY spectrum. The COSY and HSMQC 
spectra revealed that the NH proton at b 8.19 was coupled to a methine 
(bR 5.06/bC 55.4), which in turn was further coupled to another methine 
(bR 2.06/bC 31.0) to which two methyl groups (bR 0.98/bC 18.3 and bR 
0.99/bC 19.7) were attached. A valine unit was deduced: it was assumed 
that these five groups of signals represented all the protons in the spin 
system. To obtain confirmatory evidence for this assumption, a trace at b 
5.06 in the TOCSY spectrum was examined. A new amide peak at b 7.45 
was observed along with the expected b 8.19 signal, as well as other odd 
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resonances. This result can not serve as confirmation, but did imply that 
another spin system contained a proton resonating at around 0 5.06. 
More evidence for the valine assignment was extracted from the HMBC 
spectrum. Correlations from the NH to C2 (first methine), H2 to C3 
(second methine) and the carbonyl carbon at 0 174.0, H3 to C2 and C4, 
and the two methyl protons to C3 provided enough information to 
confirm valine (Fig. 4.5.5). 
If further substantiation was necessary, this was provided by the 
observation of cross-peaks in the ROESY, such as NHlH2, H2IH3, H2IH4, 
H2/H5, H31H4 and H31H5. 
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Fig. 4.5.6 HMBC and ROESY correlations of valine (1) residue 
As noted above, there is more than one resonance at 0 5.06. The trace at 
OR 5.06 in the TOCSY spectrum had indicated correlations with an NH at 
o 7.45. From this, the NH signal correlations were observed to 0 5.03, 
2.01,0.98 and 0.91. The HSMQC and DEPT spectra indicated that 0 5.03 
and 2.01 were attached to different methine carbons (oe 54.5 and oe 32.1 
respectively); 0 0.98 and 0.91 were connected to primary carbons. In the 
COSY spectrum, coupling patterns were observed that were similar to the 
valine residue described previously. As two valines were found in the 
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amino acid analysis, assignment of this spin system to another valine 
residue fitted the amino acid analysis data. 
HMBC correlations from H2 to C3, and from the protons of the two 
terminal methyl groups to C3, were observed. Although a correlation 
from NH to C2 was not found, successive connection of all segments 
within a valine subunit could still be made through the observation of 
correlations to the same carbonyl (5e 170.4) from both NH and H2. 
Because the chemical shifts of most carbons and hydrogens in the two 
valine residues were very similar, unambiguous assignment of the 
structures was not straightforward. The proton at (5 5.03 was located by 
observation of the correlations from it to two carbonyls at (5 174.4 and 
170.4. The latter had been assigned to the methoxyacetate. As this 
segment was the blocking group at the N-terminus of the peptide, the 
corresponding valine can be assigned as the N-terminal amino acid, hence 
the residue was named valine 1. The first carbonyl group must therefore 
belong to valine 1. The proton at (5 5.06 for the other valine clearly 
correlated with the carbonyl carbons at (5 174.0 and 172.9. This residue 
was designated as valine 2. 
The signals from the four terminal methyl groups of these two valines 
gave a broad peak around (5 1.0. For valine 1, the starting point chosen 
was at H3 (5 2.01). This position had been established by correlation to 
C2 in the HMBC spectrum and confirmed through the ROESY 
correlations between H3 and H2 as well as H3 and the N-methyl signal at 
(5 3.19, which had been identified as a part of an adjacent amino acid 
residue. H3 also showed correlations to two primary carbons at (5 19.6 
and 17.6. In the HSMQC spectrum, these two carbons were found to be 
connected with the protons at (5 0.98 and 0.91 respectively. Further 
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evidence for this arrangement was obtained from the correlations between 
H3 and H4, as well as H5. In addition, the correlations between H2 and 
H4, and between the N-methyl protons and H4, provided more support. 
The key correlations in both of the HMBC and ROESY spectra were 
depicted in figure 4.5.6. Using the same strategy, H3 and the two methyl 
protons in valine 2 (see Fig. 4.5.5) were determined. 
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FigA.5.7 HMBC and ROESY correlations of p-alanine residue 
The spin system of the p-alanine residue NH at 0 7.65 was established by 
comparing two TOCSY traces which originated from either the NH at 0 
7.65 or the 03.53 H. It consisted of protons resonating at 0 4.54,3.53, 
2.69 and 2.51. The first two were part of a methylene system (0 35.8), as 
were the second pair (0 35.9, from analysis of HSMQC data). The 
existence of two adjacent methylene groups was consistent with a p-
alanine partial structure. The resonances at 0 4.54 (H3a) and 3.53 (H3b) 
were assigned to the p-methylene on the basis of chemical shifts. This 
designation was supported by the HMBC correlations: NHiCO (Oc 170.8), 
H3a/CO (oc 170.8), H3b/CO (Oc 170.8), H3a/CO (oc 172.5), H3b/CO 
(Oc 172.5) and H2/CO (Oc 172.5). The complete assignment is shown in 
Fig. 4.5.7. 
The last remaining unassigned amide proton (0 7.39) was attributed to 
alanine. In the TOCSY spectrum, this resonance correlated with 0 4.53 
and 1.29. The H/C relationship was established by HMBC. The HMBC 
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Fig. 4.5.8 HMBC and ROESY correlations of alanine residue 
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correlations from NH to C2 (OC 52.3), and H2 to C3 (OC 17.9) provided 
substantiating evidence for the proposed partial structure (see Figo4.5.8). 
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Fig. 4.5.9 HMBC and ROESY correlations of N-methylleucine(1) 
residue 
N-methylleucine (Fig. 4.5.9) was identified as follows: cross peaks from 
an a-hydrogen at 05.28 in the TOCSY spectrum included resonances at 0 
2.05, 1.48, 1.06 and 0.94. The absence of an amide signal at lower field 
in this array was indicative of an N-methyl amino acid. The C-H 
connections based on one bond C-H correlations in the HSMQC spectra 
included H (0 5.28)/C (oc 5604, CH), H ( 0 2.05) and H (0 1048)/C (oc 
38.0, CH2), H (0 1.48)/C (oc 25.9, CH), H (0 1.06)/C (Oc 24.1, CH3) and 
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H (0 0.94)/C (Oc 10.7, CH3). From these HSMQC data it was clear that 
the signal at 0 1.48 comprised 2 overlapped signals, as the signal 
correlated with a me thine carbon (0 25.9) and also with a methylene (8 
38.0) (DEPT). In the HMBC spectrum, this same proton (8 1.48) also 
showed correlations to the C2 at 8 56.4. Interpretation of the full set of 
HNIBC data for all protons and carbons in this spin-system (Fig. 4.5.9) 
allowed the assignment of an N-methylleucine moiety. The assignment of 
the terminal methyl groups initially relied on HMBC correlations from 
H4 to C6, then C6 to attached hydrogen atoms by HSMQC spectrum. The 
chemical shift assignment to H5 was by default after all other the carbons 
were located. 
H2 showed a three bond correlation in the HMBC spectrum to a carbon at 
8 31.9, which was found to be connected to a three proton singlet 
resonating at 8 3.19 (HSMQC). This methyl signal also correlated with 
the H4 and H5 signals in the ROESY spectrum. These analyses located the 
N-methyl group for this residue. The other ROESY correlations between 
H2 and H3, H3 and H4, H3 and H5, and H4 and H5 offered more support 
for the above assignment (see Fig 4.5.9). 
The structures and correlations found for the two N-methylisoleucines are 
depicted in Figures 4.5.10 and 4.5.11. They were named N-
methylisoleucine 1 (Mellel) and N-methylisoleucine 2 (Melle2) 
(counting from the N-terminus of the peptide). Because the majority of 
the protons in these two residues have similar chemical shifts, the 
assignments had to be made by frequent comparison of the data from 
different spectra. For example, the 2D TOCSY trace at 0 5.20 
corresponded to the a-proton of both Melle residues and showed cross 
peaks corresponding to the protons from both residues. In contrast, the 
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Fig. 4.5.10 HMBC and ROESY correlations of N-methylisoleucine(1) 
residue 
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Fig. 4.5.11 HMBC and ROESY correlations ofN-methylisoleucine(2) 
residue 
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trace for the resonance at 8 1.13 seemed to represent only the Melle1 spin 
system. However, the HSMQC spectrum revealed that the C and H 
chemical shifts for the methylenes and methines in both residues were 
very close. The proton at 8 1.13 was placed at C6 by observing the 
HMBC correlation to a carbon at 8 61.4, the a-carbon with its attached 
proton at 8 5.22 (HSMQC). This observation also established that this 
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moiety was an N-methylisoleucine residue rather than N-methylleucine. 
The position of the residue was located as both the H2 of Melle1 and the 
NH of ~-alanine correlate to the same carbonyl carbon at 8 170.8 in the 
HMBC spectrum. The other correlations from both H2 and H6 to C3, and 
from both H6 and HS to C4 helped to assign the entire moiety. The 
ROESY spectrum provided the verifying evidences from correlations: 
H21H6, H31H6, H3INCH3 (83.24) and H31H4. 
The highest field proton (8 0.78) in the IH NMR spectrum was assigned 
to C6 of MeIle2 based on the HMBC correlation to C2 at 8 SS.S. This 
was also characteristic of N-methylisoleucine. The HMBC correlations 
from H2, H6 and HS to the same carbon (833.8) allowed the location of 
the C3 position. The methylene proton at 8 1.42 correlated with C6 
(815.8) which allowed assignment of the C4 protons in Melle2 residue. 
The ROESY correlations between H4IHS and H31H6 helped to distinguish 
the two methyl groups. 
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Fig. 4.S.12 HMBC and ROESY correlations of N-methyl-~-alanine 
residue 
N-methyl-~-alanine was the hardest residue to delineate in the 2D 
TOCSY spectrum, because the signals were mixed with many others. The 
main signals at 8 4.S8, 2.72, 2.S1 and 2.30 were picked out from 
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interfering peaks. This was done by comparison with the TOCSY trace 
of ~-alanine. The correlations in an HSMQC experhnent revealed that the 
o 4.58 and 2.72 protons were part of a methylene system (045.4), and 
that another pair, 0 2.51 and 2.30, were attached to another methylene 
carbon (0 34.7). The methylene at 045.4 was assigned to the ~-position 
based on chemical shift arguments and the correlation from aN-methyl 
proton at 0 2.75 to 0 45.4 (HMBC spectrum). The big difference in 
chemical shift between these two protons was probably due to anisotropic 
shielding from the nearby carbonyl group. This assumes that the proton 
at 0 2.72 was lying in the shielding area. Correlations from the two (J.-
protons to the C3 and a carbonyl carbon at 0 172.9 were also observed in 
the HMBC spectrum. The ROESY correlations between these four 
protons further supported the assignment (see Fig. 4.5.12). 
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Fig. 4.5.13 HMBC and ROESY correlations of N-methylalanine 
residue 
An attempt to locate the N-methylalanine spin system in the 2D TOCSY 
spectrum failed as all the signals in this spin system were overlapped with 
others. A sharp doublet at 0 1.44 remained unidentified after assignment 
of the other residues. It was presumed to be the signal of the methyl 
group in N-methyl alanine, due to its relatively low field chemical shift. 
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Later, a decoupling experiment was utilised to verify this assumption. 
When the doublet was irradiated, multiplets around 8 5.20 were 
simplified. The doublet became a sharp singlet if the 8 5.20 signal was 
irradiated. Even though this was not confirmatory evidence, it definitely 
established a relationship between these two group of protons. 
The HSMQC experiment clearly showed that the proton at 8 1.44 was 
attached to a primary carbon at 8 15.0. In the HNIBC spectrum, this 
proton correlated to a methine carbon at 8 57.5, to which the proton 
resonating at 8 5.20 was assigned by HSMQC. This methine proton was 
in turn correlated to the methyl carbon. This confirmed the N-methyl 
alanine structure as only these two groups of protons were found in the 
spin system. The ROESY correlations between the side chain methyl 
group and H2, as well as with the N-methyl protons at 8 2.69, offered 
more connectivity information (see Fig. 4.5.13). These ROESY data 
allowed assignment of the N-methyl group at 8 2.69 to the N-
methylalanine residue. 
N-methylleucine (2) was another difficult residue. The difficulties were 
compounded by the low intensities of a resonance at 8 1.66, and two weak 
signals, compared with the main peaks at 8 2.05, 1.06 and 0.98, in a 2D 
TOCSY trace from 8 3.74. The H3 (8 2.05)/C (8 38.3) correlation in the 
HSMQC spectrum was hard to distinguish from H3-C3 of N-
methylleucine (1), while H2 at 8 3.74 did not show correlations to any 
carbon atoms in the HMBC spectrum. Assignment of H2, as the a-proton 
of the amino acid, was in doubt since it appeared at much higher field 
compared with the other amino acid residues. 
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Fig. 4.5.14 HMBC and ROESY correlations ofN-methylleucine 
residue (2) 
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The COSY spectrum showed that H2 was coupled with H3, but failed to 
identify any coupling from H3 to H4 (8 1.66). The linkage between these 
three groups of protons was deduced from two 1D TOCSY experiments 
by observing correlations between Ha and Hb, and between Hb and Hc 
respectively. Examination of the ROESY spectrum resulted in 
recognition of the following correlations: H2/NCH3 (8 3.30), H2/H5, 
H2/H3, H31H5, H4/H6, H4INCH3 (83.30) and H5INCH3 (8 3.30). These 
data provided enough information to construct a profile for the N-
methylleucine spin system. 
The HSMQC experiment indicated that H2 was connected to a methine at 
863.0. The HMBC spectrum showed that the N-methyl protons at 8 3.30 
correlated with this methine carbon. These correlations not only assigned 
H2 and the a-carbon, but also assigned the N-methyl group of the second 
N-methylleucine residue. 
Because there are at least five protons appearing in the region between 8 
2.01 and 2.05 region in IH NMR spectrum, the HMBC correlations 
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related to these protons were very complex. H3 showed a strong 
correlation to the a-carbon at (3 63.0, which confirmed that H3 was part 
of the second N-methylleucine. The correlation from H4 to a carbon at (3 
38.3, rather than (3 38.0, helped assign the former to N-methylleucine (2), 
and the latter to N-methylleucine (1). The correlation from both H5 and 
H6 to the same methylene carbon proved the location of this methylene 
group. The HMBC correlation from H3 to a carbonyl carbon at (3 172.3, 
which was also correlated to the ~-proton of threonine, was recognised. 
Therefore, the carbonyl carbon was assigned to N-methylleucine (2). The 
detailed assignment of the HMBC and ROESY data are given in Fig. 
4.5.14. 
4.5.5 Assembly of the subunits 
The 14 units were joined together based on a comprehensive analysis of 
the data from the HMBC and ROESY experiments. The HMBC analysis 
gave the linkages for all the above residues. The structure was then 
confirmed by the ROESY correlations. Because both H2 of valine (1) and 
the N-methyl proton of N-methylleucine (1) showed correlations to the 
carbonyl carbon of valine (1) in the HMBC spectrum, the second amino 
acid residue from the N-terminus was determined to be N-methylleucine 
(1). H2 of this residue correlated to its own carbonyl carbon at (3 172.8, 
which in turn was correlated to H2 of the threonine residue. These 
connections established the structure of the side chain of the entire 
peptolide, since threonine was the juncture point for the lactone ring. 
From this point, the linkage goes in both directions. 
H2 of threonine was also correlated to another carbonyl carbon at (3 
169.2, the threonine CO. The N-methyl protons of the N-Me-~-Ala 
crossed with the ~-C and with the threonine CO. This observation 
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allowed the extension of the chain to N-Me-~-Ala in one direction. 
Similarly, the NH of valine (2) correlated with the carbonyl carbon of N-
Me-~-Ala and its own a-carbon. An N-methyl proton at 0 3.24 showed 
correlations to the CO of Val2 and the a-C of Mellel. In addition, 
correlations from H2 of Melle1 to CO of both Val2 and Melle1 were 
recognised. The next residue assigned was the ~-Ala, by the correlation 
of the NH with the CO of Mellel. Correlations from both the NH and H2 
of He to the CO of ~-Ala confirmed that they were adjacent residues. In 
contrast, the linkage between lle and MeIle2 was constructed via the 
correlations from H2 and NCH3 of MeHe2 to CO of He. The H2 of N-
MeAla showed cross peaks to two carbonyl carbons, which had been 
assigned to N-MeAla and Melle2 respectively. Correlations from the NH 
of Ala to the CO of MeAla and C2 of Ala put Ala next to N-
methylalanine. The 12th amino acid residue was found to be Leu because 
the NH of its peptide bond showed correlations to the CO of Ala. The 
NCH3 of the N-methylleucine (2) correlated with the CO of Leu, which 
connected these two residues. Finally, observation of a three bond 
correlation from H3 of threonine to the CO of N-methylleucine 2, the C-
terminal amino acid, closed the 36 membered ring. All HMBC 
correlations are shown in Fig. 4.5.15. 
Supporting evidence was also derived from the ROESY correlations as 
follows H2 (Vall)/NCH3 (MeLeu1), NH (Thr)/H2 (MeLeu1), H2 
(Thr)/NCH3 (Me-~-Ala), NH (VaI2)/H2 (Me-~-Ala), NCH3 (MeIle1)1H2 
(VaI2), NH (~-Ala)/H2 (Melle1), NH (lle)/H2 (~-Ala), NCH3 
(MeIle2)/H2 and H3 (Ile), NCH3/H2 (MeIle2), NCH3 (MeAla)/H2 
(MeHe2), NCH31H2 (MeAla), NH (Ala)INH (Leu), NHJH2 and H3 (Leu), 
NCH3 (MeLeu2)/H2 (Leu) and NCH31H2 (MeLeu2). Complete details of 
all the ROESY correlations were shown in Fig. 4.5.16. 
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The complete assignment of the NMR data assembled for 
theonellapeptolide UIe has been summarised in Table 4.1. 
4.5.6 Conclusion 
The work to this juncture has described the entire planer structure of 
theonellapeptolide lIIe. It was now necessary to determine the relative 
and absolute stereochemistry of lIIe for both chemical and biological 
reasons. This problem was solved by X-ray crystallography, in 
conjunction with a chiral HPLC method. 
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Fig. 4.5.15 HMBC correlations of theonellapeptolide HIe (50) 
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Table 4.1. Correlated 1 Hand 13C Spectral Data for Theonellapeptolide lIIe (SO) 
(f' 
Amino acid 
(residlle#) I3C(# H)" I H (muit.J(Hz)jC HMBcd ROESye 
L-Yal (I) I 174.4 (0) 
2 54.5 (I) 5.03 (m) 174.4,170.4,32,1,19.6,17.6 3.19,2.01, 0.98 
3 32.1 (I) 2.01 (m) 54.5, j 9.6, 17.6 5.03,3.19.0.98,0.91 
4 17.6 (3) 0.91 19.6 5.03.2.01 
5 19.6(3) 0.98 17.6 5.03. 2.01, 
NH 7.45 (d. 9.3) 170.4 5.03, 3.86. 2.72. 0.98 
D-JV-MeLeu (2) I 172.8 (0) 
2 56,4 (l) 5.28 (m) 174,4, 172.8,38.0.31.9,25.9 9.0,8.19,2.05. 1.48 
3 38.0 (2) 2.05 (m) 56.4, 25.9 1.48. 0.94 
1,48 (m) 25.9, 56.4 5.28 
.( 25.9 (I) 1.48 (m) 24.1 3.19, 2.05. 0.94 
- 10.7 (3) 0.94 38.0, 25.9, 24.1 5.28. 3.19. 2.05, 1,48 ) 
6 21.4 (3) 1.06 38.0, 25.9 2.05 
NCli3 31.9 (3) 3.19 (s) 174.4. 56.4 5.Q3. 2.01. 1,48.0.98.0.94 
L-Thr (3) I 169.2 (0) 
2 53.7 (I) 5.00 (m) 172.S, 169.2, 18.2 7.65. 2.75. 1.31 
3 71.2 (I) 5.47 (dd, 8.7, 6.3) 172.3.53.7 7.65. 3.53. 2.75. 1.31 
4 18.2 (3) 1.31 (d. 6.3) 71.2, 53.7 5.47, 5.00 
NH 9.00 (d. 6) 5.47, 5.28. 5.00 
N-MeflAla (4) 1 172.9 (0) 
2 34.7 (2) 2.30 (m) 172.9,45.4 
2.51 (m) 172.9,45.4 8.19, 4.58, 2.30 
3 45.4 (2) 2.72 (m) 
NCH1 35.0 (3) 4.58 (~) 
34.7 2.72, 2.51.2.30 
2.75 (s 169.2.45.4 7.65.5.47.5.00.2.51 
D-Yal (5) 1 174.0 (0) 
'2 55.4 (I) 5.06 (m) 172.9. 174.0.31.0, 18.3 8.19, 3.24. 2.06, 0.99, 0.98 
3 31.0 (I) 2.06 (m) 55.4, 18.3 8.19,5.06,3.24,0.98 
.( 18.3 (3) 0.98 31.0 8.19, 5.06, 2.06 
5 19.7 (3) 0.99 31.0 
NH 8.19 (d. 8.7) 172.9.55.4 5.28 5.06. 2.5 I, 2.06, 0.98 
L-N-Melle (6) I 170.8 (0) 
2 61.4 (I) 5.22 (m) 174.0, 170.8,33.1,31.6. 16.1 7.65, 3.24, 2.29, 1.13 
3 33.1 (I) 2.29 (m) 3.24, 1.43, 1.13 
4 16.1(3) 1.13 (d, 6.3) 61.4,33.1,25.3 5.22, 2.29, 1.43 
5 25.3 (2) 1.43 (m) 2.29, 0.96 
6 21.8 (3) 0.96 25.3 
NCH, 31.6 (3) 3.24 (s) 174.0. 61.4 5.06. 2.29, 2.06 
p-Ala(7) 1 172.5 (0) 
2 35.9 (2) 2.51 (m) 172.5 8.76.5.47,3.53. 1.31 
2.69 (m) 8.76. 3.53 
3 35.8 (2) 3.53 (m) 172.5. 170.8 7.65,5.47,4.54,2.51 
4.54 (m) 172.5, 170.8 3.53, 2.69 
NH 7.65 (d. 5.4) 170.8 5.47, 5.22, 5.00. 4.54, 3.53 3.24 
D-alla-Ile (8) 1 175.9 (0) 
2 53.6 (1) 5.38 (m) 175.9, 172.5,38.8. 15.5 8.76. 3.33, 1.75, 1.55, 0.98 
3 38.8 (I) 1.75 (m) 53.6, 26.9, 15.5, 12.4 5.38, 3.33, 1.04, 0.98 
4 15.5 (3) 0.98 
5 26.9 (2) 1.22 (m) 53.6, 38.8, 15.5, 12.4 1.55 
1.55 (m) 53.6, 38.8, 12.4 5.58, 1.22, 1.04 
6 12.4 (3) 1.04 
NH 8.76 (d. 9.3) 172.5 5.38. 2.69 2.51, 0.98 
L-N-Jvlelle (9) 1 172.7 (0) 
2 55.5 (1) 5.18 (m) 175.9. 172.7.33.8,31.7,29.7 3.33. 2.69 
3 33.8 (I) 2.28 (m) 3.33. 0.78 
4 15.8 (3) 0.78 (d. 12) 55.5, 33.8, 25.6 2.69, 2.28, 1.42, 
5 25.6 (2) 1.42 (m) 15.8 0.82 
6 9.8 (3) 0.82 (dd, 9.6. 6.3) 33.8, 25.6 2.28, 1.42 
NCH'l 31.7 (3) 3.33 (s) 175.9.55.5 5.38 5.18. 2.28, 1.75 1.42 
L-N-MeAla (10) I 171.1 (0) 
2 57.5 (I) 5.20 (m) 172.7. 171.7. 29.7, 15.0 2.69, 1.44 
3 15.0 (3) 1.44 (d, 6.9) 171.1,57.5 5.20,2.69 
NCH, 29.7 (3) 2.69 (si 172.7, 57.5 5.20,5.18, 1.44,0.78 
L-Ala (II) 1 174.7 (0) 
2 52.3 (1) 4.51 (m) 174.7. 17.9 1.29 
3 17.9 (3) 1.29(d,7.5) 174.7.52.3 7.39,4.51 
NH 7.39 (d, 6.3) 171.1 52.3. 17.9 8.43. 4.51, 2.69. 1.29 
D-Leu (12) 1 174.9 (0) 
2 48.8 (I) 5.15 (m) 174.9.40.8 8.43. 3.30, 1.87 
3 40.8 (2) 1.34 (rn) 1.87. 0.98 
1.87 (m) 174.9,48.8, 25.4 8.43, 5.15. 1.34 
4 25.4 (I) 1.87 (m) 21.3 1.04, 0.98 
5 21.3 (3) 1.04 40.8. 25.4. 23.9 1.87 
6 23.9 (3) 0.98 40.8, 25.4, 21.3 
NH 8.43 (d, 8.4) 174.7.48.8 7.39,5.15, 1.87. 1.34 
D·N-MeLeu (13) I 172.3 (OJ 
2 63.0(1) 3.74 (m) 3.30, 2.05, 1.06 
3 38.3 (2) 2.05 (m) 172.3, 63.0, 25.6. 23.8. 22.5 3.74, 1.06, 0.98 
4 25.6 (I) 1.66 (m) 38.3, 23.8 3.30 
5 23.8 (3) 0.98 38.3 
6 22.5 (3) 1.06 38.3, 25.6 3.74, 2.05, 1.66 
NCH1 38.8 (3) 3.30 (s) 174.9 63.0 5.15 3.74, 1.66 
MeOCH2CO I 170.4 (0) 
2 72.1 (2l 3.86 (s) 170.4,59.0 7.45,3.16 
OCH3 59.0 (4) 3.16(5) 72.1 3.86 
a Referenced to residual solvent C6D6 oH==7.27. oc=128.4. h 13C spectra recorded on a Varian XL300 at 
7S MHz. Number of attached H determined by DEPT. c 1 H spectra recorded on a Varian UNlTY 300 at 300 
MHz. d Jnxh == 8.3, 5.0 arrayed mixing times. e A mixing time of 0.15s was used. 
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4.6 Stereochemistry 
4.6.1 Crystal Structure of Theonellapeptolide llle 
A colourless, needle-like crystal of theonellapeptolide lIIe 50 was 
obtained as a polyhydrate by slow evaporation of an acetone-water (l: 1) 
solution. Data reported here were derived from an irregular chunk of 
dimensions (0.6 x 0.4 x 0.15 mm). Crystal data: formula 
C71H 127 N 130 16/(H20 h 8, FW= 1418/(324); orthorhombic, P212121, 
a=12.507(3), b=19.573(4), c=41.416(8) A, V=10139 A3, Z=4, 
Rho=1.142. 
The data collection nominally covered a hemisphere. Intensities of 
18,590 unique reflections were collected on a Siemens SMART area 
detector system, fitted with a nitrogen low-temperature gas flow device, 
using MoKa (/,,=0.71071 A) X-radiation. These data were processed 
using the program SAINT which corrects for LP effects and crystal decay 
for the duration of the experiment. 
The structure was solved by direct methods, and refined using all the 
unique intensity data in the SHELXTL system of programs. The best 
converged conventional R-factor was 0.12 for 12,029 reflections with 
FO>4cr (Fo). All numerical data discussed here came from programs in 
the SHELXTL system as well as from the perspective diagram of the 
molecule (Fig. 4.6.1 and 4.6.2), which defines the atom labelling scheme 
used throughout this work. 
In addition to the theonellapeptolide molecule shown, there were at least 
21 sites for the oxygen atoms of water molecules, 14 of which were at 
distances appropriate for hydrogen bonding to electronegative 0 and N 
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Fig. 4.6.1 Perspective view of the crystal structure of 
theonellapeptolide lIIe (SO) 
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Fig. 4.6.2 Packing structure of theonellapeptolide lIIe (50) 
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atoms of the main molecule. The other seven participated in water-to-
water hydrogen bonding. These atomic displacement parameters were 
consistent with some disorder amongst these water molecules. Six sites, 
involved in inter-atomic distance interactions between 1.6 and 2.0 A, must 
be only partially occupied. These features hindered attainment of better 
conventional agreement factors. Nevertheless, the molecule of interest 
was fully characterised by this study. 
Figure 4.6.1 shows the crystal structure of 50 with intramolecular 
hydrogen bonds, as illustrated by the dotted lines. The cyclic 
tridecapeptide backbone of 50 should be considered to be quite flexible 
and the configuration of the cyclic part complex, because of the presence 
of D-amino acids and ~-alanine.154 
The X-ray coordinates were transferred to Chem3D to allow eaSIer 
viewing of the conformation. The cyclic part of the peptide folded into 
what is most easily described as a taco shell-like shape (Fig. 4.6.3), In 
this depiction, five carbonyl groups point to the internal cavity of the taco 
shell; all the N-methyl groups point down to the base of the taco shell, and 
the side chains of isoleucine, N-methylisoleucine and leucine protrude 
over the upper lips. The presence of a ~-Ala and an N-Me~Ala allow for 
considerable flexibility in the conformation of the cyclic peptolide ring. 
The shape of the molecule is best seen from the stereo diagram (Fig. 
4.6.4). 
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Fig. 4.6.3 Taco shell-like structure from side view of 
Theonellapeptolide IIIe (50) 
Fig. 4.6.4 Stereoprojection diagram of Theonellapeptolide IIIe (50) 
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4.6.2 Hydrogen Bonds and Secondary Structures 
In Figure 4.6.1, all of the carbonyl oxygens present in theonellapeptolide 
HIe are involved in hydrogen bonding, either through intramolecular or 
intermolecular interactions. Oxygens of the carbonyl groups, including 
02, 06, 09 and 013 (corresponding to 012, 08, 05 and 01 in Fig. 
4.6.5), are directed toward the centre of the macrocyclic peptide ring and 
are hydrogen bonded to the N6, N2, NIl and N9 (corresponding to N8, 
N12, N3 and N5 in Fig. 4.6.5) amide hydrogens respectively. The crystal 
was highly hydrated, and collapsed quickly when it was separated from 
the solvent. Most of the carbonyl oxygens are directed away from the 
peptide ring, and are involved in intermolecular hydrogen bonding with 
the hydrogen atoms of water. For example, 03 has hydrogen bonding 
with two moles, 04 with one mole, 05 with at least two moles, 07 with 
three moles, 08 with one mole, 010 with one mole, 012 with one mole, 
and 015 (these oxygens corresponded to 011, 010, 09, 07, 06, 04, 02 
and the methoxy group in Fig. 4.6.5) with one mole of water. In 
addition, N3, N4 and N13 (corresponding to NIl, NI0 and Nl in Fig. 
4.6.5) were also involved in intermolecular hydrogen bonding with water 
molecules. It was interesting to note that N3 and N4 associated with the 
same water molecule, which was also close to the carbonyl oxygen of 
MeIle2 (05). This implied that these three functional groups are 
reasonably close in space (see Table 1.5 in Appendix one). Apparently 
the conformation was stabilised by both intramolecular and 
intermolecular hydrogen bonding. 
The conformation of theonellapeptolide HIe can be considered as an 
antiparallel array of two strands, in which the turns are secured at one 
end by a ~-Ala (residue 4) and at the other by a cis-peptide bond [N-
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MeIle (residue 9)1N-MeAla (residue 10)]. The resulting conformation is 
a triple loop ,154 which is more clearly depicted in the backbone 
projection diagram (Fig. 4.6.5). The two major loops were defined by 
the two H-bonds between the allo-He and the Leu (residues Sand 12) 
which are a part of an antiparallel ~-pleated sheet structure. The third 
loop is defined by weak NH ... O associations from the NH of the ~-Ala 
(residue 7) to Thr (residue 3) and Me Leu (residue 13) {N7 - 01 [~-Ala 
(residue 7)-(Thr (residue 3), 3.2SA], N7 - 011 [~-Ala (residue 7)-(N-
MeLeu (residue 13), 3.31A]}. The portion of the peptide outside the 
macrocycle is static, being held in place by two H-bonds from Val 
(residue 5) to Thr (residue 3) and Val (residue 1). The Melle2 and Leu-
MeLeu2 sequences form an anti parallel ~-sheet structure, stabilised by 
two hydrogen bonds. The Vall-MeLeu1-Thr and Val2-Melle1 sequences 
form a parallel sheet, also stabilised by two hydrogen bonds. On the 
other hand, the Thr-Me~Ala-VaI2 sequence forms a loop, in which Me-~­
Ala is located at the "bend". The sequence also has a cis-MeAl a-Melle 
amide bond (C2_ 4-N4-C1_5-C2_5 torsion angle=14.9°). 
The previously reported theonellapeptolides I and II differ mainly in 
variation among the aliphatic side chains. For example, 
theonellapeptolide Ie,138 which has the same molecular formula as 50, 
has a similar peptolide backbone, but varies in the fifth, ninth, eleventh 
and thirteenth amino acid residues from the N-terminus, corresponding to 
substitutions of D-Val for D-Leu, L-N-Melle for L-N-MeVal, L-Ala for 
~-Ala, and D-N-MeLeu for D-N-Meallo-lle respectively. These 
modifications result in a 36-, rather than 37 -membered peptolide ring for 
50. An X-ray structure has been reported in a conference abstract155 for 
theonellapeptolide Id. Theonellapeptolide Id differs from Ie only in 
substitution of a ~-Ala for a N-Me~-Ala. Despite the difference in the 
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five amino acid substituents and the change in ring size, there is a quite 
remarkable similarity in the overall conformation and H-bonding patterns 
between theonellapeptolides HIe (50) and Id, which suggests that the 
theonellapeptolide family quite probably have similar tertiary structures. 
11 
- - H-bonds 
Fig. 4.6.5 Backbone projection diagram of Theonellapeptolide HIe (50) 
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4.6.3 Absolute Stereochemistry of Theonellapeptolide HIe 
Since it was possible to determine only the relative stereochemistry from 
the crystal structure, it was necessary to find the absolute configuration of 
the amino acids by an alternative method. Considering both the 
availability and the reliability of the method, a chiral HPLC analysis was 
adopted to achieve this. 
The principle of the method is based on the observation that the 
enantiomers of dansylated amino acids (Dns-Am) can be separated by 
reversed-phase high-performance liquid chromatography (RPHPLC) 
when a chiral metal complex was added to the mobile phase. The typical 
chiral additives include the L-proline-copper complex,156 the L-valine-
copper complex,157 the L-histidine-copper or L-histidine methyl ester-
copper complex,158 the N,N-di-n-propyl-L-alanine (L-DPA)-copper 
complex,159 and the N(p-toluenesulphonyl)-D-phenylglycine-copper 
complex,160 as well as the L-2-isopropyl-4-octyl-diethylenetriamine-zinc 
complex.1 61 In all instances, a ternary metal complex was formed 
between the added chiral metal complex and the enantiomers of the Dns-
Am (see Fig. 4.6.6). The difference in the solubility of the L- and D-
Dns-Am ternary complexes is the basis for the separation. This 
difference originates from steric effects in the interaction between the 
Fig. 4.6.6 Proposed structures of the ternary complexes of L-valine and 
D,L-isomers of dansylated amino acids with copper (II) 
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a-substituents of the Dns-Am, and parts of the molecule of the chiral 
ligand in the metal complex. 
In this project, the L-valine-Copper (II) complex was chosen as the chiral 
additive to the mobile phase. A sample of the peptide was completely 
hydrolysed with 6M HCI, and the hydrolysate derivatised with Dns-Am 
using the method of Weinstein and Weiner.158 The Dns-Am amino acid 
derivatives were submitted to RPHPLC analysis followed by a co-
injection of authentic Dns-L-Thr and Dns-DL-Thr. From these 
experiments, threonine present in the peptide was found to be S (L). 
Thus, from the relative stereochemistry obtained from the X-ray data, the 
configuration of the amino acids present were assigned as: L-Val, D-N-
MeLeu(1), L-Thr, D-Val, L-N-MeIle(1), D-allo-Ile, L-N-MeIle(2), L-N-
MeAla, L-Ala, D-Leu and D-N-MeLeu(2). The structures with all chiral 
centres at the a-carbon were depicted in Fig. 4.6.7. 
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Fig. 4.6.7 Stereochemistry of Theonellapeptolide HIe (50) 
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4.6.4 Conformational Analysis of Theonellapeptolide Ille 
in Solution 
Because signal splitting was observed in the 1 H NMR spectra in some 
solvents, e. g. DMSO, and in the 13C NMR spectra for all tested solvents, 
it was assumed that multiple conformers of this cyclic peptide existed in 
solution. In contrast, the 1 H NMR spectrum did not show the resonances 
from multi-conformers when using 20% CD30D/C6D6 as solvent. This 
implied either a quick interchange between the conformers or that one 
conformer was dominant in solution. 
The solution conformation of theonellapeptolide HIe was deduced from 
an analysis of the ROESY data (see Fig. 4.5.16) in conjunction with the 
X-ray data. Cross peaks of NH (Leu)/NH (Ala) and NH (Ala)/NCH3 
(MeAla) indicated that the N-H bond of Ala was either oriented parallel to 
the N -H bond of Leu and the N -CH3 bond of MeAla, or that these three 
functional groups pointed in same direction. The crystal structure (Fig. 
4.6.1) showed that the NH of Ala was in close proximity to both the NH 
(2.67 A) of Leu and the NCH3 (2.98 A) of MeAla; the dihedral angle for 
the two N-H and for N-H and N-CH3 was 30.9° and 91.4° respectively. 
These data were in agreement with the NMR data. The correlation 
between the NH of Val2 and MeLeu1 suggested that the ring tail folded 
to the Val2 part of the ring. The distance between NH (VaI2) and H2 
(MeLeul) in the solid state was 3.03 A which can reasonably explain their 
relationship. In the ROESY spectrum it is interesting to note the 
correlations of NH (~Ala)/H2 (Thr), NH (~Ala)/H3 (Thr), H3 (~Ala)/H3 
(Thr) , H2 (~Ala)/H3 (Thr) and H2 (~Ala)/H4 (Thr). The Thr and ~Ala 
are three residues away from each other. The correlations were 
attributed to folding of the peptide backbone, which led to these two 
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amino acid residues becoming closer in space. The proximity of these 
atoms was also evident in the crystal structure (see Fig. 4.6.1). The 
measured distances for the five pairs of protons on the ~Ala/Thr system 
were 3.59, 1.97, 2.78, 2.33 and 2.63 A. In addition, the terminal methyl 
and carbonyl groups of Thr were relatively close to the C2 of MeLeu2 in 
the crystal structure. This may also account for the abnormally high field 
chemical shift of the H2 of MeLeu2 in the 1 H NMR spectrum. It is 
possible that the H2 was shielded by these groups, especially from the CO 
group of Thr. 
A correlation from the NH of Vall to the H3 of Me~Ala was observed in 
o 
the ROESY spectrum. The distance between these two groups (4.85 A) is 
too great for efficient interaction. This observation probably arose from 
the free movement of the side chain in solution. 
The evidence from both the X-ray crystal structure and the NMR data 
suggested that the backbone of theonellapeptolide lIIe adopts. a ~imilar 
conformation in both the solid and solution phases. 
This complete structural assignment of theonellapeptolide lIIe provided a 
good model for studying the structures of the minor peptides isolated 
from the same sponge. These studies will be described in Chapters 5 and 
6. 
Chapter Five 
Cytotoxic 
Theonellapeptolide IIIb 
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5.1 Introduction 
To obtain enough material for the structural study of the minor peptides, 
a recollection of the sponge, Lamellomorpha strongylata, was carried out 
in April, 1996. A total of 12 kg of fresh sponge was obtained. The 
sponge (5.96 kg) was extracted by same procedure as described 
previously. The extract was further separated by bio-assay guided rounds 
of successive C18 and Diol chromatography. The peptide-containing 
fractions, located by both bio-assay results and NMR analysis, were 
combined to give a crude peptide portion. 
The peptide fraction was subjected to LH-20 chromatography to separate 
the peptides from remaining traces of swinholide and calyculin 
compounds, as well as lower molecular weight impurities. Next, silica 
gel flash chromatography was used to eliminate the remaining swinholide. 
Finally, semi-preparative reverse phase HPLC was used to separate the 
peptide mixture. A total of nine fractions were collected. 1 H NMR 
analysis indicated that seven of them contained peptide components. 
Fractions 2-6 were purified by repeated RPHPLC to yield the 
theonellapeptolides IlIa, b, c, d and e respectively. The seventh peptide 
eluted before lIIb. It was designated as lIIg, due to the failure to 
recognise it in previous analytical HPLC analysis. In this chapter, the 
detailed structural elucidation of theonellapeptolide IIIb, will be 
presented. 
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5.2 Characterisation of Theonellapeptolide 
IIIb 
Theonellapeptolide IIIb (52) was mildly cytotoxic against the P388 cell 
line (ICso 9.9 Ilg/mL). The structure was elucidated by the following 
procedure: an examination of the IH and I3C NMR spectra to recognise 
the peptide character; IR spectrum and ninhydrin test to gain insight into 
the properties of the N- and C-termini; amino acid analysis by GCIMS 
coupled with FAB MS/MS analysis of the ring-opened peptide for 
sequencing the peptide chain; TOCSY, DEPT, HSMQC and HMBC 
spectra to establish individual spin systems and identify the isobaric amino 
acid residues; detailed analysis of the HMBC data to obtain the linkage of 
the amino acid fragments and finally the complete assignment of 1 Hand 
I3C NMR resonances. 
Theonellapeptolide IIIb 52 
Theonellapeptolide IIIb (52), obtained as an amorphous powder, [a]D 
-49.10 (c=O.745, MeOH), showed an [M+H]+ ion at mlz 1377. High-
resolution FAB mass spectral data on the [M+Cs]+ yielded the molecular 
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formula C68H121016Nl3Cs (mlz 1508.8134, ~ +2.5 mu), indicating 15 
double bond equivalents. The difference of 42 amu from 
theonellapeptolide lIIe corresponds to a difference of C3H6. The 
peptolide nature of 52 was suggested by its I Hand 13C NMR spectra, 
showing seven amide NH, 13 amide carbonyl groups and one ester 
carbonyl group, as shown in Table 5.1. The 1 H NMR spectrum exhibited 
seven methyl singlets between 0 2.68 and 3.32, corresponding to the 
resonances of N- or O-methyl groups (see Fig. 5.2.1). The IR spectrum 
showed typical peptide bands at 3352, 1672, 1626, 1522 cm-1 and a 
lactone band at 1734 cm- I. Amino acid analysis, by GCIMS, identified 13 
amino acids. These accounted for 13 degrees of unsaturation, the 14th 
arising from a methoxyacetate group (observation of a singlet methylene 
signal at 0 3.84 in the 1 H NMR spectrum and an additional carbonyl 
group at 0 170.7 in I3C NMR spectrum). The 15th double bond 
equivalent was the lactone ring. No other elements of unsaturation were 
detected in the 1 Hand l3C NMR spectra. A negative result from the 
ninhydrin test suggested that the N-terminus of the peptide was blocked. 
Therefore, a theonellapeptolide skeleton was best established from the 
initial spectral data comparison with theonellapeptolide lIIe. 
Sequencing of the ring-opened peptide (methanolysis product) gave a 
similar arrangement of amino acid residues in lIIb, compared with lIIe, 
except for the replacement of an N-methylleucine (1) with N-
methylalanine. All seven amino acid spin system corresponding to those 
with free NH group were identified by tracing down the TOCSY 
correlation spectra as described earlier. The spin systems of the N-
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Fig. 5.2.1 lH NMR spectrum of theonellapeptolide IIIb (52) 
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methyl amino acids, except for N-methylalanine (1), were determined by 
comparison with the structure of lIIe, and by careful analysis of the 
TOCSY data for IIIb. Determination of the N-methylalanine (1) residue 
was not straightforward because the resonances overlapped with other 
residues, and there was no corresponding residue in IIIe. A comparison 
between the 1 H NMR spectra of IIIb and IIIe led to the recognition of an 
additional doublet at 8 1.36 in IIIb. This new signal was presumed to be 
the methyl resonance of N-methylalanine (1). 1 H_l H decoupling 
experiment were used to verify the assumption. When the signal at 8 1.36 
was irradiated, the multiplet around 8 5.12 sharpened, when the multiplet 
at 8 5.12 was irradiated, the doublet at 8 1.36 collapsed into a sharp 
singlet. These results confirmed the spin system of N-methylalanine (1). 
The connectivities of the individual amino acid residues were primarily 
established by HMBC analysis. The two bond correlations between NHfs 
and carbonyl carbons were readily recognised. Using these as the starting 
point, the relationships with adjacent N-methyl amino acids were 
determined by observation of the correlations to the same carbonyl 
carbon, both from the a-proton and from the N-methyl protons of the 
adjacent residue. Complete 1 Hand l3C NMR resonance assignments are 
summarised in Table 5.1. 
Chapter Five-The onellap ep to lide Ilib 165 
5.3 Amino acid analysis 
Theonellapeptolide IIIb was completely hydrolysed with 6M HCl, 
followed by derivatization. The N-TFA-n-butyl derivatives of the 
hydrolysate were subjected to GC and GCIMS analysis. Several unusual 
N-methyl amino acids were synthesised for identification purposes (see 
Experimental). The individual component amino acids were identified by 
comparison against the retention times of the standard amino acid 
derivatives and by interpretation of the MS spectra. The detailed GCIMS 
analysis was similar to that described in Section 4.4. A total of 13 amino 
acids were identified, including 2 x Val, 2 x N-MeAla, 2 x N-MeIle, 1 x 
N-MeLeu, 1 x Thr, 1 x Leu, 1 x Ile, 1 x Ala, 1 x ~-Ala and 1 x N-Me-~­
Ala. 
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5.4 Sequencing of the Ring-Opened Peptide 
Because theonellapeptolide IIIb (52) is a depsipeptide, the lactone ring 
can be opened by methanolysis to form the linear peptide methyl ester 53. 
The same hydrolysis procedure, used previously in Section 4.5, was 
adapted for this peptolide. After separation/purification of the 
hydrolysate by RPHPLC, the major product was subjected to F AB MSIMS 
analysis. 
LRFABMS showed an [M+H]+ ion at mlz 1409,32 amu higher than the 
intact peptolide, which corresponded to the methyl ester of the ring-
opened peptide. This also confirmed the methanolysis of the lactone, 
rather than hydrolysis to a free carboxylic acid moiety, which would have 
afforded an increase in mass of 14 amu. 
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The collision activated decomposition (CAD) mass spectrum of compound 
53 produced two series of the ions: (a) m/z 1066, 981, 854, 741, 670, 
543, 358, 257 and 172; (b) 1238, 1153, 1052, 967, 868, 741, 556 and 429 
(Fig.5A.l). On the supposition that these ions had been formed by either 
B or Y type fragmentation, the peptide fragments 53a and 53b were 
mapped out from these data. 
(Me[3Ala) 
MeAla --
(Me Leu) (Leu) (Ala) (MeLeu) 
Melle - lie - I3-Ala -- Melle -- Val 
CH30CH2CO -- Val -- MeAla -- Thr ---Me-[3-Ala 
Peptide fragment 53a 
(Me-[3-Ala) 
MeAla Val--
(Me-[3-Ala) (MeAla) 
(MeAla) (MeLeu) 
Thr -- [Me[3Ala+Val] - Melle 
MeAla -- Melle --- Ile--
(Leu) 
[3-Ala 
(Ala) (Me-[3-Ala) (MeLeu) 
Peptide fragment 53b 
Comparison of fragment 53a with 53b indicated that fragment 53 b 
corresponded to elimination of a methoxyl-acetate valine moiety (171 
amu) from 53a. Fragment 53a showed a 344 amu difference from the 
intact peptide 53, which corresponded to a tripeptide segment. The 
postulated fragments were further confirmed by MS/MS analysis of the 
selected parent ions, which provided more connectivity information. 
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A link scan from m/z 344 (Fig. 5.4.2) gave the same daughter ions as 
those from scanning the same mass in theonellapeptolide HIe (see Fig. 
4.4.4), which suggested that HIb contains the same tripeptide fragment at 
its C-terminus, i.e., CH30-Leu-Leu-Ala. An intense 344-32 signal 
(CH30H) confirmed that the tripeptide was the C-terminal fragment. 
The N-terminal sequence of the linear peptide was confirmed as follows. 
Peaks at m/z 340, 257, 187 and 172 were daughter ions of m/z 358 (Fig. 
5.4.3). These were formed by the successive loss of H20, Thr, 
CH30CH2CO-Val and Thr-N-MeAla fragments from the parent ion. It 
was important to note that the m/z 257 ion arose from m/z 357 by 
elimination of a threonine residue. When the m/z 257 ion was scanned, 
strong m/z 172 and medium intensity of m/z 100 signals were observed 
(Fig. 5.4.4). These ions arose from elimination of a N-methylalanine 
followed by elimination of the methoxyl acetate from the N-terminus. 
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The CAD spectrum of mlz 257 also produced immonium ions of N-
methylalanine, or N-methyl-~-alanine (mlz 58) and valine (mlz 72). The 
presence of these amino acids established the side chain of the cyclic 
peptolide as CH30CH2CO-Val-N-MeAla (or N-Me-~-Ala). 
The daughter ion spectrum from the ion at mlz 1237 ion (Fig. 5.4.5) 
revealed ions at mlz 1051, 966, 867, 740, 669 and 556 which were 
assigned as [Me~Ala-Val-MeIle-~Ala-Ile-MeIle-Ala-Leu-MeLeuOCH3]+, 
[Val-MeIle-~Ala-Ile-MeIle-Ala-Leu-MeLeuOCH3]+, [MeIle-~Ala-I1e­
MeIle-Ala-Leu-MeLeuOCH3]+, [~Ala-Ile-MeIle-Ala-Leu-MeLeuOCH3]+, 
[Ile-MeIle-Ala-Leu-MeLeuOCH3]+ and [MeIle-Ala-Leu-MeLeuOCH3]+ 
fragments respectively. Besides extending the peptide chain from the N-
terminus to the C-terminus, this series of ions also suggested that N-
methylalanine was adjacent to threonine, ~-alanine to N-methylisoleucine 
(1), and the ~-alanine was followed by isoleucine. 
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Fig. 5.4.5 Link scan at mlz 1237 
Chapter Five-Theonellapeptolide [lIb 171 
In this sequence deduced from the FABMS spectrum of compound 53, 
two common ions at mil 740 and 669 should be formed by cleavage from 
either the N - or C-terminus (the Yi and Bi ion series, respectively). 
Confirmation of the origin of these two ions would help verify the 
sequence. Since mil 740 and 669 had been found as the daughter ions 
from the mil 1237 ion, which had resulted from loss of the N-terminal 
methoxyacetate and valine, the origin from the C-terminal cleavage can 
be deduced by link: scans at mil 1065, 853 and 669 ions. 
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Fig. 5.4.6 Link scan at mil 853 
Link scans from the mil 1065 ion gave abundant daughter ion signals at 
mil 980, 669 and 257, as well as a reasonably intense mil 358 ion, which 
can be attributed to Bg, B6, B2 and B3 ions. However, the intensities of 
some expected daughter ions at mil 853, 740, 542 and 443 were too low 
to afford sufficient evidence for the proposed sequence. Fortunately, ions 
at mil 740 and 542 were picked up from the link: spectrum at mil 853 
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(Fig. 5.4.6). Although the mlz 740 ion was weak, the appearance was that 
of a true signal. In addition, scanning the ion at mlz 669 yielded m/z 542, 
443, 358 and 257 ions, which complemented the suggested sequence. 
Thus, sequencing the linear peptide from both the N - and C-termini was 
accomplished with the same result. The important Bi and Yi ions and the 
intact sequence of compound 53 are depicted in Fig. 5.4.9. 
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Fig. 5.4.9 FAB MS/MS fragmentation of compound 53 
Because only one hydroxy amino acid was recognised from the GC/MS 
analysis and by NMR spectra, the lactone ring must be closed by an ester 
linkage between the carboxyl group of the C-terminal residue and the 
hydroxyl group of threonine. So, the structure of the intact peptolide can 
be deduced as 52 (Fig. 5.4.10). However, all the amino acids that are 
isobaric are exchangeable. Detailed lD and 2D NMR analysis was now 
necessary to resolve these ambiguities. 
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N-MeAla --- Val -- co - CH20CH3 
Thr---- N-Mej3Ala --- Val ---- N-Melle --- j3Ala 
I 
N-MeLeu 
I 
Leu ---- Ala ---- N-MeAla --- N-Melle ---- lie 
Intact sequence of theonellapeptolide IIIb (52) 
N.B. Alanine and ~-Alanine, N-methylalanine and N-methyl-~-alanine, N-
methylleucine, and N-methylisoleucine and N-methyl-allo-isoleucine, leucine, isoleucine 
and allo-isoleucine are isobaric isomers and their position are exchangeable. 
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5.5 Complete Assignment of the Structure of 
Theonellapeptolide IIIb 
The assigned chemical shifts and coupling constants of theonellapeptolide 
Illb are given in Table 5.1. Seven amide protons were detected at 0 9.05 
(lH, br d, l=ca. 6.3 Hz), 8.76 (lH, d, 1=8.4 Hz), 8.40 (lH, d, 1=8.4 Hz), 
8.07 (lH, d, 1=8.1 Hz), 7.64 (lH, d, 1=6.6 Hz), 7.49 (lH, d, 1=9.3Hz) and 
7.32 (lH, d, 1=5.7 Hz) in the IH NMR spectrum. Six N-methyl and one 
O-methyl groups were found at 0 3.32.3.25,3.18,3.14,2.79 and 2.68 as 
sharp singlets. The signal at 0 3.18 was again assigned to a methoxyl 
group because of its attachment to a quaternary carbon at 0 59.2 (HSMQC 
and DEPT analysis). The assignments of the spin systems corresponding 
to the individual amino acid residues were established from either the 
analysis of TOCSY spectra, or comparison with the spectral data of 
theonellapeptolide lIIe, and confirmed by detailed analysis of the DEPT, 
HSMQC, HMBC and ROESY spectra, as well as lH-lH decoupling 
experiments. 
The methylene protons of the methoxyl acetate of IlIb appeared as an 
isolated singlet at 0 3.84 in the 1 H NMR spectrum, and showed 
correlations to both its own carbonyl carbon (0 170.7) and a methoxyl 
carbon in the HNIBC spectrum. This was virtually identical to the 
behaviour of lIIe. At the same time, a correlation from the methoxyl 
protons to the methylene carbon (0 72.0) were also observed. This 
assignment provided a firm starting point and allowed the N-terminal 
residue to be located in turn. 
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Fig. 5.5.1 Selected HMBC and ROESY correlations of Vall 
The partial structure of valine 1 is shown in Fig. 5.5.1. In the TOCSY 
spectrum, the amide proton of Vall, coupled with signals at 8 4.99, 2.06, 
1.01 and 0.94, had been defined as the N-terminal residue by the 
observation of two bond correlations to the methoxy acetyl carbonyl and 
to its own a-carbon (8 54.6). Since the a-proton at 8 4.99 was correlated 
with two c;arbonyl carbons at 170.7 and 173.9, the latter signal was 
assigned as the carbonyl carbon of Vall. The correlations between CH2 
(methoxyl acetate)/NH, CH21H2, NH/H2 and H2/H3 in the ROESY 
spectrum confirmed the moiety. 
~ :HMBC 
.... -...... , 
{ '~: ROESY 
Fig. 5.5.2 Selected HMBC and ROESY correlations of Val2 
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The second valine residue (Fig. 5.5.2) was recognised by the correlations 
to 8 4.98, 2.0, 0.91 and 0.98 from the amide proton at 8 8.07 in the 
TOCSY spectrum. Both the NH and the aH were correlated with the 
same carbonyl carbon at 8 173.3, but the aH was also correlated to a 
second carbonyl carbon at 8 174.1. This latter peak was assigned to Va12. 
The ~-carbon was located by observation of the one bond H-C coupling in 
the HSMQC spectrum. One of the side chain methyl groups was 
characterised by a two bond correlation from the methyl proton to this ~­
carbon, and a correlation from the ~H to a primary carbon at high field 
(8 19.6) provided evidence for the other methyl group of valine. All 
individual protons were located from the HMBC data coupled with 
analysis of the HSMQC spectrum, and verified by ROESY correlations. 
Fig. 5.5.3 Selected HMBC and ROESY correlations of Thr 
The next residue examined was threonine. In the TOCSY spectrum, 
threonine gave a very distinctive trace. Differentiation between the H2 
and the H3 was achieved by comparison of two pairs of one bond H-C 
coupling in the HSMQC spectrum. Since a proton at 8 5.45 was coupled 
to an oxygen-bearing carbon at 870.8, a typical value for the ~-carbon of 
threonine, the other H/C (8 4.95/53.5) pair can be placed at the a-
position. The carbonyl carbon of threonine was located by correlations 
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both from its own <x-proton and from the protons of the adjacent residue 
(see Fig. 5.5.3). 
o 
Fig. 5.5.4 Selected HMBC and ROESY correlations of ~-Ala 
For assignment of ~-alanine it was noted in the TOCSY spectrum that the 
NH at 0 7.64 was coupled with signals at 0 4.55, 3.42, 2.69 and 2.40. 
These four protons were part of two methylene groups (HSMQC 
spectrum), which suggested a ~-alanine residue. The ROESY cross peaks 
of H31H3, H3/NH and H21H3 established their relative positions within the 
residue. In the HMBC spectrum, correlations were observed to the 
carbonyl of ~-alanine (0 172.8). The same carbonyl group was also 
correlated with the H2 of the neighbouring residue. 
. , 
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Fig. 5.5.5 Selected HMBC and ROESY correlations of He 
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The deduced partial structure of isoleucine is shown in Fig. 5.5.5. In this 
case the NH did not show correlations with other protons in the spin 
system by TOCSY. However, when tracing from the ~-proton at (5 1.73, 
all cross peaks except the NH in TOCSY spectrum were found. In the 
HMBC spectrum, the a-proton showed correlations to the carbonyl of ~­
Ala, its own carbonyl ((5 175.9), the ~-carbon and a methyl carbon. The 
last correlation was also good evidence for an isoleucine residue. Two 
protons in the spin system with different chemical shifts ((5 1.18, 1048) 
were assigned to a methylene (HSMQC spectrum). The assignment for 
the protons was confirmed by the ROESY correlations (see Table 5.1). 
o 
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Fig. 5.5.6 Selected HMBC and ROESY correlations of Ala 
The spin system of alanine was readily recognised in the TOCSY 
spectrum because the same AMX system was delineated from both the 
amide proton at (5 7.32 and the a-proton at (5 4048. In the HMBC 
spectrum a two bond correlation to a carbonyl from both the a-proton 
and an amide proton at (5 8040 assigned the carbonyl to alanine. The NH 
of Ala ((5 7.32) was coupled to carbonyl of the adjacent residue ((5 171.3), 
Chapter Five-Theonellapeptolide !lIb 179 
o 
f\ :HMBC 
, ............ , 
/ ',: ROESY 
Fig. 5.5.7 Selected HMBC and ROESY correlations of Leu 
In the TOCSY spectrum, correlations to 0 1.81, 1.33, .1.0 and 0.96 were 
observed from the amide proton at 0 8.40. This suggested the existence 
of a leucine segment. The protons at 0 1.81 and 1.33 were part of a 
methylene system (both coupled to 0 40.6 in the HSMQC spectrum). 
However, in the same spectrum, the 0 1.81 proton was also correlated 
with another carbon at 0 25.5. The DEPT spectlum indicated that the 
second carbon was a methine, and was assigned to the y-position of 
leucine. Despite the overlap of the 0 1.81 proton resonance of the y-CH 
and one of the p-methylene protons the correlations extracted from the 
ROESY spectrum were unambiguous. In the ROESY spectrum, 
correlations between these two p-methylene protons, between both of 
them and the a-proton, and between the y-methine proton and two 
terminal methyl groups were observed. These results provided 
supporting evidence for the assignment of this residue as leucine. 
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Fig. 5.5.8 Selected HMBC and ROESY correlations'of N-Mellel 
180 
The assignment of the two N-methylisoleucine residues are depicted in 
Figure 5.5.8 and 5.5.9 l respectively. Because the chemical shifts were 
similar and the TOCSY signals heavily overlapped, it was difficult to 
differentiate between them. Distinction from leucine was based on the 
observations that the protons of two methyl doublets were correlated to 
a-carbons at 8 61.1 (aCl) and 55.7 (aC2) in the HMBC spectrum 
respectively. The corresponding carbon signals for these methyl signals 
(8 1.10 and 8 0.80) were located and were assigned to the 8-methyl 
groups of each N-methylisoleucine. Further examination of HSMQC and 
HMBC spectra revealed that the aH (8 5.15) in the first residue was 
correlated to the carbonyl of valine (2), while the aH in the second 
residue correlated to the carbonyl of isoleucine and another carbonyl at 8 
172.5, and so was assigned to the second N-methylisoleucine. The first 
residue was designated N-MeIlel, due to its association with Va12. 
Extension within the spin system of N-Mellel was achieved by further 
analysis of the HMBC and HSMQC spectra. Both the aH and the 8-methyl 
group were correlated to a methine carbon at 8 32.5, the ~-carbon. 
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Correlations from the 0- and the E-methyl protons to a methylene carbon 
(025.2) located the y-carbon. The protons attached to these carbons were 
in turn defined by the HSMQC data. The observation of ROESY 
correlations between all protons of the N-methylisoleucine confirmed the 
spin system (see Table 5.1). 
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Fig. 5.5.9 Selected HMBC and ROESY correlations of N-MeIle2 
In a similar way, the spin system of N-MeIle2 was delineated by HMBC 
correlations from both the H2 and the E-methyl protons to the ~- and y-
carbons. The o-carbon was assigned by analogy to lIIe. The following 
ROESY cross peaks H2/H3, H2/H6, H2/H4, H3/H6, H31H5, H41H5 and 
H6/H4 were recognised, and supported the assignment (see Fig. 5.5.9). 
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Fig. 5.5.10 Selected HMBC and ROESY correlations of N-Me-~-Ala 
The spin system of N-methyl-~-alanine is described next (Fig. 5.5.10). 
Analysis of the TOCSY spectrum of IIIb failed to identify the residue 
unambiguously due to the overlapping signals. However, in IIIb one bond 
H-C couplings from protons at 0 4.63 and 2.73 to a methylene carbon at 0 
45.3, and from protons at 0 2.63 and 2.30 to another methylene carbon at 
o 34.5 in the HSMQC spectrum unambiguously supported the presence of 
a N-methyl-~-alanine spin system. The 0 4.63/2.73 protons were 
designated to ~-position due to their appearance at lower field. The large 
difference between the chemical shift values of these two protons is 
probably due to the anisotropic effect of the carbonyl group of the 
adjacent threonine residue. The proton at 0 2.73 must lie above the plan 
of the carbonyl group. The ROESY correlations between the two a-
protons, between the a-proton and the N-methyl protons as well as the 
amide proton of the adjacent Va12 provided supplementary evidences for 
this residue. Since a correlation from the ~-proton to the carbonyl of 
threonine was found in the HMBC spectrum, the carbonyl (0 173.3) that 
these protons correlated to was attributed to N-methyl-~-alanine. 
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Fig. 5.5.11 Selected HNIBC and ROESY correlations ofN-MeAla2 
Again in contrast to HIe, the spin system of N-methylalanine (2) was 
readily defined in the TOCSY spectrum. Confirmation for the partial 
structure was obtained by 1 H _1 H decoupling experiment. When the 
me thine signal at (5 5.16 was irradiated, a 3H doublet at (5 1.44 collapsed. 
The HNlBC and ROESY correlations are depicted in figure 5.5.11. 
/:1:-- .... 
i \: ROESY 
Fig. 5.5.12 Selected HNIBC and ROESY correlations ofN-MeLeu 
The N-methylleucine residue was determined by comparison with the 
NNIR data of theonellapeptolide HIe. This was followed by a detailed 
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analysis of the HMBC and ROESY spectra (see Fig. 5.5.12). It is 
noteworthy that the long-range correlations from both a methyl (N-Me) 
and from the ~-protons to a methine carbon (0 62.9), defined the (X-
carbon of N-methylleucine. As the ~H was correlated with the carbonyl 
at 0 172.3 in the HMBC spectrum, this signal was assigned to the N-
methylleucine residue. 
~ :HMBC 
/--"\... : ROESY 
Fig. 5.5.13 Selected HMBC and ROESY correlations of N-MeAlal 
Assignments for the last residue, an additional N-methylalanine, are 
shown in Figure 5.5.13. The TOCSY data failed to provide any clue for 
this spin system because of overlaps with other signals. In the 1 H NMR 
spectrum, the most likely candidate associated with this residue was an 
unassigned methyl doublet at 0 1.36. To verify this assumption, IH-IH 
decoupling was used. When the 0 1.36 signal was irradiated, a mUltiplet 
around 0 5.12 sharpened. When the latter was irradiated, the doublet at 0 
1.36 collapsed to a singlet. These two groups of signals were assigned as 
the fJ,- and ~-protons of N-methylalanine. Correlations from the (J.-
proton to the carbonyl of Vall and a carbon resonance at 0 173.7 in the 
HNIBC spectrum allowed assignment of the 0 173.7 resonance to N-
methylalanine (1). 
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The connectivities between the individual spin systems were based 
primarily on HMBC correlations from NH, NCH3 and aH signals to the 
carbonyl carbon of the adjacent residue. The important correlations 
include H2 (N-MeAlal)/CO (Vall), H2 (Thr)/CO (N-MeAlal), H3 (N-
Me~Ala)/CO (Thr) , NH (Val2)/CO (N-Me~Ala), H2 and N-CH3 (N-
MeIlel)/CO (Va12), NH (~Ala)/CO (N-Mellel), H2 (Ile)/CO (~Ala), H2 
and N-CH3 (N-MelIe2)/CO (lIe), H2 and N-CH3 (N-MeAla2)/CO (N-
MeIle2), NH (Ala)/CO (N-MeAla2), NH (Leu)/CO (Ala), and N-CH3 (N-
MeLeu)/CO (Leu). Finally, the H3 of threonine was correlated with the 
carbonyl of MeLeu, which defined the lactone ring (see Fig. 5.5.14 and 
Table 5.1). All ROESY correlations, either between the NH and the H2 
or between the N-CH3 and the H2 of the adjacent amino acid moiety were 
observed (Fig. 5.5.l5 and Table 5.1). The only exception was for N-CH3 
of N-MeAla2 to the aH of N-MelIe2. These results confirmed the 
connectivity established by HMBC analysis. 
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Fig. 5.5.14 HMBC correlations of theonellapeptolide IIIb (52) 
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Fig. 5.5.15 ROESY correlations of theonellapeptolide Illb (52) 
I 
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Table 5.1. Correlated Hand 13 C Spectral Data and 1H- H NOE Data for TheoneliapeDtolide IIlb (52) 
amino oa 
acid 13C (#H)b 1H (mull J(Hz))C HMBCd RCES'r'3 
Val (1) 1 173.9 (s) 
2 54.6 (d) 4.99 (m) 173.9, 170.7, 32.2, 19.6, 17.8 7.49, 3.84, 3.14, 2.06, 0.94 
3 32.2 (d) 2.06 (m) 54.6, 19.6 4.99, 3.14, 1.01, 0.94 
4 17.8 (q) 0.94 32.2, 19.6 4.99 
5 19.6 (q) 1.01 32.2, 17.8 
NH 7.49 (d, 9.3)' 170.7 54.6 4.99, 3.84 2.79 
MeAla (2) 1 173.7 (s) 
2 54.3 (d) 5.12 (m) 173.9, 173.7, 32.0 9.05, 8.07, 3.14, 1.34 
3 15.3 (q) 1.34 (d, 7.2) 173.7, 54.3 5.12, 3.14 
NCH3 32.019) 3.14 (s) 173,9, 54.3 5.12, 4.99, 2.06, 1.34, 1.01 
Thr (3) 1 169.3 (s) 
2 53.6 (d) 4.95 (m) 173.7, 169.3, 17.8 7.64, 2.79, 1.28 
3 70.8 (d) 5.45 (dd, 6.3, 5.7) 172.3, 53.6 9.05, 7.64, 3.42, 2.69, 1.28 
4 17.8 (q) 1.28 (d, 5.7) 70.8, 53.6 5.45, 4.95, 2.40 
NH 9.05 (d 6.3) 5.45, 5.12. 4.95 I 
Me~Ala (4) 1 173.3 (s) 
2 34.5 (t) 2.63 (m) 8.07, 2.79, 2.30 
2.30 (m) 173.3, 45.3 2.63 
3 45.3 (t) 4.63 (m) 5.45 
2.73 (m) 169.3 
NCHs 35.1 (q) 2.79 (s) 169.3 8.07, 7.49, 5.45, 4.95, 2.63 
Val (5) 1 174.1 (s) 
2 55.6 (d) 4.98 (m) 174.1, 173.3, 30.9, 19.6 8.07, 3.25, 2.00, 0.98 
3 30.9 (d) 2.00 (m) 55.6, 19.6 8.07, 4.98, 3.25 
4 18.2 (q) 0.91 30.9 8.07 
5 19.6 (q) 0.98 4.98, 3.25 
NH 8.07 (d 8.11 173.3 5.12 4.98. 2.79 2.63 2.00. 0.91 
Melle (6) 1 170.9 (s) 
2 61.1 (d) 5.15 (m) 174.1, 32.5, 31.5, 15.8 7.654, 1.10 
3 32.5 (d) 2.25 (m) 3.25, 1.42, 1.10 
4 9.7 (q) 0.87 (t, 7.8) 32.5, 25.2 1.42 
5 25.2 (I) 1.42 (m) 2.25, 0.87 
6 15.8 (q) 1.10 (d, 6.6) 61.1, 32.5, 25.2 5.15, 2.25 
NCHs 31.5 (q) 3.25 js) 174.1, 61.1 4.98, 2.25. 2.00, 0.98 
p-Ala (7) 1 172.8 (s) 
2 35.4 (t) 2.69 (m) 172.8 8.76, 7.64, 5.45, 3.42 
2.40 (m) 4.55, 1.28 
3 35.3 (t) 4.55 (m) 3.42 
3.42 (m) 7.64, 5.45, 4.55, 2.69 
NH 7.64 (d, 6.6) 170.9 5.45, 5.15, 4.95 3.42, 2.69 
alia-lie (8) 1 175.9 (s) 
2 53.7 (d) 5.34 (m) 175.9, 172.8, 38.8, 15.6 8.76, 3.32, 1.73, 1.48, 0.97 
3 38.8 (d) 1.73 (m) 15.6 5.34, 3.32. 1.00, 0.97 
4 12.3 (q) 1.00 
5 26.9 (t) 1.48 (m) 12.3 5.34, 1.18, 0.97 
1.18 (m) 53.7, 38.8, 15.6, 12.3 1.48 
6 15.6 (q) 0.97 1.48 
NH 8.76 (d 8.4) 8.40 5.34, 2.69 1.73 0.97 
Melle (9) 1 172.5 (s) 
2 55.7 (d) 5.18 (m) 175.9, 172.5, 33.9, 31.8, 25.7 2.24, 1.42, 0.80 
3 33.9 (d) 2.24 (m) 5.18, 3.32, 0.82, 0.80 
4 9.7 (q) 0.82 (I, 7.2) 2.24, 1.42 
5 25.7 (t) 1.42 (m) 5.18, 0.82, 0.80 
6 15.8 (q) 0.80 (d, 6.3) 55.7, 33.9, 25.7 5.18, 2.68, 2.24, 1.42 
NCHs 31.8 (q) 3.32 (s) 175.9, 55.7 5.34, 5.18, 2.24, 1.73 
MeAl a (10) 1 171.3 (s) 
2 57.6 (d) 5.16 (m) 172.5, 171.3, 29.7, 15.0 2.68, 1.44 
3 15.0 1.44 (d, 6.3) 171.3, 57.6 5.16, 2.68 
NCHa 29.7 Jq) 2.68 (s) 172.5, 57.6 7.32, 5.16, 1.44, 1.30,. 0.80 
Ala (11) 1 174.9 (s) 
2 52.3 (d) 4.48 (m) 174.9, 17.8 8.40, 7.32, 1.30 
3 17.8 (q) 1.30 (d, 6.0) 174.9, 52.3 8.40, 7.32, 4.48, 2.68 
NH 7.32 (d, 5.7) 171.3 52.3, 17.8 8.40 4.48 2.68, 1.30 
Leu (12) 1 174.7 (s) 
2 48.8 (d) 5.08 (m) 174.7 8.40, 3.25, 1.81, 1.33 
3 40.6 (I) 1.81 (m) 48.8 8.40, 5.08, 1.33 
1.33 (m) 5.08, 1.81, 1.00 
4 25.5 (d) 1.81 (m) 23.7, 21.2 1.00, 0.96 
5 21.2 (q) 1.00 40.6, 23.7 1.81 
6 23.7 (q) 0.96 40.6, 21.2 1.81 
NH 8.40 (d 8.4) 174.9 8.76 7.32 5.08 4.48 1.81. 1.30 
MeLeu (13) 1 172.3 (s) 
2 62.9 (d) 3.71 (m) 3.25, 1.96. 1.01 
3 38.5 (I) 1.96 (m) 172.3, 62.9, 25.5, 23.6, 22.3 3.71, 3.25, 1.01, 0.98 
4 25.5 (d) 1.65 (m) 62.9, 38.5, 23.6, 22.3 3.25, 0.98 
5 23.6 (q) 0.98 38.5, 22.3 1.96, 1.65 
6 22.3 (q) 1.01 38.5, 25.5, 23.6 3.71, 3.25, 1.96 
NCH3 38.8 (q) 3.25 (s) 174.7, 62.9 5.08, 3.71, 1.96, 1.65, 1.01 
Mea-CH2CO 1 170.7 (s) 
2 72.0 (I) 3.84 (s) 170.7, 59.2 7.49, 4.99, 3.18 
cx:H:3 59.2 (q) 3.18 (S) 72.0 3.84 
a Referenced to residual solvent C6Da OH=7.27, oc=128.4. b 13C spectra recorded on a Varian XL300 at 75 MHz. 
Number of attached H determined by DEPT. C 1 H spectra recorded on a Varian Unity 300 at 300 MHz. 
d J nxh=8.3,5.0 arrayed mixing times. a A mixing time 01 0.15s was used. 
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5.6 Stereochemistry of Theonellapeptolide 
IIIb (52) 
The solution conformation of theonellapeptolide IIIb (52) measured in 
30% CD30D-C6D6 was deduced from a detailed analysis of the ROESY 
spectra. Also, the conformation was compared with that ascertained for 
IIle. The NMR spectra of theonellapeptolide IIIb (52) indicated that 
essentially only a single conformer was present in solution in 30% 
CD30D-C6D6 at room temperature. ROESY correlations were observed 
for H2 (Thr)/NH (BAla), H3 (Thr)/NH (BAla), H3 (Thr)/H2 (BAla), H3 
(Thr)/H3 (BAla) and H4 (Thr)/H2 (BAla) as well as NH (Ile)/NH (Leu) 
(see Fig. 5.5.15), implying that the more hindered side chains all point in 
the same direction. Since a similar correlation was found in the ROESY 
spectra of IIle, it can be imagined that the peptide backbone of IIIb is also 
folded into the taco-shell shape described earlier in which all the larger 
residues are aligned along the edge of the taco-shell, while the smaller 
ones, such as Ala, MeAla and MeBAla are located at the bends. 
The ROESY spectrum also showed cross peaks between NH-LeuINH-Ala 
and between NH-Ala/NCH3-MeAla, indicating that the NH of Leu was 
oriented parallel to the N-H bond of Ala, and similarly for the NH of Ala 
to the N-CH3 of MeAla. Conformation of a cis-amide bond between 
residue 9 (N-MeIle2) and 10 (N-MeAla2) was not detected as it was not 
possible to observe an NOE between the aHs due to their similar chemical 
shifts (05.18,5.16), 
Correlations between the NH of Vall and the NCH3 of MeBAla1, as well 
as between the aH of MeAla1 and the NH of Va12, are probably a 
consequence of hydrogen bonding between Vall and Va12, which would 
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restrict the motion of the side chain. In summary, these data suggested 
that IIIb had a similar solution conformation to that of IIIe. 
The assignment of the absolute configuration was carried out as follows 
(Derivatization of the hydrolysate and standard amino acids, and LC/MS 
work were done by Dr. Shegi and Dr. Pannell at National Institute of 
Health, U.S.A.). Five pairs of optically pure N-methyl amino acids were 
prepared from corresponding amino acid enantiomers (see 
Experimental). Both diastereoisomers of the amino acids were formed by 
reaction of both the standard amino acids and the acid hydrolysate of the 
theonellapeptolide IIIb with 2,3,4,6-tetra-O-acetyl-~-D-glucopyranosyl 
isothiocyanate (GITC), and Na-(2,4-dinitro-5-fluorophenyl)-L-
alaninamide (FDAA), followed by LC/MS respectively. The derivatives 
were analysed by LC/MS and the individual amino acid was identified by 
comparison with both the mass and retention time of the authentic 
compounds. The component amino acids were determined to be L-Val, 
D-N-MeAla, L-Thr, D-Val, two residues of L-N-MeIle, D-allo-Ile, L-N-
MeAla, L-Ala, D-Leu, D-N-MeLeu. 
It should be noted that the LC/MS can not distinguish L-N-Melle from L-
allo-N-Melle. The assignment was made as L-N-Melle by considering 
that all the known theonellapeptolides contain the L-N -Melle and that the 
L-configuration of isoleucine is the predominant form of the enantiomers. 
L-Val, D-N-MeAla were arbitrarily put on the side chain of the peptolide 
by analogy to theonellapeptolide lIIe. Incorporation of these 
stereochemical features into the planar structure of theonellapeptolide IIIb 
yields its complete structure as Figure 5.5.16. 
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Fig. 5.5.6 Configuration of theonellapeptolide nIb (52) 
Chapter Six 
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6.1 Introduction 
Theonellapeptolides IlIa, c, d and three other peptide compounds were 
purified by RPHPLC (cf. Section 5.1). The eighth peptide, a very minor 
component, was only recognised in the purification stage. The Rf value 
for this peptide was greater than that for Illd. This compound was 
temporarily designated as theonellapeptolide Illh. This chapter will 
discuss the structural elucidation of theonellapeptolides IlIa, c and d using 
GCIMS, chiral LCIMS, FABMS/MS, and 1D and 2D NMR techniques. 
Following this, a brief description of the three other peptides (IIIf, g and 
h) will be given. 
Theonellapeptolides IlIa, c and d have similar I H NMR spectra to those of 
IIIb and e. The amide proton resonances appeared between 8 6.6-9.1, N-
or O-methyl signals between 8 2.35-3.32, and a sharp methylene peak 
around 8 3.8. This data implied structural similarities between these 
compounds. Negative results to ninhydrin were observed for IlIa, c and 
d, which suggested that the N-terminus of these peptides was also blocked. 
The IR spectra of them all showed a lactone absorption at 1734 cm- I , 
indicating peptolide features. Like IIlb and e, the N-terminus in each of 
these peptolides was probably blocked by a methoxyl acetate moiety. 
However, the HPLC traces and NMR spectra of these compounds also 
showed some different characters from those for IIIb and e. For 
example, after further purification on HPLC, the individual peaks were 
tested for purity on an analytical HPLC column. The peaks 
corresponding to IlIa, c and d each showed a shoulder. This behaviour 
led to confusion on the state of purity of each peptide. When this shoulder 
was shaved off by repeated chromatography, the ratio had not varied 
obviously. It was also noticed that the ratio of the shoulder was related to 
Chapter Six-Theonellapeptolides IlIa, c, d and Other Pep tides 194 
the length of time standing in the HPLC solvent. Thus, the split peaks 
were assumed to be caused by different stable conformations of the 
molecules, rather than impurities. This assumption was confirmed by a 
series of NMR experiments. Both the 1 H and the l3C NMR spectra of 
these compounds exhibited complex patterns. The ratio of the peaks 
varied with NMR solvents and concentrations. This feature caused 
problems in the assignment of the spectra. The NMR spectra were 
analysed using comparisons of the spectra obtained in different solvent 
with those of IIIb and e. 
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6.2 Theonellapeptolide IlIa 
Theonellapeptolide lIla (54), a colourless material drying to a white non-
crystalline powder, is optically active. The molecular weight of 
1584.8100 (M+Cs)+, obtained from HRFABMS, is 34 amu higher than 
that of theonellapeptolide IIIe. This mass difference suggested that either 
a chlorine atom had replaced one of the hydrogen atoms in IIIe or 
possibly an oxygen plus a sulphur had substituted for a CH2 to give IlIa. 
The ratio of the M+/M++2 peaks was difficult to interpret due to the 
inherent complexity in the vicinity of the molecular ion in a compound of 
this mass. The analysis of the isotope pattern in the vicinity of the 
molecular ion did not strongly support the presence of chlorine in the 
molecule. Based on 1 Hand l3C NMR data (no double bond was observed 
in spectra of IlIa), results of the amino acid analysis (13 amino acids were 
determined), as well as the number of double bond equivalents, a 
molecular formula C70H 1250 17N l3S is that most approximate for IlIa. 
The 1 H NMR spectrum (measured in 35% CD30D/C6D6, Fig. 6.2.1) 
showed six amide signals (8 6.78-8.11). However, seven resonances in 
this area were recognised when the spectrum was obtained in 10% 
H201CD30D. This implied that there were two signals overlapped in the 
former spectrum. A sharp singlet at 8 3.71 is characteristic of the 
methylene protons of methoxy-acetate, as contained in theonellapeptolides 
IlIb and e. Seven three-proton singlets between 8 2.38 and 3.20 can be 
attributed to six N-methyl groups and a methoxy group. Peak splitting 
was a common phenomenon in the 13C spectrum due to existence of 
several conformations in the solvent. Careful examination of the 13C 
NMR spectrum resulted in the recognition of 12 carbonyl signals 
recognised between 8 168.2 and 174.9. Obviously some overlaps existed. 
Chapter Six-Theonellapeptolides IlIa, c, d and Other Pep tides 196 
-8 
OH 
N II o~ I~O~~ Me 
o o 
Theonellapeptolide IlIa (54) 
Amino acid analysis by GC/MS revealed the presence of Val (2), Thr (1), 
N-methyl-leucine (N-MeLeu) (1), N-methyl-isoleucine (N-Melle) (2), Leu 
(1), aIle (1), Ala (1), ~-Ala (1), N-methyl-alanine (N-MeAla) (1) and N-
methyl-~-alanine (N-Me~Ala) (1) residues. A comparison with the 
GC/MS of the derivatives of the hydrolysate from IlIe indicated that all 
but one of the component amino acids in these two peptolides were the 
same. A new peak eluted just before the threonine peak in the GC trace. 
This chromatographic behaviour implied that the new amino acid was 
either of similar polarity or similar molecular weight with threonine. 
The corresponding MS spectrum had a mlz 110 ion, which is 
characteristic of N-methyl amino acids. Another characteristic signal 
appeared at mlz 61 as a base peak in this spectrum. This signal is unique 
for methionine. It suggested that the residue has a similar partial 
structure, -CH2-S-CH3, as found in methionine, but with a branch 
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Fig. 6.2.1 IH NMR spectrum of theonellapeptolide lIla (54) 
e 
Q. 
Q. 
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at the ~-carbon to make the ion more stable after cleavage of the bond 
between the ~- and ,,(-carbons. Taking account of the molecular formula 
of the component, it suggested that it was an hydroxyl group attached to 
the ~-carbon. 
This depsipeptide was sequenced by FAB MSIMS analysis after the linear 
peptide (55) was prepared by methanolysis with sodium methoxide. In 
the CAD spectrum (Fig. 6.2.2) of this ring-opened peptide, two series of 
ions were recognised. One of these series exhibited a successive loss of 
amino acid residues from an ion at m/z 1 051, which arose by elimination 
of 433 amu from the protonated parent ion. A sequence of 1051-
Me~Ala-Val-Mene-(~A1a+ne+MeIle)-MeAla-(Ala+Leu)-MeLeu-OCH3 
can be proposed. The other series can be described as (M+H)+-343-
MeAla -MeIle-(Ile+~Ala )-(MeIle+ V al+ Me~Ala+ Thr )-161-V al-
COCH20CH3. These two series of ions can be explained by Yi and Bi 
types of cleavage, respectively (cf. Fig 4.4.1 in Chapter 4). However, 
clarification of the ambiguities, such as the composition of the fragments 
of the m/z 434, 344, 160 ions, and the sequences Ile+~Ala and 
MeIle+Val+Me~Ala+Thr, required more information. This was achieved 
by examination of the daughter ion spectrum of (M+H)+ (Fig. 6.2.3), in 
which the ions were abundant in the higher mass area. Several peaks 
which had not been recognised in the original spectrum were observed in 
this link scan. The ions at m/z 1325, 1212, 1141, 929, 816 (weak), 745, 
618,434 (weak) and 333 were assignable to B12, Bll, BlO, B9, Bs, B7, 
B6, Bs, B3 and B2. The peptide fragment 55a may represent the 
corresponding sequence. 
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CHsOCH2CO -- (Val+161) --- Thr 
Leu (lie) 
I 
Ala -- MeAla -- Melle -- lie ---
(I3-Ala) (MeI3Ala) (MeLeu) (Leu) 
(MeAla) 
(Me-I3-Ala+Val) 
I3-Ala -- Melle 
(Ala) (MeLeu) 
199 
Peptide fragment 55a (contents in 0 imply either isobaric amino acid residue or loss of 
dipeptide) 
In the same spectrum, another series of ions at mlz 1313, 1152, 1051, 
867,740 and 556, corresponding to Y12, Yl1, YlO, Yg, Y7 and Ys, may 
be attributed to peptide fragment 55b. 
161 Thr ----
(MeAla) (MeLeu) 
[MeI3Ala+Val] ---- (Melle) 
lie ----
(Leu) 
I3-Ala 
(Ala) 
Peptide fragment 55b (contents in 0 imply either isobaric amino acid residue or loss of 
dipeptide) 
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Fig. 6.2.4 FABMSIMS fragmentation ions from both N- and C-termini 
of the ring-opened peptide (55) 
A comparison of the fragment 55a with the pseudo-molecular ion of 
peptide 55 revealed that there was a 159 amu difference between them. A 
methyl ester of N-methyl leucine or N-methyl isoleucine at C-terminus 
accounts for this fragment. So, the tripeptide at the C-terminus can be 
mapped as MeLeu-Leu-Ala or comprised of their isobaric amino acids. 
This tripeptide was confirmed by comparing the daughter ion spectrum of 
mlz 343 of 55 with that of ring-opened lIIe (51). 
A link scan at mlz 1051 demonstrated that the ions at mlz 966, 867 and 
740 are daughter ions, which confirmed that the dipeptide comprising the 
fourth and fifth residues from the N-terminus was Me~Ala-Val. It is 
noteworthy that a much clearer daughter ion sp~ctrum was obtained when 
the link scan was performed at three amu off mlz 1051 (Fig. 6.2.5). This 
procedure efficiently avoided overlaps of the daughter ion spectra from 
the mlz 1051 and 1056 ions. When the daughter ion spectrum of mlz 
1056 (Fig. 6.2.6) was subtracted from that of mlz 1051, it showed a series 
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of product ions formed from B-type cleavage such as Bs, B7, B6, B5, B4, 
B3 and B2. Although the ion B7 at mlz 816 was relatively weak, it could 
clearly be identified as a daughter ion from mlz 1056 as the 
corresponding peak was not apparent in the link spectrum from mlz 1051 
(actually scanned at mlz 1048). This offered further evidence for the 
sequence ~-A1a-Ile at the seventh and eighth residues from the N-
terminus. 
ttJ3:749 
I. 
100749 
10 
20 <9 fie Be 100 129 149 IGa 1M ZOO Zlia 240 2So aa :300 32:9 349 )SO 
.,. 
Fig. 6.2.5 Link scan at mlz 1048 
A mass gap between the N-terminal residue, valine and the third residue, 
threonine, was recognised in several link-scan spectra. For example, such 
as scanning at mlz 1484 (Fig. 6.2.3), 1313 and 333. The daughter ion 
spectrum for the ion m/z 333 was shown in Fig. 6.2.7. This demonstrated 
that the daughter ion mlz 172 was formed by a loss of 161 amu from the 
parent ion, while the presence of a m/z 162 ion, which may be generated 
from the same cleavage accompanying by a hydrogen transfer, gave 
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further support to the above assumption. This assignment was also 
consistent with the mass difference between the intact molecules of 
peptolides IlIa and IIIe. Hence, the new amino acid was located at the 
second residue. A strong signal at mlz 269 (Fig. 6.2.7) may be explained 
by successive loss of H20 (ion at mlz 315) and SCH3 from a 
hydroxymethionine residue. This provided more evidence for the 
assignment. Based on the above analysis, the intact sequence of 
theonellapeptolide lIla can be described as follows. 
N-MeHyMet-- Val-- CO-- CH20CH3 
Thr---- N-MepAla --- Val --- N-Melle --- ~Ala 
I 
N-MeLeu 
I 
Leu ---- Ala ---- N-MeAla --- N-Melle ---lie 
Intact sequence of theonellapeptolide IIIa (54) 
N.B. Ala and ~Ala, MeAla and Me~Ala, Leu, lle and allo-lle, and MeLeu, Melle and 
Mealle are isobaric and their positions are exchangeable. 
Spin systems corresponding to each amino acid residue were mainly 
recognised by interpretation of the COSY and TOCSY spectra of lIla. 
Integration of these data with analysis of the HSMQC and HMBC spectra 
helped to distinguish between the isobaric amino acids. Particularly 
important were the HMBC correlations from H6 to C2 of the isoleucine 
(or N-methyl isoleucine), which differentiated the Ile (N-methyl 
isoleucine) from leucine (N-methylleucine). It was not possible to define 
the spin system of the hydroxy methionine residue as the spectrum was 
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heavily overlapped in critical regions. The only supporting evidence was 
a correlation between a methyl signal at 0 2.38 and a methylene carbon at 
o 50.6 in the HMBC spectrum. 
The intact sequence of the peptolide was consolidated by observation of 
the following HMBC correlations: H2 (methoxyl acetate) and NH (Val 
l)/CO (methoxyl acetate), H2 (Vall) and N-CH3 (MeHyMet)/CO (Vall), 
H2 (Thr)/CO (MeHyMet), H2 (Thr) and N-CH3 (Me~Ala)/CO (Thr) , N-
CH3 (Me~Ala)/C3 (Me~Ala), H2 (Val 2)/CO (Me~Ala), H2 and N-CH3 
(Melle 1)/CO (Val 2), NH and H2 (lle)/CO (~Ala), H2 (lle) and N-CH3 
(Melle 2)/CO (Melle 2), H2 (Melle 2) and N-CH3 (MeAla)/CO (Melle 2), 
H2 (MeAla) and NH (Ala)lCO (MeAla), H3 (Ala)/CO (Ala), H2 (Leu) and 
N-CH3 (MeLeu)/CO (Leu), N-CH3 (MeLeu)/C2 (NleLeu), and H3 
(Thr)/CO (MeLeu). Failure to observe any correlation between the 
residues 6 (Melle 1) and 7 (~Ala), and 11 (Ala) and 12 (Leu) resulted in 
the unsuccessive peptide sequence. However, the intact sequence depicted 
in Fig. 6.2.4 was the only possible combination, when account was also 
taken of the MSIMS analysis of the sample. 
The absolute configuration of theonellapeptolide IlIa was deduced by 
analysis of the acid hydrolysate converted to Na(2,4-dinitro-5-
fluorophenyl)-L-alaninamide (FDAA) and 2,3,4,6-tetra-O-acetyl-~-D­
glucopyranosyl isothiocyanate (GITC) derivatives using non-chiral 
LC/MS. By comparing both the mass and the retention time of each 
amino acid derivative with those of the authentic (S)- and (R)- amino 
acids, it was ascertained that L-Val, L-Thr, D-Val, L-N-Melle, D-allo-lle, 
L-N-MeAla, L-Ala, D-Leu and D-N-MeLeu, as well as ~Ala, Me~Ala and 
a new residue, were present in IlIa. The optical properties of the last 
residue have not been determined. Methyl isoleucine, rather than methyl 
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aUo-isoleucine, was assigned based on an analogy to theonellapeptolide 
lIIe. On the assumption that the location of L-valine and D-valine 
residues are the same as III lIIe, the configuration of the 
theonellapeptolide IlIa can be depicted as in Fig. 6.2.8. 
-8 
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Fig. 6.2.8 Stereochemistry of theonellapeptolide IlIa (54) 
( 
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6.3 TheoneUapeptolide Ille 
Theonellapeptolide lIIc (56) exhibited cytotoxicity against P338 with an 
IC50 of 11.5 /lg/mL. In agreement with HRFABMS data on the (M+Cs)+ 
ion (1522.8339, ~+4.8), the molecular formula of lIIc was assigned as 
C69H123016N13CS. lIIc appeared as a mixture of conformers in all the 
NMR solvents tested (CDCb, CD30D, CD30D/CDCb, H20/CD30D and 
pyridine-d6). The NMR spectra were not well resolved. However, the 
spectral pattern observed was similar to those observed for Illb and lIIe, 
suggesting that lIIc shared the same basic skeleton as the other 
theonellapeptolides. The main conformer in CD30D showed seven amide 
protons (between 87.38 and 9.10), six N-methyl, plus one methoxy group 
(8 2.58, 2.63, 3.08, 3.14, 3.16 and 3.28) resonances (Fig. 6.3.1). As 
expected, split peaks caused by different conformers predominated in the 
13C NMR spectrum, especially in the carbonyl signal area. lIIc was found 
to contain the same amino acids as lIIe, but varying in ratios. For 
instance, two leucines and two N-methyl alanines vs one N-methylleucine 
Structure of theonellapeptolide IlIe (56) 
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Fig. 6.3.1 IH NMR spectrum of theonellapeptolide IlIe (56) 
III 
Q, 
Q, 
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and one valine. 
Figure 6.3.2 shows the FAB/CAD mass spectrum of ring-opened peptide 
57, in which the (M+H)+ ion was observed at mlz 1422.9. Two sequences 
of peptide fragments (57a and 57b), corresponding to successive loss of 
amino acid residues from C- and N-termini respectively, were proposed 
by incorporation of the fragmentation information from Fig. 6.3.2 and 
the daughter ion spectrum of (M+H)+ ion (Fig. 6.3.3). 
(lie) (MeAla)(Me[3Ala) 
CHsOCH2 CO -- Val -- Leu -- Thr-- (Me[3Ala+MeAla) 
MeAla --- Melle --- (lIe+13Ala) -- Melle 
(MebAla) (MeLeu) (Leu)(Ala) (MeLeu) 
Peptide fragment 57a 
(I/e) ([3Ala) (Me[3Ala) (MeLeu) 
CHsOLeu --- Leu --- Ala --- MeAla -- Melle 
[Thr+Me[3Ala+MeAla] ---- Melle --- (13Ala+lle) 
(MeAla) (Me[3Ala) (MeLeu) (Ala) (Leu) 
Peptide fragment 57b 
These sequences were confirmed by a series of link scan experiments. 
The presence of the leucine unit in the second position from N-terminus 
was demonstrated by a daughter ion mlz 172 from the mlz 285 ion. 
These two ions can be claimed to be the daughter ions of mlz 386 since 
they were both found in the daughter ion spectrum of mlz 386 (Fig. 
6.3.4). In most of the mass spectra, there was a gap of 170 amu between 
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threonine and methyl isoleucine. This mass difference can be attributed to 
a dipeptide fragment, which may contain either two methyl alanine 
(methyl p-alanine) or one valine and one alanine (p-alanine). Evidence 
supporting the former sequence is that a fragment at m/z 471 was 
observed in the original CAD spectrum. A fragment CH30CH2CO-Val-
Leu-Thr-MepAla (MeAl a) can account for the composition of this ion. A 
link scan on m/z 471 yielded a relatively abundant 284 ion, which added 
greater certainty to the assignment. However, it was not confirmatory 
because no direct evidence for the origin of the ion m/z 471 was found. 
A link scan from m/z 994 (B9) gave a fragment at m/z 271 (Fig. 6.3.5), 
which was formed from the internal cleavage and can reasonably be 
explained by a tripeptide fragment comprising Thr-MepAla-MeAla or 
Thr-Ala-Val, while a coexisting internal ion at m/z 299 has only one 
possible composition, Leu-Thr-MepAla. This provided indirect 
supporting evidence for the MepAla-MeAla sequence. The NMR data 
also offered some clues for this arrangement. The 1 H N1vIR spectrum 
showed that HIc had seven amide protons. (If the peptide has the 
seq uence, Ala-Val, the number of the amide protons will be more than 
seven.) In the linked spectrum from m/z 1079, the presence of ions at 
m/z 867 and 796 (Fig. 6.3.6) established the order of the dipeptide, p-
Ala-ne. This sequence can also be traced through the mlz 312, 241 and 
128 ions when the m/z 867 ion was scanned. Thus, a whole sequence for 
HIe, based on Fragments 57a and 57b, can be constructed (Fig. 6.3.7). 
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Chapter Six-Theonellapeptolides IlIa, c, d and Other Pep tides 214 
Leu---- Val - co - CH20CH3 
Thr --- N-Me13Ala -- N-MeAla -- N-Mellc -- I3Ala 
I 
N-MeLeu 
I 
Leu ---- Ala --- N-MeAla -- N-Melle ---- lie 
Sequence of the theonellapeptolide IIIe (56) 
N. B . Ala and ~Ala, MeAla and Me~Ala, Leu, Ile and allo-lle, and MeLeu, Melle and 
Mealle are isobaric and their positions are exchangeable. 
As for IlIa, the spin systems of IlIe were identified by COSY, TOCSY, 
HSQC and HMBC techniques. The HMBC correlations useful for 
sequencing included: H2 (methoxyl acetate) and NH (Val)/CO (methoxyl 
acetate), H2 (Val) and NH (Leu 1)/CO (Val), H2 (Thr) and N-CH3 
(Me~Ala)/CO (Thr) , N-CH3 (MeAl a 1)/CO (Me~Ala), N-CH3 (Melle 
1)/CO (MeAla), NH (HeyCO (~Ala), H2 (He) and N-CH3 (Melle 2)/CO 
(He), H2 (Melle 2) and N-CH3 (MeAla 2)/CO (MeHe 2), H2 (MeAla 2) 
and NH (Ala)/CO (MeAla 2), H2 (Ala)and NH (Leu)/CO (Ala), N-CH3 
(MeLeu)/CO (Leu), N-CH3 (MeLeu)/C2 (MeLeu), and H2 and H3 
(MeLeu)/CO (MeLeu). Due to heavy overlapping of resonances in the lH 
and 13C spectra and missing connectivities, such as those between leucine 
(1) and threonine, between N-methyl isoleucine (1) and ~-alanine, and 
between N-methylleucine and threonine, the structure of IlIe can not be 
unambiguously assigned from the NMR spectra. The sequence of the 
peptolide was deduced by cross reference to MS/MS analysis and the 
sequence of the other theonellapeptolides. 
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Theonellapeptolide IlIc was subjected to acid hydrolysis to give the free 
amino acids, which were derivatised with Na (2 ,4-dini tro- 5-
fl uoropheny 1)-L-alaninamide (FDAA) and 2,3,4,6-tetra-O-acety l-~-D-
glucopyranosyl isothiocyanate (GITC), and analysed by LC/MS. The 
configuration of each individual amino acid was determined in the same 
way as in Section 6.2. This peptolide gave a mixture of D-Val, L-Leu, L-
Thr, L-N-MeIle, D-Ile, L-N-MeAla, L-Ala, D-Leu and D-N-MeLeu, as 
well as the non-chiral ~Ala and Me~Ala. A structure showing the 
stereochemistry of theonellapeptolide IlIe was given in Fig. 6.3.8. 
~ ~o § Val Leu (1) H i ~ 
::("".... Nn' 0"", '" N Me H o 0 
NH I 0 
"'" ••.... Thr f N ldl
N rY~ 1 I ~X:/ 0 • ~ • ~ H:I~"o 
MeLeu I r Ala ~I r IIY ~~. N'~NH 
O. N N 
1 n H MeAla~ I ! a/io-lie y,o"" 0 0 ~ 
Fig. 6.3.8 Stereochemistry of theonellapeptolide IlIe (56) 
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6.4 Theonellapeptolide IIId 
Theonellapeptolide HId (58) gave a pseudo-molecular ion peaks at mlz 
1404.9 (M+H)+, 1426.9 (M+Na)+ and 1442.9 (M+K)+ in the FABMS 
spectrum. The molecular formula, C7oH12SN 13016CS, of 58 was 
determined by the HRFABMS (mlz 1536.8409, M+Cs, A -1.2 mmu). The 
molecular weight of HId was 14 amu less than that of HIe. This implied 
the difference of a methyl group between the two peptolides. There were 
many similarities in their 1 H NMR spectra. For example, they both 
exhibited seven amide proton and seven N- or O-methyl resonances; an 
isolated methylene signal appeared around 0 3.86; most of the a-protons 
of the a-amino acids appared between (54.90 and 5.47. However, the IH 
NMR spectrum of IHd (Fig. 6.4.1) was more complicated than that of HIe 
due to the existence of conformers in solution. 
Theonellapeptolide HId (58) 
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Fig. 6.4.1 IH NMR spectrum of theonellapeptolide IIId (58) 
I!i 
Q. 
Q. 
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GC/MS analysis of the TFA, butyl ester derivatives of the hydrolysate 
from HId resulted in identification of 13 amino acids. This peptolide 
comprised of threonine, valine (x 2), N-methylleucine (x 2), N-methyl-~­
alanine, ~-alanine, isoleucine, N-methyl isoleucine, alanine, N-methyl 
alanine, leucine and a new amino acid. A GC peak appeared between that 
for N-methylleucine and alanine which was unique to this compound. An 
ion at m/z 283 in the mass spectrum of this amino acid derivative 
suggested either a C6 amino acid or an N-methyl C5 amino acid. An ion 
at mlz 110, characteristic of an N-methyl amino- acid, suggested that it was 
the latter. A relatively intense m/z 140 peak, corresponding to loss of an 
isopropyl group from ion I (see Fig. 4.3.1), strongly implied that the 
identity of this new amino acid was an N-methyl valine. This assignment 
was susequently confirmed by NMR analysis. 
The sequence of theonellapeptolide lIId was deduced based on two series 
of ions, 1265, 1138, 1037, 853, 740, 669 (weak), 556, 429 and 344, and 
1277, 1164, 1093, 1008,697, 584 (weak), 400 and 299 observed in the 
FABMS and daughter ion spectra (Fig. 6.4.2 and 6.4.3) of the ring-
opened peptide (59). Fragment 59a belongs to the C-terminal 
fragmentation ions (Yi), while fragment 59b represents N-terminal 
cleavage (Bi). FAB MS/MS afforded more sequence information for the 
linear peptide. 
The sequences of the tripeptide at the N-terminus and the tetrapeptide at 
the C-terminus were confirmed by comparison of the product ion spectra 
of m/z 400 and 429 with those of theonellapeptolide lIIe. Ions at m/z 952, 
853 and 740 found in the spectrum of the link scan at m/z 1037 (Fig. 
6.4.4) afforded clear evidence for the sequence Me~Ala-Val-MeVal (or 
Ile or Leu). Similarly, the ion at m/z 740 yielded daughter ions at m/z 
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(Melle) (MeAla) 
CH30CH 2CO -- Val MeLeu -- Thr -- (Me[3Ala+Val) 
MeAla -- Melle -- lie -- ([3Ala) -- MeVaf 
(Me[3Ala) (MeLeu) (Leu) (Ala) (lie or Leu) 
Peptide fragment 59a 
(lie) C[3Ala) (Me[3Ala) (MeLeu) 
CH 30Leu---- Leu --- Ala -- MeAla -- Melle 
Thr --- [Me[3Ala+Val] --- (MeVal) --- ([3Ala+lle) 
(MeAla) (lie or Leu) (Ala) (Leu) 
Peptide fragment 59b 
669 and 556 (Fig. 6.4.5), which was indicative of the seventh and the 
eighth residues in the sequence: ~-Ala-Ile. The mass difference between 
the fifth and the seventh residue was 113 amu. This can be accounted for 
by an N-methyl valine unit. The detailed sequencing was depicted in Fig. 
6.4.6. 
The isobaric amino acids were distinguished by analysis of the lD and 2D 
NMR data. The intact amino acid sequence of theonellapeptolide HId was 
elucidated primarily by interpretation of the HMBC spectrum. Amide 
protons at 8 8.99, 8.75, 8.39,8.17,7.62,7.48 and 7.39 were assigned to 
the spin systems of Thr, He, Leu, Val, ~-Ala, Val and Ala residues 
respectively, based on the TOCSY spectrum. While the spin systems 
related to the methyl amino acids were recognised by either observation 
of the cross peaks in TOCSY spectrum or by analogy with corresponding 
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Fig. 6.4.6 FAB MS-MS fragmentation of protonated 59 
spin systems of lIIe. The N-methyl valine residue was defined by 
subtracting the resonances of N-methyl alanine and N-methyl isoleucine 
from a TOCSY trace at 8 5.22. The TOCSY spectra of these three 
residues overlapped due to the close chemical shifts (85.22,5.18 and 5.18 
for MeVal, MeAla and Melle) of the a-hydrogens (H2). Correlations 
from two methyl groups at (5 1.13 and 1.06, and from an N-methyl group 
to the same a-carbon at 8 61 in the HMBC spectrum confirmed the 
residue. 
Inter-residue cross peaks observed in the HMBC experiments were as 
follows: NH (Val1)/CO (methoxyl acetate), NH (Val1)/C2 (Vall), NCH3 
(MeLeu l)/CO (Val 1), NCH3 (MeLeu 1)/C2 (MeLeu 1), H2 (Thr)/CO 
(MeLeu 1), H2 (Thr) and NCH3 (Me~Ala)/CO (Thr) , NH (Val 2)/CO 
(Me~Ala), NCH3 (MeVal)/CO (Val 2), NH (~Ala)/CO (MeVal), H2 
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(~Ala) and H2 (Ile)/CO (~Ala), H2 (lIe) and NCH3 (MeIle)/CO (lIe), 
NCH3 (Melle)/C2 (Melle), H2 (Melle) and NCH3 (MeAla)/CO (Melle), 
NCH3 (MeAla)/C2 (MeAla), H2 (MeAla) and NH (Ala)/CO (MeAla), H2 
(Ala) and NH (Leu)/CO (Ala), H2 (Leu) and NCH3 (MeLeu 2)/CO (Leu), 
NCH3 (MeLeu 2) and H3 (MeLeu 2)/C2 (MeLeu 2), and H3 (MeLeu 2) 
and H3 (Thr)/CO (Me Leu 2). These data led to the sequence of HId as 
shown in Fig.6.4.7, which was consistent with the result of the MS/MS 
analysis. 
The absolute stereochemistry of the amino acid residues was determined 
by HPLC/MS analysis of the derivatised acid hydrolysate, and comparing 
with those of the standard amino acid derivatives as described in Section 
5.6 (also see Experimental). Like the other theonellapeptolides, IUd 
contains both L- and D-amino acids, which include L-Val, D-MeLeu, L-
Thr, D-Val, L-MeVal, D-lle, L-MeIle, L-MeAla, L-Ala and D-Leu. The 
stereochemistry of HId was shown in Fig. 6.4.7. 
Theonellapeptolide HId is cytotoxic against P388 leukemia cells at ICSO of 
8.8/lg/mL. 
~ 0 1~fva'{1} II o~ N~ Me 
H 
o o 
(I H;:al (2) 0 I?eval 
".,.", •. ~N~N N 0 
I II Me·p-Ala II I oXO 0 0 HN p-Ala 
I Melle I y ~""....... N~ = 0 ~ 0 0 
MeLeu(2) I I Ala ~I ~ II ~f;j. N'~NH 
:Yeo" ~~ M""~I ~"" 
Fig. 6.4.7 Stereochemisry of theonellapeptolide HId (58) 
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6.5 Other Cytotoxic Peptides from 
Lamellomorpha strongylata 
Theonellapeptolide IIlf was the least polar compound in the peptide 
fraction. This compound had a much longer retention time than lIIe on 
RPHPLC. FABMS of IlIf exhibited an (M+H)+ ion at 1432.9, 
accompanied by an (M+Na)+ ion at 1454.8. The IH NMR of this 
compound showed only six amide proton signals between 8 6.8-8.8, and 
several N- or O-methyl groups between 8 2.6 and 3.3 (Fig. 6.5.1, in 
CDC13). The spectral pattern was very much like that of IlIe, and 
probably only varied in the ratio of the amide protons and N-methyl 
groups. 
The IH NMR spectrum of theonellapeptolide IIlg (Fig. 6.5.2) showed at 
least six broad resonances between 8 7.5 and 9.1, which were attributed to 
the amide protons, while the sharper signals between 8 2.6-3.3 were 
probably due to the presence of the N- or O-methyls. In addition, a 
singlet around 8 3.85 was assigned to the methylene of a methoxyl acetate 
moiety. Thus, this compound can be considered as having a similar 
structural skeleton to the other theonellapeptolide components. 
IIlh was the least abundant component in this group of peptide compounds 
(-2 mg only was obtained). The IH NMR spectrum of IIlh (Fig. 6.5.3) 
was very similar to that of IlId, except for an amide resonance at 8 8.76. 
This was at a higher field than the comparable resonance in HId. A 
similar structure to IlId was suggested for this minor peptide. 
Theonellapeptolides IlIg and IlIh exhibited cytotoxicity against P388 cell 
line with ICso of 5 and 11 /lg/mL respectively. IlIf was non-cytotoxic. 
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Fig. 6.5.1 IH NMR spectrum of IIIf 
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Fig. 6.5.2 IH NMR spectrum of lUg 
Ii 
Q, 
Q, 
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Fig. 6.5.3 IH NMR spectrum of IIIh 
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6.6 Structural Variation of the Peptolides 
The structural variation of the theonellapeptolides IlIa-e is shown, in 
sunanaary, in Fig.6.6.1 
N-MeLeu--- Val- co-- CH20CHs 
IN-MeAla/ j N-MeVali 
Thr N-MeI3Ala Val N-Melle 
I 
N-MeLeu 
I 
Leu Ala N-MeAla N-Melle 
Fig. 6.6.1 Structural conaparison of theonellapeptolides IIIa-e 
I3Ala 
lie 
The base structure used was that of IIIe, the naajor peptolide. The 
residues in boxes indicate the variations which generated the different 
theonellapeptolides in the series. The structural changes occurred only at 
second, fifth or sixth residues with the second residue being that naost 
conanaonly showing variation. In IlIa the second residue becanae N-
naethyl-hydroxynaethionine, while in IIIb N-naethylalanine occupies the 
second position. In IIIe, two anaino acids are different frona those in IIIe. 
The second residue of IIIe has been replaced by Leu, while valine 2 at the 
fifth position was replaced by N-naethyl alanine. Finally, when the N-
Melle at the sixth position of IIIe was replaced by N-MeVal, the peptolide 
becanae HId. 
Theonellapeptolides lIIb, c, d, e all exhibited naild cytotoxicity against 
P388 cell line, but IlIa was not cytotoxic. This result inaplies that the 
nature of the second residue is very inaportant to naaintain the bioactivity 
of this class of conapound. 
Chapter Seven 
Experimental 
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7.1 General Methods 
7.1.1 Nuclear Magnetic Resonance 
1 H NMR spectra were recorded on a Varian UNITY 300 NMR 
spectrometer at 23°C, operating at 300 MHz. 13C and DEPT NMR 
spectra were recorded on a Varian XL 300 NMR spectrometer, at 23°C, 
operating at 75 MHz. 1D- and 2D-TOCSY, COSY, ECOSY and ROESY, 
and the reverse-detected HSMQC (or HSQC) and HMBC experiments 
were recorded either on a Varian UNITY 300 NMR spectrometer, or a 
Varian INOV A 500 NMR spectrometer. The UNITY 300 instrument was 
fitted with a Nalorac Z. spec MID300 3mm Indirect Detection Probe. 
Chemical shifts in this thesis are described in parts per million (ppm) on 
the 0 scale, and were referenced to the appropriate solvent peaks (except 
otherwise specified): CDC13 or CDC13/CD30D referenced to CHCh at OR 
7.25 (lH) and CHCh at OC 77.0 (13C); CD30D or CD30H referenced to 
CD30H at OR 4.70 (lH) and CD30D at OC 49.3 (13C); D20 referenced to 
HOD at OR 4.70 (lH); C6D6/CD30D referenced to C6HD5 at OR 7.27 
(lH) and C6D6 at OC 128.4 (13C). IH NMR spectra were recorded using 
an aquisition time (AT) of 2 s, except for those spectra run in CD30H, 
where suppression of the CD30H solvent peak was run under the 
following conditions; relaxation delay (D1) =1 s, decoupler power = 4, 
steady state = 4, decoupler mode = 'ynn'. 13C NMR spectra were 
recorded using an acquisition time of 0.5 s. Decoupling experiments 
were run with decoupler power 10 dB. ROESY experiments were run 
using an AT = 0.46 s, D1 = 0.60 s and a mixing time of 0.30 s. COSY 
experiments were recorded using an acquisition time of 0.24 s and a 
relaxation delay of 1 s. 2D-TOCSY spectra were recorded using an 
acquisition time of 0.50 s, a relaxation delay of 0.60 s and a mixing time 
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of 80 ms. 1D-TOCSY spectra were recorded using an acquisition time of 
2 s, a relaxation delay of 1 s and mixing times as indicated in the 
discussion. HSMQC experiments were recorded with an acquisition time 
of 0.2 s, a relaxation delay of 0.4 sand JX-H=130 Hz. HMBC 
experiments were recorded with an acquisition time of 0.21 s, a 
relaxation delay of 0.3 s, J = 140 Hz and JNXH = 8.3 Hz, or JNXH = 8.3, 
S.O Hz arrayed mixing times. 
7.1.2 Mass Spectrometry 
Mass spectra were obtained on a Kratos MS80RFA mass spectrometer, 
equipped with a Carlo Erba MFCSOO GC, operated at 4 kV. FAB was 
performed with an Ion Tech ZNIIFN ion gun using Xe as the reagent 
gas, operating at 8 kV and 2 rnA with either NOBA (m-nitrobenzyl 
alcohol), m-b (magic bullet, SO% thioerythritol/thiothreitol), or glycerol 
as matrix. 
HRFABMS and FABMS/MS were measured on a JEOL SX102A 
spectrometer (NIDDK, NIH, U.S.A.). NOBA, magic bullet and glycerol 
were used as matrix. 
7.1.3 GC, GC/MS and HPLCIMS 
Gas chromatography (GC) was accomplished on a Varian 3700 gas 
chromatograph equipped with a Hewlett Packard 3390A Integrator. 
GC/MS spectra were measured on a Kratos MS80RF A mass spectrometer 
equipped with a Carlo Erba MFCSOO GC. LC/MS was carried out on an 
HPII00 Integrated LCMS System with a C18 Stable Bond Zorbax (1S0 x 
4.6 mm) column. 
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7.1.4 High Performance Liquid Chromatography 
Analytical HPLC was performed on a Philips PU4100 Liquid 
Chromatograph equipped with a Philips PU4120 Diode Array Detector 
interfaced to a PC General 486 computer running Philips PU6003 Diode 
Array Detector System Software (V3.0) and a Hewlett Packard 7475A 
Plotter. Semipreparative HPLC was performed on a Shimadzu LC-4A 
Liquid Chromatograph equipped with SPD-2AS Spectrophotometric 
Detector. H20 was purified using a MilliQ deionising system. MeOH 
(J.T. Baker, HPLC reagent grade) and acetonitrile (BDH, HiPerSolv) 
solvents were used undistilled. All other solvents were of technical grade 
and were purified and re-distilled before use. Hexane was prepared from 
petroleum ether (10 L, b.pt. 60-70"C), nitrated with a mixture of c. 
HN03 (1 L) and c. H2S04 (1 L) for two days. After this time, the 
nitrating mixture was removed and the organic layer washed with H20 
(20 L), and dried over CaCh overnight. The resulting solution was 
filtered through activated alumina (Laporte, 100 mesh) and distilled. All 
solvents (with the exception of MilliQ water) were filtered through a 
Millipore filter apparatus, equipped with a Rainin Nylon-66 filter (0.45 
~m) prior to use. All samples were filtered through a syringe filter 
(All tech, 0.45 ~m) prior to injection. 
The analytical reverse phase C18 column used were Microsorb-MV, 
86200-C5, 5 ~m, 100 A, 250 x 4.6 mm, and 3 ~m, 100 A, 100 x 4.6 mm 
(Rainin Instrument Company Inc, USA). The analytical Diol column used 
was a LiChrospher® 5 ~m, 100 A, 250 x 4.6 mm (E. Merck, Darmstadt, 
Federal Republic of Germany). The analytical CN column used was a 
ZORBAX® CN, 5 ~m, 250 x 4.6 mm (Dupont Instruments). The 
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semipreparative reverse phase 18 column used was a Microsorb-MV, 80 
299-C5, 5 11m, 100 A, 250 x 10 mm (Rainin Instrument Company Inc, 
USA). 
Medium pressure column chromatography was performed on a Lobar 
chromatography setup, with a variable speed electric pump, to achieve a 
typical flow rate of 10 mL/min. The Diol lobar column used was a 
Lichroprep® DIOL, 40-63 11m, 310 x 25 mm (E. Merck, Darmstadt, 
Federal Republic of Germany). 
7.1.5 Column Chromatography 
All column chromatography was performed on various sizes of glass 
columns. "Flash" columns were run under N2 gas (oxygen free) pressure 
(0.5 kPa). Solvents used were all commercial grade, distilled once in a 
glass distillation apparatus, except methanol (MeOH), which was distilled 
twice. 
Reverse-phase C18 packing used for preparative and flash column 
chromatography was prepared from silica gel (Davisil, 35-70 11m) using a 
solution of octadecyltrichlorosilane (2 % vlv, EGA-Chemie) in carbon 
tetrachloride. 162 The silica gel was stirred gently with a teflon-coated 
magnetic follower overnight before washing with carbon tetrachloride (x 
2). Unreacted chloro groups were removed by washing with dry MeOR. 
A carbon tetrachloride solution of trimethylchlorosilane (2 % vlv, 
Aldrich) was used to end-cap any unreacted hydroxyl groups. The 
reverse-phase material was finally washed with dichloromethane 
(CH2C12) (x 2) and MeOH (x 2) to remove the reagents. The C18 
reverse-phase material was extensively washed with MeOH immediately 
before use. 
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Small scale preparative C18 reverse-phase column chromatography was 
performed using Alltech disposable cartridges (200 mg). Bakerbond Diol 
(Bb)(40 Jl.m APD) or Merck Diol (NIk)(40 Jl.m APD), and Alltech Silica 
gel (35-70 Jl.m) were used for normal phase chromatography. 
Pre-swollen Sephadex LH-20 (Pharmacia Biotic AB) was used for gel 
permeation chromatography. Sephadex G-25 (SIGMA) was used for gel 
filtration chromatography. 
Celite filtration and coating was performed using diatomaceous earth 
(Celite Corporation). 
7.1.6 Thin Layer Chromatography 
The silica analytical TLC described in this thesis was performed on 
Merck silica gel 60 F254 aluminium-backed sheets, 0.2 mm in thickness. 
Diol analytical TLC was performed on Merck F254 glass-backed plates of 
0.2 mm thickness. Whatman MKC 18F TLC plates of 0.2 mm thickness 
were used for analytical C18 TLC. Amino analytical TLC was 
performed on Merck F254 glass-backed plates of 0.2 mm thickness. All 
TLC plates were visualised initially under short-wave (A 254 nm) light, 
or, subsequently, with a phosphomolybdic acid in ethanol spray (10 % 
phosphomolybdic acid in ethanol w/v), except for analysis of 
theonellapeptolides. Those TLC plates were visualised with Iz. 
7.1.7 Dry Solvents 
Dichloromethane was dried initially over calcium chloride then distilled 
from calcium hydride. Dry tetrahydrofuran was achieved by distillation 
over calcium hydride. Dry methanol was distilled from magnesium metal 
and iodine. Dry isopropyl alcohol was obtained by refluxing with 
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calcium oxide, and then distillation. n-Butanol was treated with 
anhydrous calcium sulphate, and fractionated after filtration from the 
desiccant. All dry solvents were distilled immediately prior to use. 
7.1.8 Other Experiments 
MPs were determined on an Electrothermal melting point apparatus and 
are uncorrected. Optical rotations were measured on a JASCO J-20 
recording spectropolarimeter. IR spectra were recorded on a Shimadzu 
FTIR-8201PC infrared spectrophotometer. High speed countercurrent 
chromatography was run on an Ito Multi-Layer Coil Separator-Extractor. 
The X-ray diffraction data was collected on a Siemens SMART area 
detector system. 
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7.2 
7.2.1 
Work Related to Chapter 2 
Chemical Screening of the Organic Extract from 
Mycale sp. 
Organic extracts from Nfycale sp. were dissolved in 50% DCM/MeOH 
(reserved 200 ilL of this solution as the primary standard, and 200 ~L 
aliquot for gel permeation chromatography), and coated onto celite to 
make a material containing 20 mg extract per 100 mg celite. The C18, 
Diol, PEl WP, CBA WP and LH-20 cartridges were chosen for testing of 
this sample. All cartridges, except LH-20, were Bond Elut solid phase 
extraction columns from Analytical InternationaL The LH-20 column 
was prepared in the laboratory using the previously described method. 123 
The selected cartridges were pre-equilibrated with MeOH (3 mL), 
followed by the initial eluting solvent (10 mL). The organic extract (10 
mg) (either 50 mg coated celite, or 200 ~L solution for LH-20) was 
loaded onto each of the cartridges. The volume of each solvent used in 
elution was 3 mL, except for the initial solvent (2 mL) for PEl WP and 
CBA WP, and the three fractions (1.3, 1.5 and 4 mL) from LH-20· 
column. A total of 14 fractions were collected, including F1 (50% 
MeOH/H20), F2 (MeOH) and F3 (50% MeOH/DCM) from C18, F4 
(DCM), F5 (EtOAc) and F6 (MeOH) from Diol, F7 (0.025 M NH4Ac), 
F8 (0.5 M HOAc) and F9 (0.5 M sodium citrate) from PEl WP, FlO 
(0.025 M NH4Ac) and F11 (0.5 M HOAc) from CBA WP, and F12, F13 
and F14 (50% MeOHIDCM) from LH-20. The P388 assay results (ICSQ, 
dilution) for these collections were summarised as follow: F1, 230; F2, 
<97.5; F3, 310; F4, 768, F5, 1373; F6, <97.5; F7, 2758; F8, <97.5; F9, 
120; FlO, 455; F11, <97.5; F12, 286; F13, <97.5; F14, 115; and standard, 
<97.5. 
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All 14 fractions were analysed by RPHPLC using a C2 column. The 
elution was made in a gradient mode with acetonitrile/water from 20% 
through to 80%. The eluate was monitored at 225,254 and 270 nm with 
a PU 4120 diode array detector. The peak corresponding to pateamine 
was observed as one of the major peaks in the HPLC traces of F2, F6, F8, 
Fll and F13. It was also recognisable in the trace of F14. 
7.2.2 Chemical Screening of the Organic Extract from 
Lamellomorpha strollgylata 
The organic extract from L. strongylata was analysed by the same 
chemical screening procedure as used in Section 7.2.1. The cytotoxicity 
test revealed F1, 9908; F2, <97.5; F3, 106; F4, <97.5; F5, <97.5; F6, 
<97.5; F7, <97.5; F8, <97.5; F9, 160; FlO, <97.5; F11, <97.5; F12, 
<97.5; F13, <97.5; F14, 574; and standard, <97.5. 
All 14 fractions were processed by RPHPLC on an ODS column. 
Gradient elution was used with an acetonitrile/water system (containing 
0.05% TFA) , starting a 40% and ending up with 100% acetonitrile 
(monitored at 214, 268 and 344 nm), The peaks with retention time 320 
and 580 sees, which corresponded to swinholide and calyculin compounds 
respectively, were readily recognised in the HPLC traces of all the active 
fractions (ICso<97.5). 
7.2.3 
Collection 
Study of Anti-HIV components from Cholldropsis 
kirkii 
The sponge was collected by SCUBA at Lighthouse 
Reef Point, Moeraki, South Hand, New Zealand, in 1993. Chondropsis 
kirkii belongs to the family Desmacidonidae, order Poecilosclerida. 
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Extraction Frozen sponge (380 g) was crushed and soaked in 
MeOH (300 mL) overnight. After blending, the sample was filtered 
through a sintered funneL The residue was extracted with MeOH (2x150 
mL), 50 % MeOHIDCM (150 mL), and DCM (150 mL) for one hour for 
each extraction. These extracts were combined. After removing the 
organic solvents from the extract, an equal volume of absolute ethanol 
was added to form a 50% aqueous alcohol solution. Most of the 
biopolymers, such as proteins and polysaccharides, were precipitated, and 
removed by filtration. The aqueous portion (after removal of the EtOH 
under vacuum) was partitioned against EtOAc (3x100 mL). The 
combined EtOAc extract was the organic portion (558 mg). The aqueous 
solution was freeze-dried to afford the aqueous extract (2.12 g). 
Chemical screening of the Aqueous Extract A C4 WP 
cartridge and a Sephadex G-25 cartridge were chosen for analysis of the 
extract. The Sephadex G-25 column was prepared by putting the H20-
soaked Sephadex G-25 gel (1 g) into a 6 mL empty cartridge. Both 
columns were pre-equilibrated with H20, and loaded with the aqueous 
sample. The C4 WP column was eluted with H20, 33% MeOHJH20, 66% 
MeOH/H20 and MeOH. The Sephadex G-25 column was eluted with 
H20. Four fractions from each column were collected, and tested for 
both anti-HIV and cytotoxic activities. The former was evaluated by the 
inhibition %, while the latter was judged by the percentage of killed cells. 
The anti-HIV and cytotoxic activities (in brackets) were recorded as (%): 
F1, 136 (36); F2, 5 (0); F3, 1 (56); F4, 0 (14) from C4; F5, 106 (0); F6, 
86 (0); F7, 0 (14); F8, 0 (9) from Sephadex G-25. 
Chemical screening of the Organic Extract C18, Diol and PEl 
WP cartridges were selected for processing of the extract. The solvents 
and operations were the same as those used in Section 7.2.1. The assay 
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results were summarised as (the fractions were numbered in elution order 
from individual column and in a series of C18, Diol and PEl) HlV 
inhibition% and cytotoxicity% (in brackets): F1, ° (31); F2, ° (99); F3, 
54 (31); F4, 51 (34), F5, ° (100); F6, 0 (100); F7, 0 (l00); F8 0 (100); 
F9, 0 (l00). 
Sephadex G-2S Chromatography of the Aqueous Extract The 
aqueous extract (50 mg) was dissolved in H20 (500 ~L), and loaded onto 
the head of a G-25 column, containing Sephadex G-25 (15 g). The 
solvent (H20) was delivered with an LKB 2132 Microperpex Peristaltic 
pump. 22 Fractions (25 mL/fraction) were collected. They were 
combined into 9 fractions corresponding to 9 peaks. Bioassay tests 
afforded the following results (cytotoxicity% was in parenthesis): F1, 103 
(13); F2, 73 (11); F3, 0 (28); F4, 0 (15); F5, 0 (17); F6, 0 (16); F7, 0 
(20); F8, 0 (99); F9, 0 (15). 
A sample of the precipitate (20 mg) from 50% aqueous ethanol was 
redissolved in H20, and analysed in the same way as the supernatant on 
Sephadex G-25 column. The five of seven resultant fractions (labelled 
with PI-P5) showed strong anti-HIV activity and low cytotoxicity (in 
parentheses): PI, 91 (10); P2, 107 (11); P3, 113 (21); P4; 103 (30), P5, 
103 (4). 
Toluidine Blue Dye Binding Test Toluidine blue (1 mg) was 
dissolved in H20 (100 mL) to give a blue-coloured solution (10 ~g/mL). 
A 10% aqueous dextran sulphate was used as positive standard. To 
toluidine blue (1 mL), was added series of Dextran sulphate standards 
(10, 20, 30 and 40 ~LL). To toluidine blue (2 mL), were also added 
dextran sulphate standards (10, 20, 30, 40, 50, 60 and 70 ~L). Samples 
(10, 20 and 50 ~L) from each fraction (before combination) from the 
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Table 7.2.1 Toluidine blue test results 
Sample Name Concentration Absorbance (A) Sample Name Concentration Absorbance (A) 
(~U2 mL) (J.lU2 mL) 
Siandard (1 mL) 0 0.83742 F8 1 0 0.81760 
10 0.64651 20 0.78391 
20 0.42670 50 0.79201 
30 0.21564 
40 0.17943 
Standard (2 mL) 0 0.83240 F9 1 0 0.80745 
10 0.66655 20 0.75948 
20 0.56210 50 0.77408 
30 0.45123 
40 0.35185 
50 0.28566 
60 0.21336 
70 0.17464 
Pl 10 0.72450 FlO 10 0.78522 
20 0.72110 20 0.77020 
50 0.69055 50 0.74821 
P2 10 0.74402 F11 10 0.78758 
20 0.68571 20 0.80524 
50 0.59718 50 0.79704 
P3 10 0.69980 F12 1 0 0.77457 
20 0.65649 20 0.77571 
50 0.56662 50 0.72334 
P4 10 0.72490 F13 10 0.68822 
20 0.67249 20 0.70253 
50 0.55156 50 0.63510 
P5 10 0.70126 F14 1 0 0.63884 
20 0.68712 20 0.67935 
50 0.59273 50 0.70958 
P6 10 0.74568 F15 1 0 0.63194 
20 0.71267 20 0.68692 
50 0.65625 50 0.71089 
P7 10 0.71436 F16 10 0.71570 
20 0.69433 20 0.72198 
50 0.68712 50 0.70078 
F1 10 0.78510 F17 10 0.70349 
20 0.79169 20 0.69724 
50 0.77525 50 0.69475 
F2 10 0.75233 F18 1 0 0.68693 
20 0.71169 20 0.66440 
50 0.55945 50 0.68764 
F3 1 0 0.79483 F19 10 0.68958 
20 0.74599 20 0.69745 
50 0.72418 50 0.70332 
F4 10 0.76369 F20 10 0.77040 
20 0.74011 20 0.72729 
50 0.79123 50 0.69064 
F5 1 0 0.80962 F21 10 0.70761 
20 0.79553 20 0.71284 
50 0.77437 50 0.70232 
F6 10 0.80414 F22 10 0.78301 
20 0.77777 20 0.76959 
50 0.77676 50 0.77655 
F7 10 0.78522 
20 0.7 4899 
50 0.79402 
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G-25 column on the aqueous extract were each then added to toluidine 
blue (2 mL). The absorbance of all the sample-dye mixtures were 
measured on a Hewlett Packard 8452 diode array spectrophotometer at 
620 nm. The results are summarised in Table 7.2.1. 
Isolation of HIV -inhibiting compounds from C. kirkii A n 
initial separation of the anti-HIV components from the organic extract 
was achieved using C-18 reverse phase flash chromatography, monitoring 
by bioassay and Diol TLC (1 % MeOH/DCM). Further column 
chromatography on Diol (13 g) of the active fractions, using 30% 
DCM/petroleum ether through to 70% DCM/petroleum ether, 
concentrated the activity into three fractions, eluted by 30% 
DCM/petroleum. The active fractions were loaded onto an LH-20 (40 g) 
column, which was eluted with 10% MeOH/DCM (10 mL/fraction). IH 
NMR spectroscopy indicated that fractions 2 and 3 contained mainly 
steroidal compounds, and exhibited medium anti-HIV activity. These 
fractions were combined and further purified on a CN HPLC column (4.6 
mm x 25 em, in normal phase mode) using 5% DCMlhexane as eluent. A 
total of seven fractions were collected. The bioassay results from the 
selected fractions are given in Table 2.3.1. 
The steroidal fraction (29 mg) was dissolved in pyridine (300 ilL), to 
which an equal amount of acetic anhydride was added. The reaction 
mixture was shaken, and then left at room temperature overnight. The 
solution was transferred into a separating funnel, diluted with water (6 
mL) and the product extracted with DCM (5 x 10 mL). The solvent was 
evaporated under vacuum to yield acetylated sterols (30 mg). The 
derivative was analysed on a Diol HPLC column, using 5% DCMlhexane 
as eluent. The peaks were still overlapping. 
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7.2.4 Studies on HIV -inhibitory Components from a Styela 
sp. 
Collection The ascidian was collected at the break-water, Lyttelton 
Harbour, Christchurch, New Zealand, in 1993 and belongs to the family 
Styelidae, order Pleurogonia 
Extraction A frozen sample of the ascidian (100 g) was soaked in 
MeOH (200 mL) overnight, ground in a blender, and filtered. The 
residue was successively extracted with MeOH (2 x 80 mL), 50% 
MeOH/DCM (80 mL), and DCM (80 mL). The five extracts were 
combined, concentrated to an aqueous solution (about 100 mL), and 
absolute ethanol (100 mL) added to precipitate the polysaccharides. After 
filtration (the filter pad was washed with 3 x 30 mL EtOH), the EtOH was 
removed under vacuum. The resultant aqueous portion was partitioned 
against EtOAc (3 x 80 mL) to yield the organic (290 mg) and aqueous 
extracts (3.69 g). 
Chemical screening for anti-HIV activity Sephadex G-25 and C4 
Wide Pore (WP) cartridges were chosen for the aqueous, while C18, Diol 
and PEl WP were selected for the organic extract. The experimental 
procedures were the same as those described in Sections 7.2.1 and 7.2.3. 
The HIV-inhibitory activity was observed in three fractions (F1, F2 and 
F4 with inhibition % 37, 106 and 18, respectively) from the C4 column. 
The third fraction (F11) from C18, the second fraction (F13) from Diol, 
and the third fraction (F17) from PEl WP columns showed only trace 
activity (inhibition %<10). No activity was found in any fractions from 
the G-25 column. 
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Attempt at isolation of the anti-HIV compounds from Styela 
Spa A portion (200 mg) from the aqueous extract was dissolved in 
water and chromatographed on C-18 (8 g). This column was eluted 
initially with H20, then with MeOHlH20 mixture (5% to 50%). The anti-
HlV activity was observed in the first three fractions (inhibition% 17, 1 
and 15 for F1, F2 and F3, respectively). 
7.2.5 Chemical Screening of an Unidentified Sponge (code 
No. 9401·01) 
Extraction The frozen sponge (550 g) was crushed to small pieces, 
soaked in MeOH (600 mL) for 3 h, and blended. Further extraction was 
achieved successively with MeOH (500 mL), 50% MeOHIDCM (400 mL), 
DCM (2 x 400 mL). After removing the organic solvents, the extract was 
partitioned between water and EtOAc. The combined EtOAc extract was 
evaporated to dryness to afford the organic extract (340 mg). The 
aqueous portion was freeze-dried to yield aqueous extract (2.04 g). 
Chemical screening The chemical screening was carried out in the 
same way as described in Sections 7.2.1 and 7.2.3 for the organic and 
aqueous extracts, respectively. The best results were found for F2 and F3 
with inhibition % 11 and 14 respectively. 
7.2.6 Chemical Screening of Organic Extract from 
Callyspongia irregularis 
C18, Diol and LH-20 cartridges were used for screening the organic 
extract using the same method as described in Section 7.2.1. The anti-
viral and cytotoxic activity were evaluated by evaluation of the viral 
inhibition, or cytotoxic zones (+- for least active, 4+ for most active). 123 
The antiviral activity was observed in the second (4+) and third (2+) 
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fractions from C 18 column, the first (+) and the second (4+) fractions 
from Diol, and the second fraction (4+) from LH-20 column. 
7.2.7 Chemical Screening of an Unidentified Sponge (code 
No. 95CR4-18) 
Extraction Frozen sponge (5 g) was crushed to small pIeces, 
soaked in MeOH/DCM (66%, 50 mL), blended, and left at room 
temperature for 3 h. The material was centrifuged at 3000 rpm for 20 
min. The supernatant was evaporated under vacuum. 
Chemical screening The organic extract was dissolved in MeOHIDCM 
(3:1) (50 mg extract/mL). A sample of this solution (100 ~L) was coated 
onto celite (200 mg). The chemical screening was carried out in the same 
way as described in Sections 7.2.1, using C-18, Diol, PEl WP, CBA WP 
and LH-20 cartridges. The cytotoxicity (lCSO, dil.) was found in the 
fractions 2 (969) and 3 (526) from C18 column, fraction 3 (233) from 
Diol, fraction 2 (3688) from CBA WP, fraction 2 «97.5) from LH-20. 
The active fraction from LH-20 was loaded onto a C18 cartridge, and 
eluted with the same solvent as used in the above procedure. The second 
fraction showed a weak cytotoxicity (ICSO=1057). The other two 
fractions from the same column were not cytotoxic (lCSO> 12500). 
7.2.8 Chemical Screening of an Unidentified Sponge (code 
No. 95CR2-10) 
The primary screening on the aqueous extract from this sponge indicated 
that it was strongly cytotoxic against the P388 cell line (ICso <97.5). A 
sample of the frozen sponge (5g ) was extracted with water (50 mL), and 
analysed in the same way as described in Section 7.2.7. The aqueous 
extract was further analysed on C4 WP, PEl WP, CBA WP and Sephadex 
Chapter Seven-Experimental 244 
G-25 cartridges using the same methods described in Sections 7.2.1 and 
7.2.3. Only trace cytotoxicity (ICso=3909 dil.) was recognised in the 
first fraction from CBA column, while the standard still exhibited intense 
activity (ICso <97.5). 
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7.3 
7.3.1 
Work Related to Chapter 3 
Studies on Antiviral and Antitumour Components of 
Callyspongia irregularis 
Collection The sponge was collected by SCUBA diving at 
Lighthouse Reef Point, Moeraki, South Island, New Zealand. The genus 
Callyspongia belongs to family Callyspongiidae, order Haplosclerida. 
Extraction of Callyspongia irregularis Frozen sponge (380g) 
was thawed in MeOH (600 mL), blended and filtered through a sintered 
funnel. The residue was in turn extracted with MeOH (600 mL), 50% 
MeOH/DCM (200 mL), and finally H20 (600 mL). The extracts were 
combined and the organic solvent was removed under vacuum. To the 
remained aqueous portion absolute alcohol was added to make a 50% 
ethanol solution. The resultant solution plus precipitate was filtered off 
through celite. After evaporation of the ethanol under vacuum, the 
aqueous portion was freeze-dried to yield an extrcat (18.3g). 
Isolation and purification of mycalamide A The organtc 
extract (16 g) was suspended in 50 % MeOH/DCM, and filtered. The 
residue was washed with the same solvent until the colour of the filtrate 
was a very light straw colour. The total organic solvent was removed 
under vacuum, the residue redissolved in a minimum valume of (4 mL) 
50 % MeOH/DCM and coated onto celite (13 g). This material was 
loaded onto the head of a column (9 cm i.d.), containing C18 (30 g). This 
column had been equilibrated to water, and was then eluted with water 
(200 mL). Step gradient elution using MeOHlH20, MeOH, DCMlMeOH, 
and DCM (50 mL/fraction) afforded 39 fractions. Finally, the column 
was washed with MeOH and DCM alternatively, producing a 40th 
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fraction. The fractions were combined to six new fractions based on both 
bioassay results and the TLC behaviour. 
Fraction I.3 (Scheme 3.3.1) was separated by high-speed countercurrent 
chromatography (HSCCC), using petroleum ether/EtOAc/MeOH/H20 
(6:11:6:4), upper phase as mobile phase. A total of 26 fractions were 
collected from each run. The active fractions were then combined, and 
repeatedly separated with HSCCC using same solvent system as above. 
The antiviral activity was concentrated in fraction 11.2 (Scheme 3.3.1). 
This active fraction (3.9 mg) was further purified on a Diol cartridge 
(500 mg, Bond Elut 20H), eluted with a gradient system using 
EtOAc/DCM, MeOHlEtOAc, and MeOH (5 mL/fraction). The eluates 
were re-combined to five fractions based on bioassay results. The 
fraction II1.2 (Scheme 3.3.1) mainly contained a highly active antiviral 
component. The 1 H NMR spectrum showed signals characteristic of 
mycalamide, as well as impurities. However, no further purification was 
made due to the limited amount of the material (about 200 Ilg) available. 
Negative FABMS (NOBA) spectrum exhibited (M-H)- ion at mlz 502 
(very weak). The molecular formula C23H41NOlO was deduced from a 
comparison of the molecular weight with the HRF ABMS of an abundant 
daughter ion at mlz 472. 
IH NMR data of mycalamide (CDC13) 8 7.49 (d, 1=8.7 Hz, NH), 
5.87 (t, 1=9.9 Hz, H10), 5.13 (d, 1=6.9 Hz, 10-0CHR), 4.87 (d, 1=6.9 Hz, 
10-0CHS), 4.85 (m, 4=CHZ), 4.74 (m,4=CHE), 4.30 (s, H7), 4.23 (dd, 
1=6.8, 7.3 Hz, HI2), 3.99 (dq, 1=2.7, 6.6 Hz, H2), 3.85 (dd, 1=6.8, 9.7 
Hz), 3.74 (m, H17), 3.62 (d, 1=5.5 Hz, HIS), 3.57 (dd, 1=3.5, 11.3 Hz, 
H18), 3.55 (s, 13-0CH3), 3.45 (d, 1=10.3, H13), 3.38 (dd, 1=6.2, 11.3 Hz, 
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H18), 3.30 (s, 6-0CH3), 2.36 (m, H5), 2.24 (m, H3), 1.19 (d, 1=2.6 Hz, 
2-CH3), 0.99 (d, 1=7.0 Hz, 3-CH3), 0.97 (s, 14-CH3R), and 0.87 (s, 14-
CH3S). 
Isolation of other compounds from C. irregularis Fraction ILl 
(Scheme 3.3.1) was processed on a RPHPLC (C18) column, using 57% 
MeOH/H20 (containing 0.05% TFA). There was no antiviral activity 
found in any of the fractions. A similar result was obtained when 
fraction II.5 was also chromatographed on the same system using 60% 
MeOH/H20 (containing 0.05% TFA). 
The cytotoxic components in fraction I.4 (Scheme 3.3.1) was concentrated 
in fraction IX.2 by HSCCC. The wealdy cytotoxic fraction was purified 
further using RPHPLC, using 80% MeOHIH20 (containing 0.05% TFA). 
No activity was detected in any of the subsequent fractions. 
Fraction V.1, which displayed mild cytotoxicity, was loaded onto a 
column (containing 15 g LH-20). The column was eluted with DCM, and 
yielded two active fractions (fractions VI.4 and VI.5). These fractions 
were chromatographed on a Diol (3.6 g) column, which was eluted with 
DCM, and 2-30% MeOH/DCM. The ICso values recorded for fractions 
VIlLI, 2 and 3 in a P388 bioassay were >12500, 2455, and >12500. 
7.3.2 Isolation of Cytotoxic Compounds from 
Callyspongia sp. 2 
Extraction of Callyspongia sp. 2 Frozen sponge (1.6 Kg) was 
steeped in MeOH (1.7 L) at room temperature for 3 h, then blended. The 
material was filtered through celite. The residue was in turn extracted 
with MeOH (1.2 L), 50% MeOHIDCM (1.2 L), and DCM (2x1.2 L), each 
for 1 h. The MeOH extracts were combined, and partitioned against 
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EtOAc after removal of the MeOH using a cyclone evaporator. The 
EtOAc extract was combined with the organic extracts to give the crude 
extract (810 mg). 
Chemical screening of the organic extract Organic extract 
(corresponding to about 5 mg solid material) was coated onto celite (300 
mg). C18, Diol and PEl WP cartridges (3 mL, 3 mL and 6 mL 
respectively) were chosen for the chemical screening. The screening was 
carried out in the same way as described in Section 7.2. The cytotoxic 
activity was distributed as following: >25000 (50% MeOH/H20), 6250 
(MeOH), 2265 dil. (50 MeOH/DCM) from C18; >12500 (DCM), 3144 
(EtOAc), >6500 dil. (MeOH) from Diol; >12500 (0.025 M NH4Ac), 
> 12500 (0.5 M HOAc), >25000 (0.5 M sodium citrate). 
Isolation of the cytotoxic components The organic extract (810 
mg) was coated onto celite, and loaded onto a C18 column (8 g). The 
column was eluted with a gradient mode using H20, MeOHlH20, MeOH, 
and DCM. A total of 16 fractions were collected. They were combined 
to just 6 fractions based on bioactivity. Fraction 1.4 (Scheme 3.4.1), the 
most active fraction (lCso 31 ng/mL), was proces'sed further by RPHPLC, 
using 85% MeOH/H20 as eluent. The resultant bioactive fractions were 
combined to give fraction V.3 (Scheme 3.4.1), which was then combined 
with fraction II.3 (Scheme 3.4.1) from the previous Diol column. The 
material was dissolved in DCM, and chromatographed on an LH-20 
column (2 x 60 em, 30 g) equilibrated to DCM. Eleven fractions were 
collected from the column, which was eluted with DCM (Fl-9), 2% 
MeOHIDCM (FlO), then washed with MeOH and DCM (Fll). The active 
components were contained in fractions 8-10, which were combined to 
afford fraction VI.3 (Scheme 3.4.1). The less active material (F3-7) 
formed VI.2. The 1 H NMR spectrum of the fraction VI.3 indicated that it 
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was still a complex mixture. To purify the active compounds, normal 
phase Diol HPLC was used. The column was eluted with a gradient using 
IP A1hexane from 5% to 40%. Good resolution was achieved (a total of 
10 peaks were resolved and collected individually). However, the most 
potent ICso was just 1120 ng/mL, implied a major loss of the activity. 
Fractions having similar activity were combined. 
Fraction 1.3 (Scheme 3.4.1) was loaded onto a Diol column (l4g), which 
was eluted with a gradient of DCM/petroleum ether from 70% to 100%, 
and MeOH/DCM from 2% to 10%. The active fraction (11.3) showed 
similar IH NMR spectrum and ICso value to V.3 (Scheme 3.4.1). These 
two fractions were combined. A less active fraction (11.4) was also 
chromatographed on Diol, eluting with 50% MeOHIDCM. There was no 
increase in the bioactivity observed, while a decrease in bioactivity was 
recognised in the bioassay results of the eluates from a RPHPLC column. 
Fraction 1.5 (Scheme 3.4.1) was processed by loading it onto a Diol 
column (2.5x60 cm, 18 g). A solvent gradient from 40% petroleum 
ether/DCM to 10% MeOHIDCM was used in the chromatography. The 
cytotoxicity was concentrated in fractions 11-14, which were combined to 
yield F VIII.3. Before a Lobar column was chosen for further 
purification, test runs were carried out on the fraction using the RPHPLC 
(ODS column) solvent systems. The bioactivity was found to spread in a 
wide range of fractions in all cases. So, all collections were combined, 
and chromatographed instead on a Diol Lobar column with IP Alhexane 
(30%) as eluent. The active components were still distributed, but the 
first and last fractions did not contain any activity. This suggested the 
active fraction must be a complex mixture. After passage through a Diol 
cartridge, the active fraction (IX.2, in Scheme 3.4.1) was divided into 
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three parts. The IH NMR spectrum of the most active one (X.l) showed 
that it contained at least one major as well as several minor components 
(see Fig. 3.4.1). 
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7.4 Work Related to Chapters 4 .. 6 
7.4.1 Common Methods 
Collection Lamellomorpha strongylata was collected in February 
1995, and recollected in April 1996 by benthic dredging (-80 to -100 m) 
from the Mernoo Bank, Chatham Rise, New Zealand. A voucher 
specimen is held in the museum at NlWA, Wellington, New Zealand. 
Extraction and Isolation The extraction of the sponge and separation 
of the theonellapeptolide fraction from the calyculin and swinholide 
fractions has been reported previously. I IS Final purification of the 
peptolides was carried out by reverse-phase HPLC on a Philips PU4100 
using an ODS column (4.6 mm x 25 cm) eluting with H20 (0.1 % 
TFA)lMeOH (0.1 % TFA) (11:89). A limited sample (2 mg) of the crude 
peptide was injected in each run. Cutting the appropriate peak in multiple 
runs gave pure theonellapeptolide lIIe (50) (94 mg). 
Large Scale Separation of Theonellapeptolides: To obtain 
enough quantity of the minor pep tides for structural studies, a larger scale 
separation was carried out. Frozen sponge (5.96 kg) was ground and 
extracted with MeOHIDCM (3:1, 2 x 6L). The combined extracts were 
concentrated to an aqueous suspension, and partitioned against 
dichloromethane (3 x 750 mL). After removal of solvent, the organic 
extract were coated onto ODS silica, loaded onto a C 18 column (90 g) and 
eluted using a steep, step-gradient pattern from 100% water to 100% 
methanol, followed by stripping the column with 50% DCMlMeOH and 
100% DCM. The cytotoxic fractions were combined and 
chromatographed on a Diol column with a step gradient elution pattern 
using hexane-dichloromethane mixtures. The fractions eluting at 
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dichloromethane (70-100%) were found to contain theonellapeptolides. 
The crude peptolides (2.6g) were dissolved in 50% MeOHIDCM (5 mL), 
and chromatographed on LH-20 (3m length, 200 cm id., 250g). Elution 
of the column with the same solvent afforded 23 fractions. Combination 
of fractions 7-17, based on both the bioactivity and Rf value on TLC, 
yielded a mildly cytotoxic fraction (1.83 g). The IH NMR showed that 
the majority of the mixture was the peptolides. This fraction was further 
chromatographed on silica gel (40 g) equilibrated to 5% hexanelEtOAc. 
Elution with 5% hexane/EtOAc, followed by EtOAc and 90% 
EtOAclMeOH (20 mL/fraction), produced 22 fractions. Fractions 16-22 
were combined according to their Rf values on TLC and their 1 H NMR 
spectra, which yielded the peptolide mixture (1.76 g). The peptolides 
were isolated and purified by semipreparative C18 HPLC column (10 mm 
x 2 5 cm, 5 J.lm, 100A) using a Shimadzu LC-4A solvent delivery system. 
The column was eluted with 10% H20IMeOH (containing 0.1 % TFA) in 
an isocratic mode. A total of ten fractions were collected. Of these, eight 
contained peptolide components (including the mass from the analytical 
column) of IlIa (24 mg), Illb (20 mg), IIIe (20 mg), IIId (113 mg), IIIe 
(1.3g), IlIg (84 mg), IIIh (26 mg), IIIf (2 mg). 
Acid Hydrolysis of Peptolides A sample of each theonellapeptolide 
(1 mg) was placed in an hydrolysis tube and HCI (6 M) (1 mL) was 
o 
added. After sealing under N2, the tube was heated at 110 C for 17 hrs. 
In each case, the acid solution was evaporated to dryness under vacuum to 
give the product. 
Amino Acid Analysis by GC/MS The N -trifluoroacetamide-n-
butyl esters of the amino acids were prepared under standard 
conditions. 145 The acid hydrolysate of each theonellapeptolide (1 mg) 
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was transferred to a Reacti-vial (1 mL) and dried under vacuum before 
HCl-n-BuOH (2 M) (400 JlL) was added. The vial was sealed with a 
Teflon-lined cap and, after sonication (15 s), was heated at 110°C in an oil 
bath (10 min), followed by further sonication (10 s) and heating (20 min). 
After cooling the solvent was evaporated under vacuum. A 
trifluoroacetic anhydride-DCM mixture (750 JlL) (1:2) was added to each 
sample, which was then heated (150°C) for 5 min. The remaining reagent 
and solvent were removed under N2 at 50°C and the product then 
dissolved in dry DCM (600 JlL) for GC analysis. The GC-MS analysis of 
each sample was performed on a DB Wax column (30 m x 0.25 mm) with 
an initial column temperature of 50°C which was held for 15 min post-
injection, then increased to 130°C at 1 ° Imin, to 250°C at 23° Imin and 
finally held at 250°C for 20 min. The individual amino acids were 
identified on the basis of retention time against standards, and by analysis 
of the MS data. 
Methanolysis of the theonellapeptolides Each theonellapeptolide 
(-1 mg) was dissolved in dry MeOH (220 JlL) with NaOMe/MeOH (4%) 
(66 JlL). The MeOH solution of each theonellapeptolide was stirred at 
room temperature for 3 h before pouring into ice water and extraction 
with EtOAc. Evaporation of the solvent gave the products (-0.9 mg) 
which were purified by reverse-phase HPLC [H20 (0.1 % TFA)/MeOH; 
18:82]. 
7.4.2 Synthesis of Amino Acid Derivatives 
Synthesis of N-methyl L-alanine (60) L-Ala (268 mg) was 
dissolved in 2M NaOH (1.5 mL) and stirred in an ice-water bath for 20 
min. Benzyl chlorocarbonate (1.04 mL) and 2M NaOH 0.7 mL) were 
added alternatively, while the mixture was vigorously stirred in the ice 
Chapter Seven-Experimental 254 
bath. After continued stirring at room temperature for another 2 h, the 
solution was adjusted to pH 10 with NaOH. The basic solution was 
partitioned against ether, then acidified to pH 2 with 6M HCI, before 
extraction with the ether (4 x 4 mL). The solvent was removed under 
vacuum to yield benzyloxycarbonyl-L-Ala (584 mg). 
Benzyloxycarbonyl-L-Ala (3 mmol) was dissolved in tetrahydrofuran 
(THF) (2 mL) in a reacti-vial. To this solution CH31 (200 JlI) was added. 
After the solution was cooled to O°C in an ice-bath NaH (40 mg) was 
added to the vial. The reaction mixture was stirred under N2 at room 
temperature for 24 h. The remained NaH was destroyed by adding water, 
and the resulting solution was partitioned against ether (3 x 3 mL). The 
aqueous portion was acidified to pH 2 with 6N HCI, and extracted with 
EtOAc (4 x 3 rnL). The ethyl acetate extract was washed with 5% sodium 
thiosulfate (2 x 1 mL) and water (2 x 3 mL), and dried over MgS04. 
The solvent was removed under vacuum. The product (591 mg) was 
purified on a Microsorb-MV C18 column using 50% MeOH/H20 as 
eluent. 
The benzyloxycarbonyl N-methyl alanine (587 mg) was vigorously 
stirred with 10% Pd-C (20 mg) in ethanol (2 mL) under hydrogen at 
room temperature until the C02 evolution ceased. After the residual 
hydrogen was replaced by N2, the catalyst was filtered off over celite 
under N2. The solvent was removed to give a crude product (158 mg). 
The residue was dissolved in water, and passed through a C18 cartridge, 
which was eluted with H20. The aqueous eluate was dried under high 
vacuum to yield pure L-MeAla (153 mg). 
IH NMR (D20) 8 3.43 (lH, q, 1=7.2 Hz, H2), 2.51 (3H, s, NCH3), 1.29 
(2H, t, 1=7.2 Hz, H3). 
Chapter Seven-Experimental 255 
Synthesis of N-methyl-~-alanine (61) ~ Ala (198 mg) was 
dissolved in 2M NaOH (1.0 mL) and stirred in an ice-water bath for 20 
min. Benzyl chlorocarbonate (930 ilL) and 2M NaOH (1.5 mL) were 
added alternatively, while the mixture was vigorously stirred in the ice 
bath. N-methylation was carried out as for L-MeAla (see above) to yield 
N-methyl-~-alanine (124 mg). 
lH NMR (D20) 8 2.92 (2H, t, J=6.6, 4.4 Hz, H3), 2.45 (3H, s, NCH3), 
2.29 (2H, t, J=6.9, 6.3 Hz, H2). 
Synthesis of N-methyl-L-isoleucine (62) L-Ile (262 mg) was 
dissolved in 2M NaOH (1.5 mL) and stirred in an ice-water bath for 20 
min. Benzyl chlorocarbonate (700 ilL) and 2M NaOH (1.2 mL) were 
added alternatively, while the mixture was vigorously stirred in the ice 
bath. N-methylation was carried out as for L-MeAla (see above) to yield 
N-methyl-L-isoleucine (144 mg). 
IH NMR (10% CD30D/D20) 0 3.33 (lH, d, 1=3.9 Hz, H2), 2.55 (3H, s, 
NCH3), 1.78 (lH, m, H3), 1.39 (1H, m, H4), 1.15 (lH,'m, H4), 0.81 (3H, 
d,d, 1=7.2, 6.9Hz, H5), 0.83 (3H, d, 1=7.2 Hz, H6). 
Synthesis of N-methyl-D-isoleucine (63) D-Ile (29 mg) was 
dissolved in 2M NaOH (400 ilL) and stirred in an ice-water bath for 20 
min. Benzyl chlorocarbonate (60 ilL) and 2M NaOH (600 ilL) were 
added alternatively, while the mixture was vigorously stirred in the ice 
bath. N-methylation was carried out as for L-MeAla (see above) to yield 
N-methyl-D-isoleucine (17 mg). 
IH NMR (10% CD30D/D20) 03.35 (lH, d, 1=3.9 Hz, H2), 2.57 (3H, s, 
NCH3), 1.80 OH, m, H3), 1.40 OH, m, H4), 1.16 OH, m, H4), 0.82 (3H, 
d,d, 1=7.5, 6.9 Hz, H5), 0.84 (3H, d, 1=7.5 Hz, H6). 
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Synthesis of N-methyl-L-alloisoleucine (64) L-allolle (14 mg) 
was dissolved in 2N NaOH (200 ~L) and stirred in an ice-water bath for 
20 min. Benzyl chlorocarbonate (30 ~L) and 2N NaOH (400 ~L) were 
added alternatively, while the mixture was vigorously stirred in the ice 
bath. N-methylation was carried out as for L-MeAla (see above) to yield 
N-methyl-L-alloisoleucine (8 mg). 
1 H NMR (D20) D 3.38 (lH, d, J=3.9 Hz, H2), 2.59 (3H, s, NCH3), 1.87 
(lH, m, H3), 1.36 (1H, m, H4), 1.17 (lH, m, H4), 0.84 (3H, d,d, J=7.5, 
7.2 Hz, H5), 0.86 (3H, d, J=7.2 Hz, H6). 
Synthesis of N-methyl-D-alloisoleucine (65) D-allolle (100 mg) 
was dissolved in 2M NaOH (500 ~lL) and stirred in an ice-water bath for 
20 min. Benzyl chlorocarbonate (300 ~L) and 2M NaOH (500 ~L) were 
added alternatively, while the mixture was vigorously stirred in the ice 
bath. N-methylation was carried out as for L-MeAla (see above) to yield 
N-methyl-D-alloiso1eucine (57 mg). 
1 H NMR (D20) D 3.49 (lH, d, J=3.9 Hz, H2), 2.72 (3H, s, NCH3), 2.00 
(lH, m, H3), 1.49 (lH, m, H4), 1.30 (lH, m, H4), 0.97 (3H, d,d, J=10.2, 
7.5 Hz, H5), 0.99 (3H, d, J=7.5 Hz, H6). 
7.4.3 Theonellapeptolide HIe (50) 
Theonellapeptolide HIe (50) colourless plates (acetone/H20: 1:1): 
MP 184-186°; [a]22o -48.6° (c 1.0, MeOH); IR (CHCb) vrnax 3352,3006, 
2966, 2935, 1734, 1672, 1628, 1533, 1468, 1173 em-I; IH NMR 
(CD30D/C6D6, 2:8) see Table 4.1; 13C NMR (CD30D/C6D6, 2:8) see 
Table 4.1; HRFABMS, mlz 1550.8577 [(M+Cs)+, -0.1 mmu for 
C71H127N13016CS). FABMS, mlz 1419 (M+H)+, 1248, 1219, 1206, 
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1121,1106,1038,924,810,712,694,655,525,496,439, 380,299,269, 
211, 182, 144, 100, 86, 72, 58, 44. 
Methyl Ester of Theonellapeptolide HIe (51) HRFABMS, m/z 
1582.8860 [(M+Cs)+, +2.0 mmu for C72H131N 130 17CS). FABMS, m/z 
1451 (M+H)+, 1421,1280,1152,1107,1051,1022,966,926,895,867, 
740,711,669,654,615,584,556,527,496,485,429,400, 369, 344, 
299,277, 185, 172, 100,72,57,44. 
Methanolysis of 50 Theonellapeptolide HIe (50) (9 mg) was 
dissolved in dry MeOH (2 mL) with NaOMe/MeOH (4%) (0.6 mL). 
After incubation for 3 h, the sample was treated in the same way as 
described in Section 7.4.1 to give the methanolysis product 51 (6 mg). 
X-ray Structure Determination of Theonellapeptolide HIe 
A colourless crystal of theonellapeptolide lIIe 50, obtained as a 
polyhydrate from acetone-water (1: 1), was used in the data collection. 
Data reported here were derived from an irregular chunk of dimensions 
(0.6 x 0.4 x 0.15 mm3) .. Crystal data: formula C71H127N 130 16/(H20)I 8, 
FW::::1418/(324); orthorhombie, P212121, a::::12.507(3), b::::19.573(4), 
c::::41.416(8) A, V::::10,139 A3, Z=4, Rho:::: 1. 142. 
The data collection nominally covered a hemisphere. Intensities of 
18,590 unique reflections were collected on a Siemens SMART area 
detector system, fitted with a nitrogen low-temperature gas flow device, 
using MoKa (/\,,=0.71071 A) X-radiation. These data were processed 
using program SAINT which corrects for LP effects and crystal decay 
for the duration of the experiment. 
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The structure was solved by direct methods and refined usmg the 
SHELXTL system of programs and all the unique intensity data. The best 
converged conventional R-factor was 0.12 for 12,029 refractions with 
Fo>40 (Fo). All numerical data discussed here came from programs in 
the SHELXTL system as well as the perspective diagram of the molecule 
(Figure 4.6.1), which defines the atom labelling scheme used for the 
crystal structure. 
Determination of Absolute Configuration A sample of the acid 
hydrolysate of theonellapeptolide lIIe 50 (1 mg) was dissolved in aq. 
Li2C03 (0.04M) (3 mL) and reacted with dansyl chloride (Dan-CI 2.2 
mg/AcCN 1mL) (2.3 mL)I58 at room temperature (2 h). The solvent was 
removed under vacuum. The Dan-amino acids were further purified on a 
Diol cartridge with DCM-ether-HOAc (5:1:1) as eluent. The first 
fraction (0.8 mL) was collected and dried under N2 (0.8 mg). The Dan-
derivatives were analysed on a reverse-phase HPLC column (ODS, 4.6 x 
220 mm) run isocratically using L-Val (4 mM)-copper acetate (2 mM) 
-sodium acetate (0.3 M) (pH 7) as chiral eluent (1 mL/min). Standard 
Dan-L-Thr and Dan-DL-Thr were coinjected with the dansyl derivatives. 
The retention times of the standard Dan-D-Thr and Dan-L-Thr were 720 
and 780 s, respectively. The Dan-Thr in the hydrolysate eluted at 780 s, 
which indicated an L.;.configuration for this residue. 
7.4.4 Theonellapeptolide IIIb (52) 
IH and l3C NMR data in Table 5.1; a colourless powder; [a]D -490 (c 0.7, 
MeOH); IR (CHCb) vmax 3352, 3024, 3008, 2966, 2936, 2878, 2484, 
1734,1672,1626,1522,1464,1416,1117,1099,1045 cm- I; HRFABMS 
m/z 1508.8134 ([M+Cs]+, +2.5 mmu for C68H121N 13016CS); FABMS 
(glycerol) m/z 1377 (M+H)+, 1304, 1205, 1120, 1106, 1037, 923, 767, 
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708, 669, 651, 623, 524,496, 468, 380, 368, 340, 312, 257, 211, 144, 
100, 86, 72, 58, 44. 
Amino Acid Analysis by GC/MS The N-trifluoroacetamide-n-
butyl esters of the hydrolysate were prepared and analysed as described in 
Section 704.1. 
Methanolysis of 52 Theonellapeptolide IIIb (52) (l mg) was 
dissolved in dry MeOH (220 J.lL) with NaOMelMeOH (4%) (66 J.lL). For 
details see Section 704.1. The methanolysis product 53 (0.9 mg) was 
produced. 
Methyl Ester ofTheonellapeptolide IIIb (53) FABMS, m/z 
1447 (M+K)+, 1431 (M+Na)+, 1409 (M+H)+, 1237, 1152, 1065, 1051, 
1037, 1011,980,966,867,853,740,669,654,556,527,496,429.400, 
344,337,299,223,172,100,72,58,44. 
Determination of Absolute Configuration: 
GITC method A solution of standard amIno acids, or a 
theonellapeptolide hydrolysate (20 J.lL; -5.05 mg/mL each) was combined 
with triethylamine (6%,10 J.lL) and 2,3,4,6-tetra-O-acetyl-~-D­
glucopyranosyl isothiocyanate (GITC; Aldrich 33.858-3) (1 %) in acetone 
(20 J.lL) and stood at room temperature for 5 min. An aliquot of the 
product (10 J.lL) was analysed on an LCIMS system using an ODS column 
(150 x 4.6 mm). The identity and chirality of the individual amino acids 
were identified by comparison of their mass and retention time prepared 
from GITC derivatives against those of the optically pure standard 
samples. 
Chapter Seven-Experimental 260 
FDAA method A standard mixture of amino acids was prepared (0.05 
mg/mL for each amino acid in 0.05% TFA). An aliquot of this amino 
acid mixture (20 JlL), or the theonellapeptolide hydrolysate (20 JlL) was 
combined with triethylamine (6%, 10 JlL) and Na-(2,4-Dinitro-5-
fluorophenyl)-L-alaninamide (FDAA; Aldrich 36,605-6) in acetone (l %). 
This mixture was incubated at 40°C for 1 hour in a mierovial (l00 JlL), 
then diluted with water (50 JlL). The product was analysed as above. 
(GITC and FDAA derivatives were prepared and analysed by Dr, Shegi 
and Dr. Pannell at NIDDKlNIH, USA). 
7.4.5 Structural Study on Theonellapeptolide IlIa (54) 
Theonellapeptolide IlIa (54): a colourless powder; [a]D -400 (c 0.8, 
MeOH); IR (CHCI)) Vrnax 3346, 3030, 3014, 2935, 1734, 1670, 1643, 
1624, 1522, 1466, 1416, 1306, 1196, 1140, 1099, 1049 em-I; HRFABMS 
mlz 1584.8110 ([M+Cs]+, mmu for C70HI2SN13017SCS); FABMS 
(glycerol) mlz 1453 (M+H)+, 1281, 1252, 1187, 1120,923, 843,776, 
745, 654, 612, 569, 524, 495, 470, 439, 397, 380, 333, 312, 269, 224, 
196, 172, 144, 100, 86, 72, 58,44; NMR data: OR (35% CD30D/CDCI)) 
methoxyl acetate [3.69 (2H, s, H2), 3.21 (3H, s, OCH3)], Vall [7.07 (lH, 
d, 1=8.7 Hz, NH), 4.62 (lH, m, H2), 1.84 (lH, m, H3), 0.73 (3H, CH3), 
0.68 (3H, CH3)], MeHyMet [4.54 (lH, H2), 2.80 and 2.39 OH, 1H, H4), 
2.50 (3H, s, NCH3), 2.38 (3H, s, SCH3)], Thr [8.11 (IH, brs, NH), 4.94 
(lH, m, H3), 4.58 (lH, m, H2), 0.79 (IH, d, 1=6 Hz, H4)], Me-~-Ala 
[3.74 (lH, m, H3), 3.02 (lH, m, H3), 2.69 (3H, s, NCH3), 2.23 (IH, m, 
H2), 2.10 (lH, m, H2)], Val 2 [8.12 OH, brs, NH), 4.99 (lH, m, H2), 
1.41 (lH, m, H3)], Melle 1 [4.80 (lH, d, 1=11.1 Hz, H2), 3.08 (3H, s, 
NCH3), 1.98 OH, m, H3), 1.17 (lH, m, H4), 0.84 (3H, H5), 0.64 (3H, d, 
1=4.2 Hz, H6)], ~-Ala [6.98 OH, brs, NH), 3.68 (lH, m, H3), 2.97 (IH, 
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ill, H3), 2.24 (IH, ill, H2), 2.00 (lH, ill, H2)], lIe [7.86 (IH, d, 1=9.0 Hz, 
NH), 4.62 (lH, ill, H2), 1.36 (lH, ill, H3), 1.13 (lH, ill, H4), 0.71 (3H, 
H5), 0.69 (3H, H6)], Melle 2 [4.58 (lH, ill, H2), 3.08 (3H, s, NCH3), 2.38 
(lH, ill, H3), 1.12 (lH, ill, H4), 0.71 (3H, H5), 0.52 (3H, d, 1=6.3 Hz, 
H6)], MeAla [4.72 (lH, ill, H2), 2.99 (3H, s, NCH3), 1.18 (3H, d, 1=6.6 
Hz, H3)], Ala [6.77 (lH, d, 1=4.5 Hz, NH), 4.04 (lH, ill, H2), 0.94 (3H, d, 
1=5.7 Hz, H3)], Leu [7.52 (lH, t, 1=6.0 Hz, NH), 4.63 (lH, ill, H2), 1.71 
(lH, ill, H3), 1.60 (lH, ill, H3)], MeLeu [4.32 (lH, ill, H2), 2.94 (3H, s, 
NCH3)]. 
Dc (35% CD30D/CDC13) illethoxyl acetate [169.6 (s, C1), 71.0 (t, C2), 
58.6 (s, OCH3)], Vall [171.5 (s, CO), 53.7 (d, C2), 31.7 (d, C3)], 
MeHyMet [169.7 (s, C1), 60.7 (d, C2), 56.2 (d, C3) 50.6 (t, C4); 3704 (s, 
SCH3)], Thr [168.2 (s, CO), 70.0 (d, C3), 52.3 (d, C2), 16.7 (q, C4)], 
Me~Ala [171.0 (s, CO), 44.3 (t, C3), 35.0 (q, NCH3), 33.5 (t, C2)], Val 2 
[174.9 (s, CO), 52.3 (d, C2), 37.6 (d, C3)], Melle 1 [171.7 (s, CO), 55.1 
(d, C2), 32.9 (d, d3), 30.9 (q, NCH3), 15.0 (q, C6)], ~-Ala [173.3 (s, 
CO), 34.7 (t, C3), 33.5 (t, C2)], lIe [174.9 (s, CO), 54.1 (d, C2), 39.5 (d, 
C3), 11.2 (q, C5) 20.3 (q, C6)], Melle 2 [17304 (s, CO), 52.3 (d, C2), 
37.9 (q, NCH3), 37.6 (d, C3), 25.8 (t, C4), 14.1 (q, C6)], MeAla [ 169.7 
(s, CO), 56.2 (d, C2), 34.7 (q, NCH3), 13.9 (q, C3)], Ala [173.1 (s, CO), 
50.6 (d, C2), 17.3 (q, C3)], Leu [172.6 (s, CO), 47.7 (d, C2), 36.6 (t, 
C3)], MeLeu [173.7 (s, CO), 60.7 (d, C2), 30.6 (q, NCH3)]. 
Amino Acid Analysis by GC-MS The N-trifluoroacetaillide-n-
butyl esters of the hydrolysate were prepared and analysed as described in 
Section 704.1. 
Methanolysis of 54 Theonellapeptolide IlIa (54) (l ill g) was 
dissolved in dry MeOH (220 I-lL) with NaOMelMeOH (4%) (66 ilL). The 
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methanolysis product 55 (l.1 mg) was isolated and purified as described 
in Section 704.1 .. 
Methyl Ester of Theonellapeptolide IlIa (55) F AB MS, m I z 
1485 (M+H)+, 1141, 1056, 1051,867,787,745,740,695,679,603,581, 
521,489,429.400,375,337,315,223, 172, 131, 100,72,57,45. 
Determination of Absolute Configuration The configurations of 
the component amino acids of theonellapeptolide IlIa were determined in 
the same way as described in Section 70404. 
7.4.6 Structural Study of Theonellapeptolide Illc (56) 
Theonellapeptolide Illc (56): a colourless powder; [a]D -41 0 (c 0.8, 
MeOH); IR (CHCb) Vmax 3346, 3015, 2966, 2936, 2878, 2361, 1734, 
1672, 1627, 1522, 1466, 1416, 1138, 1099 cm- I ; HRFABMS mlz 
1522.8339 ([M+Cs]+, +7 mmu for C69H123N13016CS); FABMS 
(glycerol) mlz 1391 (M+H)+, 1318, 1219, 1120, 1106, 1092, 1037, 923, 
795, 781, 726, 654, 640, 581, 524, 496, 468, 439, 425, 397, 380, 368, 
312,299,285,271,211,199,182,172,144,100,86,72,58, 44; NMR 
data: OR (CD30H) methoxyl acetate [3.81 (2H, S, H2), 3.30 (3H, s, 
OCH3)], Val [7041 (lH, d, 1=8.7 Hz, NH), 4.70 (lH, m, H2), 1.94 (lH, m, 
H3), 0.80 (3H, H4), 0.76 (3H, H5)], Leu 1 [7.99 (lH, d, 1=4.5 Hz, NH), 
4.74 (lH, m, H2), 1.79 (lH, m, H3), 1.15 (lH, m, H4), 0.79 (3H, H5)], 
Thr [8.86 (IH, d, 1=6 Hz, NH), 5.10 (lH, m, H3), 4.59 (lH, m, H2), 0.92 
(lH, d, 1=4.2 Hz, H4)], Me~Ala [4042 (lH, m, H3), 2.68 (lH, m, H3), 
2.65 (3H, s, NCH3), 2046 (lH, m, H2), 2.08 (lH, m, H2)], MeAla 1 [4.93 
(lH, m, H2), 3.14 (3H, s, NCH3), 1.29 (3H, d, 1=4.2 Hz, H3)], Melle 1 
[4.91 (lH, d, 1=7.8 Hz, H2), 3.09 (3H, S, NCH3), 2.03 (IH, m, H3), 1.30 
(lH, m, H4), 0.95 (3H, H5), 0.75 (3H, d, 1=7.5 Hz, H6)], ~-Ala [7.52 (lH, 
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dd, 1=9.0, 5.4 Hz, NH), 4.09 (lH, m, H3), 2.98 (lH, m, H3), 2.23 (lH, m, 
H2), 2.03 (lH, m, H2)], lIe [8.48 (IH, d, 1=6.0 Hz, NH), 5.05 (lH, m, 
H2), 1.55 (lH, m, H3), 1.00 (2H, m, H4), 0.87 (3H, H5), 0.66 (3H, H6)], 
Melle 2 [4.99 (lH, m, H2), 3.17 (3H, s, NCH3), 2.08 (lH, m, H3), 1.24 
(2H, m, H4), 0.73 (3H, H5), 0.74 (3H, d, 1=7.5 Hz, H6)], MeAla 2 [4.92 
(lH, m, H2), 2.60 (3H, s, NCH3), 1.23 (3H, d, 1=4.5 Hz, B3)], Ala [7.23 
(IH, d, 1=4.2 Hz, NH), 4.03 (lH, m, H2), 1.09 (3H, d, 1=4.5 Hz, H3)], 
Leu 2 [8.13 (lH, t, 1=4.8 Hz, NH), 4.72 (lH, m, H2), 1.58 (lH, m, H3), 
1.16 (lH, m, H3)], MeLeu [3.41 (lH, m, H2), 3.20 (3H, s, NCH3), 1.70 
(2H, m, H3), 1.49 (lH, m, H4), 0.93 (3H, H5), 0.84 (3H, H6)]. 
be (35% CD30D/CDC13) methoxyl acetate [171.7 (s, Cl), 72.4 (t, C2), 
59.6 (s, OCH3)], Val [174.7 (s, CO), 55.8 (d, C2), 32.1 (d, C3), 19.4 (q, 
C4), 17.8 (q, C5)], Leu 1 [171.7 (s, CO), 48.7 (d, C2)], Thr [169.9 (s, 
CO), 71.2 (d, C3), 54.0 (d, C2)], Me~Ala [175.6 (s, CO), 45.7 (t, C3), 
35.2 (q, NCH3), 34.7 (t, C2)], MeAl a 1 [174.0 (s, CO), 56.4 (d, C2), 32.1 
(q, NCH3), 15.1(q, C3)], Melle 1 [61.0 (d, C2), 32.4 (d, C3), 31.6 (q, 
NCH3), 15.0 (q, C6), 9.9 (q, C5)], ~-Ala [173.2 (s, CO), 35.8 (t, C2), 
35.4 (t, C3)], lIe [176.4 (s, CO), 54.2 (d, C2), 39.1 (d, C3), 27.3 (t, C4), 
11.7 (q, C5), 15.7 (q, C6)], Melle 2 [173.7 (s, CO), 56.4(d, C2), 34.6 (d, 
C3), 31.9 (q, NCH3), 15.5 (q, C6)], MeAla 2 [ 172.2 (s, CO), 58.2 (d, 
C2), 30.0 (q, NCH3)], Ala [175.6 (s, CO), 52.9 (d, C2), 18.3 (q, C3)], 
Leu 2 [175.1 (s, CO), 49.2 (d, C2), 40.8 (t, C3)], MeLeu [172.7 (s, CO), 
63.6 (d, C2), 38.9 (q, NCH3), 38.8 (t, C3), 25.7 (d, C4), 23.5 (q, C5), 
22.4 (q, C6)]. 
Amino Acid Analysis by GC/MS The N-trifluoroacetamide-n-
butyl esters of the hydrolysate were prepared and analysed as described in 
Section 7.4.1. 
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Methanolysis of 56 Theonellapeptolide lIIc (56) (1 mg) was 
dissolved in dry MeOH (220 ilL) with NaOMelMeOH (4%) (66 IlL). The 
treatment was the same as in Section 7.4.1. Methanolysis product 57 (1.0 
mg) was produced. 
Methyl Ester of Theonellapeptolide HIc (57) F AB MS, m I z 
1423 (M+H)+, 1377, 1251, 1079, 1037, 994, 867, 669, 683, 654, 563, 
521,471,429,343,337,315,223, 100,72,57,45. 
Determination of Absolute Configuration The configurations of 
the component amino acids of theonellapeptolide IlIc were determined in 
the same way as described in Section 7.4.4. 
7.4.7 Structural Study of Theonellapeptolide IIId (58) 
Theonellapeptolide HId (58): a colourless powder~ [a]D -470 (c 1.4, 
MeOH); IR (CHCI)) Vmax 3352, 3026, 3007, 2966, 2936, 2876, 1734, 
1674, 1626, 1526, 1468, 1416, 1467, 1416, 1117, 1092, 1053 em-I; 
HRFABMS mlz 1536.8409 ([M+Cs]+, -1.2 mmu for C70H125N13016CS); 
FABMS (glycerol) mlz 1405 (M+H)+, 1333, 1204, 1037, 1023, 909,809, 
795,711,654,640,581,524,496,468,439,425,397,380, 368, 312, 
299,285,211,199,182,172,144,100,86,72,58,44; NMR data: OB 
(CD30H) methoxyl acetate [3.85 (2H, s, H2), 3.19 (3H, s, OCH3)], Vall 
[7.48 (lH, d, 1=8.7 Hz, NH), 4.98 (lH, m, H2), 1.99 (1H, m, H3), 0.90 
(3H, H4)], MeLeu 1 [5.26 (lH, m, H2), 3.19 (3H, s, NCH3), 2.03 (lH, m, 
H3), 1.45 (lH, m, H3), 1.45 (lH, m, H4), 1.03 (3H, H5), 0.79 (3H, H6)], 
Thr [9.03 (lH, d, 1=6 Hz, NH), 5.42 (lH, m, H3), 4.94 (lH, m, H2), 1.27 
(lH, br, H4)], Me~Ala [4.68 (lH, m, H3), 2.72 (lH, m, H3), 2.72 (3H, s, 
NCH3), 2.53 (lH, m, H2), 2.29 (lH, m, H2)], Val 2 [8.18 (lH, br, NH), 
5.02 (lH, m, H2), 2.01 (1H, m, H3), 0.96 (3H, H4)], MeVal [5.22 (lH, 
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H2), 3.24 (3H, s, NCH3), 2.05 (lH, m, H3), 1.13 (lH, H4), 1.06 (3H, 
H5)], ~-Ala [7.62 (lH, d, brs, NH), 4.54 (lH, m, H3), 3.43 (lH, m, H3), 
2.68 (lH, m, H2), 2.48 (lH, m, H2)], He [8.74 (lH, br, NH), 5.33 (lH, m, 
H2), 1.72 (lH, m, H3), 1.41 (lH, m, H4), 1.18 (lH, m, H4), 1.03 (3H, 
H5), 0.96 (3H, H6)], Melle [5.18 (lH, m, H2), 3.31 (3H, s, NCH3), 2.23 
(lH, m, H3), 1.36 (2H, m, H4), 0.81 (3H, d, 1=4.8 Hz, H6)], MeA1a 2 
[5.18 (lH, m, H2), 2.68 (3H, s, NCH3), 1.42 (3H, d, 1=6.0 Hz, H3)], Ala 
[7.41 (lH, brs, NH), 4.48 (lH, m, H2), 1.27 (3H, br, H3)J, Leu [8.38 (lH, 
d, 1=7.5 Hz, NH), 5.07 (lH, m, H2), 1.85 (lH, m, H3), 1.29 (lH, m, H3), 
1.85 (lH, m, H4), 1.06 (3H, H5), 0.94 (3H, H6)], MeLeu 2 [3.69 (lH, m, . 
H2), 3.26 (3H, s, NCH3), 1.97 (2H, m, H3), 1.63 (lH, m, H4), 1.04 (3H, 
H5), 0.98 (3H, H6)]. 
be (35% CD30D/CDC13) methoxyl acetate [170.5 (s, C1), 72.0 (t, C2), 
59.1 (s, OCH3)], Vall [174.1 (s, CO), 54.7 (d, C2), 30.8 (d, C3)], MeLeu 
1 [172.9 (s, CO), 56.4 (d, C2), 38.1 (t, C3), 25.9 (d, C4)], Thr [169.2 (s, 
CO), 71.0 (d, C3), 53.7 (d, C2), 17.8 (q, C4)], Me~Ala [172.7 (s, CO), 
45.3 (t, C3), 34.7 (q, NCH3), 34.7 (t, C2)], Val 2 [174.1 (s, CO), 55.5 (d, 
C2), 31.8 (d, C3)], MeVal [61.0 (d, C2), 31.5 (q, NCH3), 31.0 (d, C3)], 
~-Ala [173.0 (s, CO), 35.7 (t, C2), 35.5 (t, C3)], He [175.9 (s, CO), 53.7 
(d, C2), 38.8 (d, C3), 15.4 (q, C6)], Melle [172.5 (s, CO), 55.5(d, C2), 
33.8 (d, C3), 31.7 (q, NCH3), 15.8 (q, C6)], MeAla [ 171.2 (s, CO), 57.5 
(d, C2), 29.7 (q, NCH3), 15.0 (q, C3)], Ala [174.6 (s, CO), 52.2 (d, C2), 
17.6 (q, C3)], Leu [174.8 (s, CO), 48.8 (d, C2), 40.7 (t, C3), 25.5 (d, 
C4)], MeLeu [172.4 (s, CO), 63.0 (d, C2), 38.5 (t, C3), 38.3 (q, NCH3), 
25.6 (d, C4)]. 
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Amino Acid Analysis by GC/MS The N -trifluoroacetamide-n-
butyl esters of the hydrolysate were prepared and analysed as described in 
Section 704.1. 
Methanolysis of 58 Theonellapeptolide HId (58) (11.5 mg) was 
dissolved in dry MeOH (204 mL) with NaOMeIMeOH (4%) (0.7 mL). 
The methanolysis product 59 (9.8 mg) was isolated and purified as 
described in Section 704.1. 
Methyl Ester of Theonellapeptolide HId (59) FAB MS, m / z 
1437 (M+H)+, 1093, 1051, 1037, 1008, 881, 853,726,711,697,669, 
654,603,581,556,521,429.400,344,337,299,223,172, 100,72,57, 
45. 
Determination of Absolute Configuration The configuration of the 
component amino acids of theonellapeptolide HId was determined as 
described in Section 70404. 
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Table A1.1 Atomic coordinates ( x 104) and equivalent isotropic 
displacement parameters (A2 x 103) for 50. 
U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor. 
x y z U(eq) 
011 1685(6) 1091(3) 1629(2) 55(2) 
C11 2377(9) 760(5) 1508(2) 42(2) 
C21 3037(7) 217(4) 1684(2) 43(2) 
C3'l 2506(8) 7(5) 1999(2) 46(2) 
C31 3114(10) -535(7) 2201(3) 73(3) 
C41 4170(12) -270(10) 2327(4) 126(6) 
C51 2396(13) -804(9) 2455(3) 116(6) 
N1 3206(6) -376(3) 1465(2) 38(2) 
CN1 4346(8) -548(6) 1394(3) 72(3) 
022 1470(5) -395(3) 1345(1) 42(2) 
C12 2367(7) -642(4) 1312(2) 28(2) 
C22 2532(6) -1285(4) 1116(2) 32(2) 
C3'2 2454(8) -1914(5) 1347(2) 46(2) 
C32 2796(9) -2585(5) 1195(2) 53(3) 
C42 4009(10) -2648(6) 1165(3) 93(4) 
C52 2339(12) -3201(5) 1391(3) 92(4) 
N2 1719(5) -1353(3) 864(2) 34(2) 
033 2691(5) -884(3) 463(1) 41(2) 
C13 1854(7) -1174(4) 561(2) 32(2) 
C23 939(6) -1304(4) 331 (2) 31(2) 
C33 229(7) -687(4) 287(2) 46(2) 
N3 315(6) -1915(4) 428(2) 33(2) 
044 1699(5) -2610(3) 374(1) 44(2) 
C14 754(8) -2508(5) 440(2) 35(2) 
C24 98(7) -3117(4) 579(2) 44(2) 
C34 515(9) -3806(5) 445(3) 81(4) 
N4 -1064(6) -3039(4) 529(2) 44(2) 
CN4 -1424(8) -3127(5) 193(2) 59(3) 
055 -2769(6) -3093(3) 701(2) 55(2) 
C15 -1803(8) -3029(4) 762(2) 44(2) 
C25 -1473(8) -2929(4) 1121(2) 45(2) 
C35 -1827(10) -3531(5) 1333(3) 69(3) 
C45 -1338(11) -4188(5) 1196(3) 76(4) 
C55 -1405(19) -3400(7) 1691(3) 145(8) 
C65 -1801(17) -3941(10) 1927(4) 152(7) 
N5 -1921(6) -2258(4) 1219(2) 53(2) 
CN5 -3069(9) -2191(7) 1273(4) 117(6) 
066 -271(5) -1793(3) 1167(1) 44(2) 
C16 -1226(9) -1716(5) 1234(2) 44(2) 
C26 -1648(9) -1042(5) 1364(2) 58(3) 
C36 -1676(13) -1076(6) 1738(3) 88(4) 
C46 -535(14) -1108(8) 1889(3) 99(5) 
C56 -2376(18) -437(7) 1862(4) 133(8) 
C66 -2931(21) -458(10) 2087(10) 330(28) 
N6 -975(6) -494(4) 1249(2) 41(2) 
077 -2366(6) 142(4) 1063(2) 70(2) 
C17 -1403(9) 66(5) 1098(2) 54(3) 
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C27 -611(8) 563(5) 958(2) 53(3) 
C37 -930(9) 1318(5) 999(3) 62(3) 
N7 -574(8) 1612(6) 1304(3) 88(4) 
088 -1819(9) 1267(7) 1600(2) 133(5) 
C18 -1017(10) 1615(6) 1570(3) 64(3) 
C28 -531(8) 2009(5) 1851(2) 52(3) 
C38 -1038(11) 1839(6) 2171(3) 75(4) 
C48 -622(16) 1077(6) 2269(3) 118(6) 
C58 -737(11) 2341(6) 2445(3) 81(4) 
C68 1310(16) 2219(8) 2755(3) 121(6) 
N8 -544(6) 2743(4) 1765(2) 49(2) 
CN8 -1614( 10) 3056(8) 1728(3) 94(4) 
099 1229(6) 2800(3) 1737(2) 57(2) 
C19 360(9) 3083(5) 1705(2) 42(2) 
C29 365(9) 3830(5) 1604(2) 56(3) 
C39 725(20) 4280(6) 1893(3) 133(8) 
C49 919(20) 5048(6) 1767(3) 151 (8) 
C59 238(23) 4240(8) 2155(4) 186(12) 
N9 1130(6) 3932(4) 1345(2) 51(2) 
01010 -74(6) 4178(4) 962(2) 67(2) 
ClIO 866(8) 4111(5) 1053(2) 48(3) 
C210 1770(8) 4243(5) 821(3) 63(3) 
C310 1978(9) 3671(5) 577(3) 66(3) 
NlO 2593(6) 3110(4) 717(2) 53(2) 
CNI0 3758(8) 3204(6) 707(3) 69(3) 
01111 1094(6) 2526(3) 861(2) 69(2) 
Cl11 2077(10) 2572(5) 851(2) 52(3) 
C211 2776(8) 2039(4) 1022(2) 49(3) 
C311 2229(8) 1332(4) 1004(2) 52(3) 
C411 2255(11) 1018(6) 664(3) 80(4) 
NIl 2933(6) 2282(3) 1351(2) 40(2) 
011 2799(5) 869(3) 1215(2) 48(2) 
01212 4741(6) 2156(4) 1370(2) 71(2) 
C112 3851(9) 2354(5) 1492(2) 48(2) 
C212 3833(7) 2698(4) 1823(2) 40(2) 
C3'12 4050(8) 2189(5) 2093(2) 49(3) 
C312 3897(10) 2475(6) 2429(2) 68(3) 
C412 4427(12) 2010(9) 2686(3) 111(5) 
C512 2718(12) 2568(8) 2508(3) 104(5) 
N12 4599(5) 3284(4) 1819(2) 38(2) 
CN12 5714(7) 3149(5) 1892(2) 47(2) 
01313 3337(6) 3897(3) 1559(2) 52(2) 
Cll3 4245(8) 3865(5) 1677(2) 38(2) 
C213 5000(7) 4474(4) 1636(2) 38(2) 
C313 4429(8) 5148(5) 1638(2) 54(3) 
C413 5176(9) 5743(5) 1569(3) 77(3) 
C513 3885(10) 5251(6) 1972(3) 74(3) 
N13 5597(7) 4349(4) 1341(2) 45(2) 
01414 7260(5) 4436(3) 1567(2) 55(2) 
C114 6679(9) 4357(5) 1323(2) 47(2) 
C214 7149(8) 4227(5) 996(2) 53(3) 
01514 6533(6) 3779(4) 797(2) 68(2) 
C014 6670(12) 3060(6) 885(3) 88(4) 
X115 2596(5) -25(3) 85(2) 61(2) 
X215 -3712(6) -4359(4) 566(2) 70(2) 
X315 -4710(6) -2647(4) 374(2) 83(2) 
X415 -612(6) 4349(4) 331(2) 69(2) 
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X515 2964(6) 5198(4) 248(2) 87(2) 
X615 6108(6) 3975(4) 144(2) 76(2) 
X715 3417(6) -3416(4) 248(2) 83(2) 
X815 -1979(6) -1534(4) 466(2) 75(2) 
X915 4452(7) 4941(4) 772(2) 91(3) 
X1015 -962(7) 792(4) 109(2) 84(2) 
XI115 11017(8) 4768(5) 1(2) 103(3) 
X1215 4788(9) -1336(6) 585(3) 122(3) 
X1315 7888(14) 1938(9) 260(4) 193(6) 
X1415 6228(15) 2599(10) -13(5) 207(7) 
X1515 6046(16) 1289(10) 945(5) 216(7) 
X1615 9383( 18) 3118(11) -59(5) 241(8) 
X1715 -3603( 19) -1015(12) 922(5) 249(9) 
X1815 -5265(104) 931(55) 888(25) 1058(97) 
X1915 -3538(8) -501(5) 574(2) 111 (3) 
X2015 -4158(11) 1024(7) 1719(3) 151(5) 
X2115 6563(34) 1427(22) 368(9) 416(20) 
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Table A1.2 Bond lengths[A] for 50. 
Bond lengths Bond lengths 
o 11-C 11 1.192(11) C28-N8 1.480(13) 
Cll-Oll 1.343(11) C28-C38 1.51(2) 
Cll-C21 1.530(14) C38-C58 1.55(2) 
C21-N1 1.488(11) C38-C48 1.63(2) 
C21-C3'l 1.521(13) C58-C68 1.49(2) 
C3'l-C31 1.55(2) N8-C19 1.335(12) 
C31-C51 1.48(2) N8-CN8 1.480(14) 
C31-C41 1.51(2) 099-C19 1.227(11) 
N1-C12 1.331(11) C19-C29 1.522(14) 
N1-CN1 1.495(12) C29-N9 1.449(13) 
022-C12 1.229(10) C29-C39 1.55(2) 
C12-C22 1.513(12) C39-C59 1.25(2) 
C22-N2 1.462( 1 0) C39-C49 1.61(2) 
C22-C3'2 1.563(12) N9-C110 1.304(12) 
C3'2-C32 1.518(13) o 1O lO-C 110 1.241(11) 
C32-C42 1.53(2) CllO-C21O 1.506(14) 
C32-C52 1.56(2) C210-C310 1.53(2) 
N2-C13 1.313(11) C31O-NlO 1.459(13) 
033-C13 1.258(10) NlO-Clll 1.353(13) 
C13-C23 1.510(12) N10-CN10 1.469(13) 
C23-N3 1.484(10) Ollll-Clli 1.234(12) 
C23-C33 1.510(12) Cll1-C2ll 1.54(2) 
N3-C14 1.285(11) C2ll-Nll 1.456(12) 
044-C14 1.229(10) C211-C311 1.546(13) 
C14-C24 1.557(13) C311-011 1.447(11) 
C24-N4 1.476(12) C3ll-C411 1.53(2) 
C24-C34 1.548(13) N11-Cl12 1.295(12) 
N4-C15 1.340(12) 01212-Cl12 1.283(12) 
N4-CN4 1.472(12) Cl12-C212 1.528(13) 
055-C15 1.241(11 ) C212-N12 1.494(11) 
C15-C25 1.552(14) C212-C3'12 1.523(13) 
C25-N5 1.486(12) C3'12-C312 1.511(14) 
C25-C35 1.536(13) C312-C512 1.52(2) 
C35-C45 1.53(2) C312-C412 1.55(2) 
C35-C55 1.59(2) N12-Cl13 1.355(11) 
C55-C65 1.52(2) N12-CN12 1.451(11) 
N5-C16 1.374(12) 01313-C1l3 1.238(10) 
N5-CN5 1.459(13) C1l3-C213 1.530(13) 
066-C16 1.236(11) C213-N13 1.452(12) 
C16-C26 1.520(14) C213-C313 1.500(13) 
C26-N6 1.444(11) C313-C413 1.520(14) 
C26-C36 1.55(2) C313-C513 1.55(2) 
C36-C46 1.56(2) N13-Cl14 1.355(12) 
C36-C56 1.61(2) 01414-C1l4 1.255(11) 
C56-C66 1.17(3) Cl14-C214 1.496(14) 
N6-C17 1.370(13) C214-01514 1.430(12) 
077-Cl7 1.222(12) 01514-C014 1.464(13) 
Cl7-C27 1.505(14) X1515-X1815#1 1.80(12) 
C27-C37 1.541(14) X1715-X1915 1.76(2) 
C37-N7 1.455(14) X1815-X1515#2 1.80(12) 
N7-C18 1.235(14) 
088-C18 1.219(13) 
C18-C28 1.52(2) 
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Table A1.3 Bond angles n for 50 
Bond angles Bond angles 
o ll-C 11-0 11 125.4(9) 066-CI6-N5 120.5(8) 
011-Cll-C21 124.6(9) 066-C 16-C26 121.5(8) 
011-CII-C21 109.3(9) N5-CI6-C26 117.8(8) 
NI-C21-C3'1 112.0(7) N6-C26-CI6 109.0(7) 
NI-C21-C11 109.0(7) N6-C26-C36 111.9(8) 
C3'I-C21-Cll 111.1 (8) CI6-C26-C36 108.9(9) 
C21-C3'I-C31 115.6(8) C26-C36-C46 112.4(10) 
C51-C31-C41 113.9(11) C26-C36-C56 107.3(12) 
C51-C31-C3'1 109.2(11) C46-C36-C56 113.6(12) 
C41-C31-C3'1 112.3(11) C66-C56-C36 124(2) 
CI2-N1-C21 118.9(7) CI7-N6-C26 121.1(8) 
CI2-NI-CNI 124.7(7) 077-C17-N6 122.5(9) 
C21-N1-CNI 115.6(7) 077-CI7-C27 121.6(10) 
022-CI2-Nl 120.9(7) N6-C17-C27 115.8(9) 
022-C 12-C22 120.7(7) CI7-C27-C37 114.0(9) 
NI-C12-C22 118.3(7) N7-C37-C27 113.4(9) 
N2-C22-C12 111.4(6) C18-N7-C37 129.6(10) 
N2-C22-C3 '2 108.7(7) 088-CI8-N7 117.2(11) 
CI2-C22-C3'2 108.5(6) 088-C 18-C28 122.3(12) 
C32-C3'2-C22 114.2(7) N7-CI8-C28 120.3(10) 
C3'2-C32-C42 112.6(9) N8-C28-C38 114.9(8) 
C3'2-C32-C52 110.4(8) N8-C28-CI8 107.8(8) 
C42-C32-C52 110.1(9) C38-C28-C18 113.1(9) 
CI3-N2-C22 124.6(7) C28-C38-C58 113.7(9) 
033-CI3-N2 122.4(8) C28-C38-C48 106.7(11) 
.033-CI3-C23 120.2(8) C58-C38-C48 108.8(9) 
N2-C13-C23 117.4(8) C68-C58-C38 114.3(11) 
N3-C23-C33 111.6(7) CI9-N8-C28 121.2(8) 
N3-C23-C13 111.4(7) C19-N8-CN8 122.7(9) 
C33-C23-C13 112.8(7) C28-N8-CN8 115.9(9) 
C14-N3-C23 120.9(7) 099-C19-N8 120.4(8) 
044-CI4-N3 123.3(8) 099-C19-C29 117.4(9) 
044-C 14-C24 117.7(8) N8-C19-C29 122.3(9) 
N3-C14-C24 118.7(8) N9-C29-C19 109.8(8) 
N4-C24-C34 111.8(8) N9-C29-C39 107.4( 11) 
N4-C24-C14 112.8(7) C 19-C29-C39 109.5(8) 
C34-C24-C 14 110.9(7) C59-C39-C29 120(2) 
CI5-N4-CN4 118.3(8) C59-C39-C49 114.4(13) 
CI5-N4-C24 125.5(8) C29-C39-C49 108.9(10) 
CN4-N4-C24 115.0(8) Cll0-N9-C29 123.7(8) 
055-CI5-N4 121.5(9) 0101O-CIlO-N9 123.4(9) 
055-C15-C25 118.0(8) 0101O-CIlO-C210 120.0(9) 
N4-C15-C25 120.6(8) N9-C110-C210 116.6(9) 
N5-C25-C35 114.3(8) C110-C21O-C31O 115.0(8) 
N5-C25-CI5 105.8(8) Nl 0-C31 0-C210 112.2(9) 
C35-C25-CI5 112.1(7) CI11-NlO-C31O 119.8(9) 
C45-C35-C25 108.3(9) C111-NlO-CNlO 125.5(9) 
C45-C35-C55 110.4(11) C3 10-N lO-CN 10 114.7(8) 
C25-C35-C55 108.4(9) 01111-Cll1-NI0 123.2(10) 
C65-C55-C35 112.1(14) o l111-C l11-C211 120.0(9) 
C16-N5-CN5 123.2(8) N 1 O-C l11-C211 116.6(10) 
CI6-N5-C25 117.1(7) N 11-C211-C 111 106.7(7) 
CN5-N5-C25 119.6(8) N11-C211-C311 113.6(7) 
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C lll-C211-C3 11 
o II-C31 I-C411 
011-C311-C211 
C411-C3 1l-C21l 
Cl12-NI1-C211 
C 11-0 II-C3l1 
Ol2l2-C112-Nl1 
01212-C112-C212 
NII-C112-C212 
N12-C212-C3'12 
N12-C212-CI12 
C3'12-C212-CI12 
C312-C3'12-C212 
C3'12-C312-C512 
C3'12-C312-C412 
C512-C312-C412 
Cl13-N12-CN12 
Cl13-N12-C212 
CN12-N12-C212 
01313-C113-N12 
01313-CI13-C213 
N12-CI13-C213 
N13-C213-C313 
N13-C213-ClI3 
C313-C213-CI13 
C213-C313 -C413 
C213-C313-C513 
C413-C313-C513 
C114-N13-C213 
01414-CI14-N13 
01414-C114-C214 
NI3-CI14-C214 
01514-C214-C114 
C214-0 1514-CO 14 
Bond angles 
109.5(8) 
107.0(8) 
108.2(7) 
113.3(8) 
125.2(8) 
117.0(8) 
124.0(8) 
120.0(9) 
116.0(9) 
113.4(7) 
108.6(7) 
111.5(7) 
114.2(8) 
111.4(10) 
111.1(10) 
109.6(10) 
123.9(7) 
116.0(7) 
118.3(7) 
121.0(8) 
118.8(8) 
120.0(8) 
113.5(8) 
106.3(7) 
113.0(7) 
112.3(8) 
109.2(8) 
109.7(9) 
123.9(8) 
122.4(9) 
121.4(9) 
116.1(9) 
114.5(8) 
112.5(8) 
Symmetry transformations used 
togenerate equivalent atoms: 
#1 x+l, y,z #2 x-I, y, z 
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Table AI.4. Anisotropic displacement parameters (A2 x 103) for 50. 
The anisotropic displacement factor exponent takes the fOlm: 
- _211:2 [(ha*)2 UII + ... + 2 h k a* b* UI2] 
vn V22 V33 V23 Vl3 Vl2 
11 69(5) 37(4) 60(4) -7(3) -1(4) 0(4) 
11 52(6) 27(6) 46(7) -15(5) 0(6) -10(5) 
21 43(5) 37(5) 48(6) -12(5) -16(5) -12(5) 
3' 163(6) 42(6) 33(5) -18(5) -8(5) -6(5) 
31 79(8) 84(9) 57(7) 7(7) -18(6) -10(7) 
41 105(11) 171(16) 103(11) 37(11) -31(9) 23(11) 
51 120( 12) 147(14) 83(10) 64(10) -3(9) -29(11) 
1 31(5) 40(4) 43(4) -4(4) -2(4) -1(4) 
Nl 57(7) 83(8) 76(8) -23(7) -3(5) -1(6) 
22 42(4) 37(4) 47(4) -1(3) -5(3) 0(3) 
12 21(6) 27(5) 36(5) -4(4) -4(4) 0(5) 
22 24(4) 35(5) 36(5) 2(4) -4(4) 0(4) 
3' 246(5) 49(6) 42(5) 11(5) -3(4) 10(5) 
32 70(8) 34(6) 56(6) 5(5) 0(5) 21(5) 
42 105(10) 63(8) 112(10) 11(7) 50(8) 25(7) 
52 134(11) 28(6) 114(10) 17(6) 0(9) 12(7) 
2 30(4) 32(4) 40(5) -6(3) -4(4) -5(3) 
33 40(4) 46(4) 36(3) 4(3) 8(3) -16(3) 
13 48(6) 15(4) 32(6) -4(4) 0(5) 9(4) 
23 35(5) 33(5) 26(5) -5(4) 10(4) -5(4) 
33 46(6) 33(5) 58(6) -3(5) 1(5) -8(5) 
3 32(4) 34(5) 34(4) -7(3) 2(3) -10(4) 
044 43(4) 36(4) 52(4) -6(3) 3(3) 2(3) 
C14 31(6) 37(6) 38(5) -3(4) 6(4) 13(5) 
C24 49(6) 34(6) 48(6) 1(4) 1(4) 0(5) 
C34 60(7) 20(5) 164(12) -6(6) 38(7) -9(5) 
N4 46(5) 37(4) 50(5) -6(4) -2(4) -9(4) 
CN4 64(7) 67(7) 47(6) 3(5) -10(5) -12(6) 
055 41(5) 51(4) 74(5) 3(3) 8(4) -6(3) 
C15 39(7) 26(5) 66(7) -2(5) 11(6) -7(4) 
C25 53(6) 31(6) 50(6) -3(4) 18(5) -14(5) 
C35 87(8) 45(7) 75(8) 6(6) 6(6) -25(6) 
C45 108(10) 54(7) 67(7) 13(6) -20(7) -34(7) 
C55 312(25) 81 (1 0) 42(8) 35(7) 70(11) -12(13) 
C65 184(18) 167(17) 106(12) -32(12) 8(12) -59(15) 
N5 44(5) 42(5) 74(6) -21(4) 29(4) -17(4) 
CN5 49(8) 88(9) 215(17) -86(10) 71(9) -44(7) 
066 47(4) 35(4) 49(4) 0(3) 15(3) -17(3) 
C16 49(7) 46(6) 35(5) -8(4) 19(5) -9(5) 
C26 62(7) 34(6) 79(7) -26(5) 34(6) -27(5) 
C36 141(12) 60(7) 62(8) -31(6) 58(9) -40(8) 
C46 152(15) 103(11) 42(7) 2(7) 29(8) -34(10) 
C56 244(21) 55(8) 99(11) -33(8) 131(13) -40(11) 
C66 222(27) 89(15) 680(72) 139(27) 315(40) 97(17) 
N6 41(4) 28(4) 53(5) 3(4) 0(4) -8(4) 
077 54(5) 59(5) 97(6) -10(4) -3(4) -16(4) 
C17 41(7) 53(8) 68(7) -21(6) -14(5) -15(6) 
C27 72(7) 42(6) 43(5) -2(5) 10(5) -3(5) 
C37 75(7) 53(7) 59(7) -14(6) -4(6) -7(6) 
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N7 57(6) 93(8) 115(9) -67(7) 14(6) -23(6) 
088 138(9) 89(11) 73(6) -11(7) 9(6)- 99(9) 
C18 55(8) 72(8) 65(8) 5(6) 0(7)- 23(7) 
C28 59(6) 40(6) 56(7)- 13(5) -4(5) -18(5) 
C38 102(9) 62(8) 62(7) -4(6) -15(7) -33(7) 
C48 236(20) 48(8) 72(9) 0(7) -27(11) -26(10) 
C58 107(10) 60(8) 77(8) 2(6) 7(7) -1(7) 
C68 189(17) 115(12) 58(9) -3(8) 8(10) -58(12) 
N8 42(5) 56(6) 49(5) -3(4) -8(4) 9(5) 
CN8 69(8) 115(11) 96(10) 4(8)- 17(7) 29(8) 
099 54(5) 46(4) 71(5) 13(3) 20(4) 10(4) 
C19 49(7) 37(6) 39(5) -2(4) -7(5) 15(6) 
C29 90(8) 42(6) 37(6) 1(5)- 10(6) 16(6) 
C39 319(27) 37(7) 44(8)- 10(6) 16(12) 4(11) 
C49 325(27) 42(8) 86(10) 5(7) -20(13) 20(12) 
C59 422(36) 75(11) 62(10) 1(8) 29(15) -86(17) 
N9 51(5) 45(5) 57(6) 15(4) -17(5) -9(4) 
01010 41(5) 99(6) 59(5) 34(4) -13(4) -2(4) 
C110 46(7) 48(6) 50(7) 24(5)- 11(5) -11(5) 
C210 52(6) 48(6) 90(8) 18(6) -4(6) 11(5) 
C310 71(7) 57(7) 70(7) 14(6) 7(6) -8(6) 
NlO 49(5) 47(5) 63(5) 23(4) -5(4) -3(4) 
CN10 48(7) 67(7) 92(8) 21(6) 0(6) -16(6) 
01111 44(5) 56(4) 108(6) 21(4) -6(4) -13(4) 
Clll 77(9) 36(7) 43(6) -3(5) 11(6) -8(6) 
C211 62(6) 30(5) 54(6) -2(5) 2(5) -15(5) 
C311 64(6) 30(5) 62(6) 3(5) -2(5) -13(5) 
C411 126(10) 60(7) 55(7) -8(6) -16(7) -24(7) 
NIl 44(5) 33(4) 43(5) -5(4) 1(4) -8(4) 
011 73(4) 33(4) 38(4) 1(3) 5(4) -5(3) 
01212 51(5) 94(6) 67(5) -32(4) 3(4) 9(4) 
C112 51(7) 40(6) 53(6) -4(5) 8(6) -12(5) 
C212 50(5) 30(5) 38(6) -12(4) 5(4) -6(5) 
C3'12 74(7) 29(5) 44(6) 2(5) -3(5) -3(5) 
C312 90(9) 55(7) 59(7) 4(6) 3(6) -3(7) 
C412 116(11) 152(14) 65(8) 46(9) 3(8) 8(10) 
C512 121(12) 120(12) 70(9) 9(8) 45(8) 53(10) 
N12 43(5) 34(5) 37(4) -1(4) -13(3) -2(4) 
CN12 43(6) 50(6) 47(6) 12(5) -9(5) 4(5) 
01313 55(5) 40(4) 60(4) 12(3) -21(4) -3(3) 
CI13 38(6) 38(6) 38(5) 1(5) -15(5) 5(5) 
C213 39(5) 29(5) 46(6) -7(4) -15(4) 4(4) 
C313 58(6) 38(6) 66(7) -5(5) -17(5) 5(5) 
C413 76(8) 44(7) 111(10) 16(6) -14(7) -18(6) 
C513 86(8) 53(7) 83(8) -9(6) -2(7) 12(6) 
N13 54(6) 46(5) 36(5) 1(4) -11(4) -9(4) 
01414 57(4) 53(4) 55(4) 3(3) -12(4) -3(3) 
C114 51(7) 38(6) 50(7) 9(5)- 10(6) -14(5) 
C214 57(6) 54(6) 47(6) 0(5) 15(5) -11(5) 
01514 85(5) 57(5) 64(4) -1(4) -23(4) -2(4) 
C014 124(11) 58(8) 82(9) -6(7) -4(8) -1(7) 
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Table A1.5 Hydrogen coordinates ( x 104) and isotropic 
displacement parameters (A2 x 103) for 50. 
x y z U(eq) 
H2A1 3738(7) 414(4) 1735(2) 51 
H3'A1 1799(8) -170(5) 1951(2) 55 
H3'Bl 2413(8) 412(5) 2132(2) 55 
H3Al 3276(10) -916(7) 2055(3) 88 
H4A1 4517(49) -621(23) 2450(27) 189 
H4Bl 4046(15) 120(41) 2462(25) 189 
H4Cl 4617(41) -141(64) 2148(4) 189 
H5Al 1777(50) -1006(56) 2357(4) 175 
H5Bl 2179(78) -437(14) 2595(18) 175 
H5C1 2768(36) -l144(46) 2579(19) 175 
HNA1 4391(11) -772(35) 1188(9) 108 
HNB1 4616(19) -847(30) 1559(10) 108 
HNC1 4764(13) -137(7) 1389(18) 108 
H2B2 3243(6) -1274(4) 1016(2) 38 
H3'C2 2896(8) -1829(5) 1535(2) 55 
H3'D2 1720(8) -1957(5) 1420(2) 55 
H3B2 2492(9) -2605(5) 977(2) 64 
H4D2 4294(13) -2237(20) 1073(21) 140 
H4E2 4181(10) -3029(30) 1028(18) 140 
H4F2 4315(12) -2719(48) 1375(4) 140 
H5D2 1583(17) -3142(24) 1420(19) 138 
H5E2 2681(54) -3221(28) 1598(9) 138 
H5F2 2472(66) -3617(7) 1275(11) 138 
HOA2 1110(5) -1522(3) 918(2) 41 
H2C3 1255(6) -1405(4) 120(2) 38 
H3F3 -300(29) -783(11) 126(10) 68 
H3G3 654(10) -304(9) 221(13) 68 
H3H3 -120(35) -583(18) 488(4) 68 
HOB 3 -350(6) -1872(4) 477(2) 40 
H2D4 219(7) -3122(4) 812(2) 52 
H314 38(38) -4166(8) 508(18) 122 
H3J4 1215(30) -3895(21) 531(16) 122 
H3K4 552(63) -3783(15) 214(4) 122 
HND4 -1898(41) -2760(19) 136(5) 89 
HNE4 -1792(45) -3555(16) 172(4) 89 
HNF4 -816(10) -3123(33) 51(3) 89 
H2E5 -691(8) -2899(4) 1130(2) 54 
H3L5 -2608(10) -3565(5) 1334(3) 83 
H4G5 -1571(52) -4248(22) 977(7) 114 
H4H5 -1565(52) -4571(7) 1323(12) 114 
H415 -572(11) -4156(17) 1201(18) 114 
H5G5 -630(19) -3398(7) 1690(3) 174 
H5H5 -1645(19) -2954(7) 1763(3) 174 
H6A5 -1488(102) -3863(50) 2135(11) 229 
H6B5 -1599(111) -4386(12) 1850(21) 229 
H6C5 -2566(21) -3915(54) 1943(29) 229 
HNG5 -3255(18) -1716(7) 1285(30) 176 
HNH5 -3259(17) -2413(54) 1472(15) 176 
HNI5 -3450(9) -2401(55) 1098(15) 176 
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H2F6 -2377(9) -971(5) 1283(2) 70 
H3M6 -2054(13) -1495(6) 1799(3) 105 
H4J6 -588(15) -1072(56) 2119(3) 148 
H4K6 -112(30) -737(32) 1807(20) 148 
H4L6 -203(35) -1534(24) 1833(22) 148 
H5I6 -2335(18) -30(7) 1747(4) 159 
H6D6 -2780(333) -76(173) 2225(71) 496 
H6E6 -2806(347) -875(147) 2203(82) 496 
H6F6 -3665(21) -440(310) 2020(12) 496 
HOC6 -295(6) -519(4) 1276(2) 49 
H2G7 -530(8) 467(5) 729(2) 63 
H2H7 78(8) 490(5) 1060(2) 63 
H3N7 -628(9) 1581(5) 823(3) 75 
H307 1702(9) 1356(5) 986(3) 75 
HOD7 36(8) 1815(6) 1297(3) 106 
H2I8 221(8) 1872(5) 1865(2) 62 
H3P8 -1817(11) 1831(6) 2146(3) 90 
H4M8 -499(97) 815(22) 2076(3) 178 
H4N8 -1155(44) 854(24) 2398(25) 178 
H408 31(54) 1113(7) 2389(26) 178 
H5J8 26(11) 2308(6) 2484(3) 98 
H5K8 -887(11) 2803(6) 2373(3) 98 
H6G8 -1038(76) 2522(48) 2917(9) 181 
H6H8 1202(86) 1754(21) 2822(16) 181 
H6I8 -2061(22) 2301(64) 2725(9) 181 
HNJ8 -1571(18) 3536(12) 1775(22) 140 
HNK8 -2106(20) 2843(34) 1874(17) 140 
HNL8 -1859(35) 2993(43) 1510(7) 140 
H2J9 -351 (9) 3967(5) 1532(2) 67 
H3Q9 1445(20) 4113(6) 1943(3) 160 
H4P9 1081(132) 5338(18) 1947(6) 227 
H4Q9 286(46) 5210(30) 1661(34) 227 
H4R9 1507(82) 5053(15) 1618(30) . 227 
HSL9 554(106) 3889(75) 2285(21) 279 
H5M9 -499(41) 4131(107) 2115(4) 279 
H5N9 283(150) 4670(35) 2266(24) 279 
HOE9 1797(6) 3871(4) 1388(2) 61 
H2K10 2419(8) 4319(5) 945(3) 76 
H2LIO 1618(8) 4660(5) 703(3) 76 
H3RlO 1300(9) 3496(5) 499(3) 79 
H3S10 2365(9) 3855(5) 394(3) 79 
HNM10 4057(10) 3095(36) 914(6) 103 
HNN10 3919(8) 3670(11) 654(18) 103 
HNOIO 4058(10) 2907(28) 546(13) 103 
H2MII 3471(8) 2014(4) 914(2) 58 
H3T11 1485(8) 1372(4) 1076(2) 62 
H4S11 1942(61) 570(18) 670(5) 120 
H4T11 2983(12) 984(39) . 592(8) 120 
H4U11 1858(56) 1302(23) 518(5) 120 
HOFI1 2372(6) 2387(3) 1461(2) 48 
H2N12 3114(7) 2885(4) 1856(2) 47 
H3'E12 3577(8) 1800(5) 2066(2) 59 
H3'F12 4779(8) 2025(5) 2073(2) 59 
H3U12 4243(10) 2924(6) 2438(2) 82 
H4V12 5190(12) 2033(45) 2665(18) 166 
H4W12 4195(70) 1547(12) 2655(17) 166 
H4X12 4223(73) 2161 (36) 2898(3) 166 
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H5012 2382(22) 2832(47) 2341(14) 156 
H5P12 2648(12) 2802(49) 2710(13) 156 
H5Q12 2380(21) 2129(9) 2522(25) 156 
HNP12 6125(10) 3558(9) 1860(13) 70 
HNQ12 5976(15) 2796(21) 1752(10) 70 
HNR12 5779(9) 3004(29) 2113(5) 70 
H2013 5507(7) 4470(4) 1816(2) 46 
H3V13 3873(8) 5139(5) 1472(2) 65 
H4Y13 5339(52) 5755(25) 1343(5) 115 
H4Z13 5825(28) 5687(22) 1690(16) 115 
H4[A13 4836(27) 6163(7) 1631(18) 115 
H5R13 3418(49) 5640(25) 1963(6) 111 
H5S13 4422(10) 5326(40) 2134(4) 111 
H5T13 3478(51) 4851(17) 2026(9) 111 
HOG13 5243(7) 4264(4) 1167(2) 55 
H2P14 7228(8) 4661(5) 886(2) 63 
H2Q14 7857(8) 4034(5) 1024(2) 63 
HOH14 6233(55) 2781(7) 748(15) 132 
HOI14 6460(68) 2996(10) 1106(7) 132 
HOJ14 7406(17) 2933(13) 860(20) 132 
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Theonellapeptolide llle, a New Cyclic Peptolide from the 
New Zealand Deep Water Sponge, Lamellomorpha 
strongylata. 
Shangxiao Li,+ Eric J. Dumdei,+ John W. Blunt,*+ 
Murray H. G. Munro,*+ Ward T. Robinson,+ and Lewis K. PannellJ 
Department of Chemistry, University of Canterbury, Christchurch, NEW 
ZEALAND, AND Laboratory of Bioorganic Chemistry, NIDDK, NIH, 
Bethesda, MD 20892-0805, USA. 
The structure, stereochemistry and conformation of theonellapeptolide 
lIIe (1), a new 36-membered ring cyclic peptolide from the New Zealand 
deep-water sponge Lamellomorpha strongylata, is described. The 
sequence of the cytotoxic peptolide was determined through a 
combination of NMR and MS/MS techniques and confirmed by X-ray 
crystal structure analysis, which, with chiral HPLC, established the 
absolute stereochemistry. 
Since 1982, more than 5,000 specimens of marine organisms have 
been collected from the oceans around New Zealand in a continuous 
endeavour to find bioactive natural products. Over that period, 
compounds with a wide degree of structural diversity and bioactivity have 
been discovered. 1-3 To further explore the potential pharmaceutical 
resources of deep-water marine organisms, an expedition to the Chatham 
Rise, 200 km off the East Coast of the South Island, was carried out in 
early 1995. Preliminary assays on the crude extracts indicated that deep-
water organisms are a rich source of bioactive compounds.4 
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A bioassay-guided separation of the extract from Lamellomorpha 
strongylata from the collection resulted in the isolation of three distinct 
classes of cytotoxic compounds. We have previously reported the 
characterisation of calyculins A, B, E, and F, calyculinamides A and B, 
and swinholide H,4 which comprise two of the classes of cytotoxins from 
this sponge. We now present the structure of theonellapeptolide IIIe (1), 
the major component in the third cytotoxic fraction from the extract. 
Results and Discussion 
A frozen sample of L. strongylata (l kg) was homogenised, 
extracted with MeOH:DCM (1:1) and subjected to rounds of C18, DIOL 
and LH-20 chromatography, as described previously.4 LH-20 
chromatography (MeOH:DCM; 1:1) of the more polar DIOL fractions 
resulted in a fraction with weak P388 activity (ICso 25 ~g/mL) which 
eluted just prior to the calyculinamides A and B. The peptidic nature of 
the fraction was indicated by both the IH NMR (doublets between 87.39-
9.00) and the l3C NMR (resonances between 8 169-176) spectra. 
Purification, by repeated RPHPLC, yielded five new active compounds, 
theonellapeptolides lIla, IIIb, lIIc, HId and HIe, in order of elution. 
Theonellapeptolide HIe (1), the most abundant peptide, exhibited an 
MH+ ion at m/z 1419 in the LRFAB mass spectrum. The molecular 
formula C71H127N 13016 was determined by HRFABMS (m/z 1550.8577, 
[M+Cs]+, L). -0.1). A negative result against ninhydrin suggested that the 
N-terminus was blocked, or part of a cyclic peptide, while the observation 
of a lactone carbonyl stretch (1734 cm- 1) in the IR spectrum, coupled 
with the unsaturation requirements of the molecular formula, indicated 
that 1 was most likely a peptolide rather than a peptide. The 1 H NMR 
spectrum showed seven amide proton signals (89.00, 8.76, 8.43, 8.19, 
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7.65, 7.45, 7.39) and six N-methyl singlets (0 3.33, 3.30, 3.24, 3.19, 
2.75, 2.69). Searching of the MarinLit5 database revealed structural 
similarity of this new compound to the known theonellapeptolides.6-8 
Amino acid analysis by GC-MS of the N-trifluoroacetamide-n-buty1 
ester derivatives9 , 10 formed after complete acid hydrolysis of the 
peptolide confirmed thirteen amino acids: Ala, N-MeAla, ~-Ala, N-Me~­
Ala, Ile, N-Melle (x2), Leu, N-MeLeu (x2), Thr and Val (x2). An 
additional carbonyl resonance in the 13C NMR spectrum, as well as 
signals corresponding to isolated methylene (03.86, s, 2H) and methoxy 
(0 3.16, s, 3H) functionalities in the IH NMR spectrum, indicated the 
probable existence of a 2-methoxyacetyl group, blocking the N-terminus 
of the peptolide. 
To determine the amino acid sequence, the ring-opened methyl 
ester (2) was prepared by methanolysis. Detailed examination of MSIMS 
data from the FAB spectrum of 2 established the sequence shown in 
Figure 1. Of particular note was the observation of daughter ions at mlz 
299, 172 and 100 in the link scan from the ion at mlz 400. These ions 
corresponded to the loss of Thr, N -MeLeu or N -Melle and 2-
methoxyacetyl (from mlz 172) respectively, thus confirming the N-
terminus region. 
In analysing FABMS data it is not possible to distinguish between 
isobaric amino acids, such as Ala and ~-Ala, N-MeAla and N-Me~-Ala, 
Leu and the lle!s, and N-MeLeu and the N-MeIle!s Therefore, the 
suggested sequence had to be confirmed by other methods. This 
confirmation of the amino acid sequence in 1 was accomplished by IH-IH 
decoupling experiments and extensive analyses of the TOCSY, COSY, 
ROESY, HSMQC 11 and HMBC NNIR spectra. The spin systems (see 
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Table 1) for each of the individual amino acid partial structures, except 
for N-MeAla (residue 10) and N-MeLeu (residue 13), were defined by 
COSY and 2D TOCSY experiments. The N-MeAla subunit was 
subsequently defined by specific 1 H _1 H decoupling experiments, which 
showed that the unassigned methyl doublet at 8 1.44 was coupled into an 
a-methine multiplet at 8 5.20. For the N -MeLeu (residue 13) 
examination of the 2D TOCSY spectrum indicated that an unassigned 
methine signal at 8 3.74 gave correlations to 1H resonances at 8 2.05, 1.06 
and 0.98, as well as a weak correlation to 8 1.66, but the 8 3.74 methine 
resonance was not correlated to any carbons in the HMBC spectrum. 
However, a correlation between the protons at 8 3.74 and 2.05 in the 
COSY spectrum, and correlations to 8 2105 from both 8 3.74 and 1.66 in 
ID TOCSY experiments were observed, which suggested the signal at 8 
3.74 was indeed the a-proton for an N-MeLeu. A 1H N-methyl signal (8 
3.30) and the 1 H resonance at 8 2.05 which were correlated with a carbon 
(8 63.0) resonance in the HMBC spectrum supported the given 
assignments. 
Correlations between NH, N-Me or a-protons to carbonyl carbons 
in the HMBC spectrum afforded much of the connectivity data. For 
example, the correlations from H3 of Thr (residue 3) to the carbonyl 
resonance of N-MeLeu (residue 13) suggested that the Thr and N-MeLeu 
were linked by an ester bond, and so established the ring system of the 
peptolide. Complete assignments for NMR resonances, based on ID and 
2D NMR experiments, are summarised in Table 1. Correlations observed 
in the ROESY experiment confirmed the sequence of peptide bonds 
deduced in the HMBC experiment. Interestingly, the ROESY spectrum 
also showed cross peaks between the NH of ~-Ala (residue 7) and the N-
Me of N-Melle (residue 6), between the NH's of Ala and Leu (residues 11 
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and 12), and between the NH of Ala and the N-Me of N-MeAla (residues 
11 and 10), indicating syn orientations about N-MeIle/~-Ala, Ala/Leu and 
A1a1N-MeAla peptide bonds. The same syn orientations were also 
observed in the X-ray analysis (vide infra) suggesting at least comparable 
geometries for the solution and solid phases for 1. The peptide sequence 
deduced from analysis of the NMR data was consistent with the MS/MS 
analysis. 
At this point, the stereochemistry of the component amino acids had 
not been addressed. This was resolved by a combination of X-ray 
crystallography and chiral HPLC. The structure was solved by direct 
methods and refined using the SHELXTL system of programs and all the 
unique intensity data.12,13 The best converged conventional R-factor was 
12.9% for 12,029 reflections with Fa>4cr (Fa). All numerical data came 
from programs in the SHELXTL system.12,13 
In addition to the theonellapeptolide molecule shown (Figure 2), 
there were at least 21 sites for the oxygen atoms of water molecules, 14 
of which were at distances appropriate for H-bonding to carbonyl 0 and 
N atoms of the main chain. These water molecules are labelled in the 
Supplementary Tables. The other 7 water molecules participated in 
water-to-water H-bonding. The atomic displacement parameters were 
consistent with some disorder amongst these water molecules. Six sites, 
involved in inter-atomic distance interactions between 1.6 and 2.0 A, must 
be only partially occupied. These features have so far hindered 
attainment of better conventional agreement factors. Nevertheless, the 
structure is fully characterised by this study. 
Because the X-ray analysis gave only the relative stereochemistry of 
the cyclic peptolide the absolute configuration of at least one of the 
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indi vidual ammo acid residues needed to be determined. This was 
achieved by chiral HPLC analysis of the constituent amino acids. 14 A 
sample of the acid hydrolysis product was derivatized with dansyl 
chloride (Dan-Cl).15 The dansylated derivatives of amino acids were 
coinjected with standard Dan-L-Thr (2S,3R stereogenic centres) and Dan-
D,L-Thr respectively. The Dan-Thr from the hydrolysate was found to 
co-elute with standard Dan-L-Thr, establishing 2S,3R stereochemistry at 
the Thr stereogenic centres. From the relative stereochemistries of 
theonellapeptolide lIIe (1), established by X-ray crystallography, it was 
then possible to assign the stereochemistry at all stereogenic centres. 
Thus, the chiral amino acids of 1 could be assigned as: L-Val, L-Thr, D-
Val, D-allo-Ile, L-N-Melle (x 2), L-N-MeAla, L-Ala, D-Leu and D-N-
MeLeu (x 2). 
Based on the general A - B bond length (2.79 ± 0.12 A) for N-
H ... O bonds, three intramolecular H-bonds can be assumed; 
(crystallographic numbering [residues,distance]) N9 - 013 [Val (residue 
5)-Val (residue 1) 2.89 A], NIl - 09 [Thr (residue 3)-Val (residue 5) 
2.85 A], and N2 - 06 [Leu (residue 8)-aUo-Ile (residue 12) 2.91 A], with 
a further, weaker H-bond that should also be taken into consideration, N6 
- 02 [allo-Ile (residue 8)-Leu (residue 12), 3.08 A]. The latter three of 
these H-bonds are across the peptolide ring and stabilise the complex 
conformation found in 1. The presence of a ~-Ala and a N-Me~-Ala 
allow for considerable flexibility in the conformation of the cyclic 
peptolide ring, which despite this flexibility, can be considered as an 
antiparallel array of two strands in which the turns are secured at one end 
by a ~-Ala (residue 4) and at the other by a cis-peptide bond [N-Melle 
(residue 9)IN-MeAla (residue 10)]. The resulting conformation is a triple 
loop,12 which is more clearly depicted in the backbone projection 
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diagram (Figure 3). The two major loops are defined by the two H-bonds 
between the alia-He and the Leu (residues 8 and 12) which forms an 
antiparallel ~-pleated sheet structure. The third loop is defined by weak 
NH ... O associations from the NH of the ~-Ala (residue 7) to Thr (residue 
3) and MeLeu (residue 13) {N7 - 01 [~-Ala (residue 7)-(Thr (residue 3), 
3.28A], N7 - 0 11 [~-Ala (residue 7)-(N-MeLeu (residue 13), 3.31An. 
That portion of the peptide outside the macrocycle is static, being held in 
place by two H-bonds from Val (residue 5) to Thr (residue 3) and Val 
(residue 1) .. The overall conformation of 1 resembles a "taco shell" 
(Figure 2) with all the larger aliphatic groups aligned along the lip of the 
"taco shell", while the base is composed of the smaller amino acids (Ala, 
~-Ala, N-Me~-Ala).a 
The reported theonellapeptolides I and II differ mainly in variation 
among the aliphatic side chains. For example, theonellapeptolide Ie,7 
which has the same molecular formula as 1, has a similar peptolide 
backbone, but varies in the fifth, ninth, eleventh and thirteenth amino acid 
residues from N-terminus, corresponding to substitutions of D-Val for D-
Leu, L-N-Melle for L-N-MeVal, L-Ala for ~-Ala, and D-N-MeLeu for 
D-N-Meallo-Ile respectively. These modifications result in a 36-, rather 
than 37-membered peptolide ring for 1. An X-ray structure has been 
reported in a conference abstract 16 for theonellapeptolide Id. 
Theonellapeptolide Id differs from Ie only in substitution of a ~-Ala for a 
N-Me~-Ala. Despite the substitution of five amino acid substitutions and 
the difference in ring size there is· a quite remarkable similarity in the 
overall conformation and H-bonding patterns between theonellapeptolides 
IIIe (1) and Id, which suggests that the theonellapeptolide family quite 
probably have similar tertiary structures. 
a Best seen in stereo projection. See Supplementary Figure. 
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Theonellapeptolide lIIe exhibited modest cytotoxicity (7.4 J.lg/mL) 
against the P388 cell line. This sample was also tested for antiviral and 
anti-HIV activities. However, only cytotoxicity and no protection was 
observed. Other reported biological activties for the theonellapeptolide 
family are ion-transport properties for theonellapeptolide Id (Na+, K+, 
and Ca2+) and Ie (Na+, K+ across human erythrocyte membranes).6-8 It 
is pertinent to note that the theonellapeptolide III compounds were 
isolated from a Lamellomorpha sp. sponge, which is in a different order 
from Theonella swinhoei, from which both the theonellapeptolides I and 
II were isolated.6-8 
As it is rare to find so many interesting structures and associated 
bioactivities in one species, further chemical and biological studies are 
currently under way on Lamellomorpha strongylata. In particular, the 
question of what symbiotic microorganisms are present, and their role in 
the production of the bioactive metabolites will be addressed. 
Experimental Section 
General Experimental Procedures. MPs were determined on 
an Electrothermal melting point apparatus and are uncorrected. Optical 
rotations were measured on a JASCO J-20 recording spectropolarimeter. 
IR spectra were recorded on a Shimadzu FTIR-8201PC infrared 
spectrophotometer. GC-MS spectra were measured on a Kratos 
MS80RFA mass spectrometer equipped with a Carlo Erba MFC500 GC. 
F AB and high resolution F AB mass spectra were recorded on a JEOL 
SX 102A spectrometer. 1 H and all 2-D NMR spectra were recorded on a 
Varian UNITY 300 NMR spectrometer. 13C NMR spectra were recorded 
on a Varian XL 300 NMR spectrometer. 
Appendix Two-Publication 301 
Extraction and Isolation. The formal description' of 
Lamellomorpha strongylata and the extraction and separation of the 
theonellapeptolide fraction from the calyculin and swinholide fractions 
has been reported previously. 4 Final purification of the peptolides was 
carried out by reverse-phase HPLC on a Philips PU4100 using an ODS 
column (4.6 mm x 25 em) eluting with H20 (0.1 % TFA)/MeOH (0.1 % 
TFA) (11:89). A limited sample (2 mg) of the crude peptide was injected 
in each run. Cutting the appropriate peak in multiple runs gave pure 
theonellapeptolide lIIe (1) (94 mg). 
TheoneUapeptolide HIe (1): Colorless plates (acetoneIH20: 
1:1); mp 184-186 DC; [a,f2D -48.6° (c 1.0, MeOH); IR (CHCb) vmax 3352, 
3006,2966,2935, 1734, 1672, 1628, 1533, 1468, 1173 em-I; IH NMR 
(CD30D/C6D6, 2:8) see Table 1; 13C NMR (CD30D/C6D6, 2:8) see 
Table 1; HRFABMS, mlz 1550.8577 [M+CsJ+, (caled. for 
C71H127N13016CS 1550.8578). 
Acid Hydrolysis of 1. Theonellapeptolide lIIe (1) (1 mg) 
was placed in a hydrolysis tube and HCl (6 M) (1 mL) was added. After 
sealing under N2, the tube was heated at 110°C (17 h). The acid solution 
was evaporated to dryness under vacuum to give the product (1 mg), 
Methanolysis of 1. Theonellapeptolide lIIe (1) (9 mg) was 
dissolved in dry MeOH (2 mL) with NaOMe/MeOH (4%) (0.6 mL). The 
MeOH solution was stirred at room temperature (3 h), before pouring 
into ice water and extracted with EtOAc (3 x 1 mL). Evaporation of the 
solvent gave a product which was purified by reverse-phase HPLC [H20 
(0.'1 % TFA)/MeOH; 18:82J to give the methanolysis product 2 (6 mg). 
HRFABMS mlz 1582.8860 [M+CsJ+, Cealed. for C72H131N13017CS 
1582.8840). 
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Amino Acid Analysis by GC-MS The N-trifluoroacetamide-
n-butyl esters of the amino acids were prepared under standard 
conditions. IO The acid hydrolysate of 1 (1 mg) was transferred to a 
Reacti-vial (1 mL) and dried under vacuum before HCl-n-BuOH (2 M) 
(400 ilL) was added. The vial was sealed with a Teflon-lined cap and 
after sonication (15 s), was heated at 110°C in an oil bath (10 min), 
followed by further sonication (10 s) and heating (20 min). After cooling 
the solvent was evaporated under vacuum. A trifluoroacetic anhydride-
DCM mixture (750 ilL) (1:2) was added to the sample, which was then 
heated (150 oC for 5 min). The remaining reagent and solvent were 
removed under N2 at 50°C and the product then dissolved in dry DCM 
(600 ilL) for GC analysis. The GC-MS analysis was performed on a DB 
Wax column (30 m x 0.25 mm) with an initial column temperature of 50 
°C which was held for 15 min post-injection and then increased to 130°C 
at 1 a/min, to 250°C at 23 o/min and finally held at 250°C for 20 min. 
The individual amino acids were identified on the basis of retention time 
against standards, and by analysis of the MS data. 
X-ray Structure Determination of Theonellapeptolide IIIe 
(1). A colourless crystal of theonellapeptolide lIIe (1), obtained as a 
polyhydrate from acetone-water (1: 1), was used in the data collection. 
Data reported here were derived from an irregular chunk of dimensions 
(0.6 x 0.4 x 0.15) mm3. Crystal data: formula C71H127N 130 16/(H20h8, 
FW=1418/(324); orthorhombic, P212121, a=12.507(3), b=19.573(4), 
c=41.416(8) A, V=10,139(8) A3, Z=4, P (calculated) = 1.142 Mg/m3, T 
= -70°C. 
The data collection nominally covered a hemisphere. Intensities of 
18,590 unique reflections were collected on a Siemens SMART area 
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detector system, fitted with a nitrogen low-temperature gas flow device, 
using MoKa ("-=0.71073 A) X-radiation. These data were processed 
using program SAINT which corrects for Lp effects and crystal decay for 
the duration of the experiment. All crystallographic data is reported in 
the Supplementary Tables. 
Determination of Absolute Configuration. A sample of 
the acid hydrolysate of theonellapeptolide lIIe 1 (l mg) was dissolved in 
aq. LhC03 (0.04 M) (3 mL) and reacted with dansyl chloride (Dan-CI 
2.2 mgl AcCN 1mL) (2.3 mL) 15 at room temperature (2 h). The solvent 
was removed under vacuum. The Dan-amino acids were further purified 
on a DIOL cartridge with DCM-ether-HOAc (5: 1: 1) as eluent. The first 
fraction (0.8 mL) was collected and dried under N2 (0.8 mg). The Dan-
derivatives were analysed on a reverse-phase HPLC column (ODS, 4.6 x 
220 mm) run isocratically using L-Val (4 mM)-copper acetate (2 mM)-
sodium acetate (0.3 M) (pH 7) as chiral eluent (l mL/min). Standard 
Dan-L-Thr and Dan-DL-Thr were coinjected with the dansyl derivatives. 
Supplementary Material Available: Copies of tables of final 
fractional atomic coordinates and the full list of bond lengths and angles 
from the X-ray crystallographic study of 1, stereoprojection figure. This 
material is contained in libraries on microfiche, immediately follows this 
article in the microfilm version of the Journal, and can be ordered from 
the ACS. See any current masthead page for ordering information. 
Acknowledgments. We thank the University of Canterbury, 
PharmaMar SA, Canterbury Medical Research Foundation, and the New 
Zealand Lotteries Board (Scientific) for financial support; Dr M. R. Boyd 
Appendix Two-Publication 304 
and Dr M. J. Currens (NCI/DTPILDDRD) for HIV assays, Ms G. Ellis 
(University of Canterbury) for other biological assays, and Mr. B. M. 
Clark (University of Canterbury) for mass spectral analyses. 
References 
(1) Perry, N. B.; Blunt, J. W.; Munro, M. H. G. Tetrahedron 1988, 
44,1727-1734. 
(2) Perry, N. B.; Blunt, J. W.; Munro, M. H. G.; Thompson, A. M. 1. 
Org. Chem. 1990, 55, 223-227. 
(3) Litaudon, M.; Hart, J. B.; Blunt, J. W.; Lake, R. J.; Munro, M. H. 
G. Tetrahedron Lett. 1994, 35, 9435-9438. 
(4) Dumdei, E. J.; Blunt, J. W.; Munro, M. H. G.; Pannell, L. K. 1. 
Org. Chem. 1997, 62, 2636-2639. 
(5) Marine Chemistry Group, University of Canterbury, New Zealand; 
M arinLit, A Database of the Literature on Marine Natural 
Products. 
(6) Kobayashi, M.; Lee, N. K.; Shibuya, H.; Momose, T.; Kitagawa, L 
Chem. Pharm. Bull. 1991,39, 1177-1184. 
(7) Kitagawa, I.; Lee, N. K.; Kobayashi, M.; Shibuya, H. Chem. 
Pharm. Bull. 1987, 35, 2129-2132. 
(8) Kitagawa, L; Ohashi, K.; Kawanishi, H.; Shibuya, H.; Shinkai, K.; 
Akedo, H. Chem. Pharm. Bull. 1989,37, 1679-1681. 
Appendix Two-Publication 305 
(9) Leimer, K. R.; Rice, R. H.; Gehrke, C. W. J. Chromatogr. 1977, 
141, 121-144. 
(10) Zumwalt, R. W.; Desgres, l; Kuo, K. C.; Pautz, J. E.; Gehrke, C. 
W. J. Assoc. Off. Anal. Chem. 1987, 70, 253-262. 
(11) Torres, A. M.; Nakashima, T. T.; MeLung, R. E. D. J. Mag. Res. 
Ser. A 1993,102, 219-227. 
(12) Sheldriek, G. M. J. Appl. Crystallogr. In Press. 
(13) Sheldriek, G. M. Acta. Crystallogr., Sect. A. 1990,46,467. 
(14) Armani, E.; Barazzoni, L.; Dossena, A.; Marehelli, R. J. 
Chromatogr. 1988, 441, 287-298. 
(15) Weinstein, S.; Weiner, S. J. Chromatogr. 1984,303, 244-250. 
(16) Bemardinelli, G.; Jefford, C. W.; Sakai, R.; Higa, T. Proceedings, 
Seventh International Symposium on Marine Natural Products, 
July, 1992, Capri, Italy. P29. 
Appendix Two-Publication 
Scheme 1 
MeO-Ac 
6 
L-N-Melle -
789 
~-Ala - D-alio-lie - L-N-Melle 
I I 
1 L-Yal --------. D-Yal 5 
/' 
N-Me-p-Ala 
4 " 
I 
L-N-MeAla 
I 10 
D-N-MeLeu - L-Thr - D-N-MeLeu- D-Leu -- L-Ala 
2 3 13 12 11 
--- --- H-bond. Residue numbers shown for each amino acid. 
Theonellapeptolide IIle (1) 
I 172-, 
o I I 
299----' 
I 
I 
I 
I 
I 
400-, 
I 
OHi 584"'-'-"'" 
I 
: \: I I I 
MeoJi"N i~N 
I H I 
01 
I 
I 
I 
: ......... N 
i H 
0: : I 485-. 1 I 
I I H l"N~~N I :N 
MeO 
I I 
; 0; 
I 
I 
L-,..1378 
L-.-1279 
I 
I 
L-.-1152 
I I 
I I 0: 0; 
t-.....1051 : 
'-966 
429-; 556...-.-...., 
: 344...-.-...., I I 
\\0 Hlf [0 : m/z160 ~ o I I 
I 
I 
10 
I 
I 
1 
I 
I 
: N,i : 
N/i ; N--: 
H ; : I ! 
I 10 I 
I I 1 
'--+1178 I I 
1 I 
I i 
t-.....1291 I 
'--1107 : 
'-----"1022 
r~~T NH , 
740 
I 
I 
'--+782 
Figure 1 F AB MS/MS Fragmentation of 2 (protonated) 
306 
Appendix Two-Publication 307 
- - - H-bonds 
Figure 2. Perspective View of Theonellapeptolide IIle (1) 
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- - - H-bonds 
Figure 3. Backbone Projection of Theonellapeptolide Ille (1) 
I 
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Table 1. Correlated I Hand 13C Spectral Data for Theonellapeptolide IIIe (1) 
I:f' 
Amino acid 
13gl1 H)b IH (mull,KHz))C HMScd (residue #) ROESye 
L-Vnl (I) I 174.4 (0) 
2 545 (1) 5.03 (m) 174.4, 170.4,32.1. 19.6, 17.6 3,19, 2.01, 0.98 
3 32.1 (I) 2.01 (m) 54.5, 19.6, 17.6 5.03,3.19,0.98,0.91 
4 17.6 (3) 0.91 19.6 5.03. 2.01 
5 19.6 (3) 0.98 17.6 5,03, 2.01, 
NH 7.45 (d. 9,3) 170.4 5.03. 3.86. 2.72. 0.98 
D-N-MeLeu (2) I 172.8 (0) 
2 56.4 (I) 5.28 (m) 174.4, 172.8, 38.0, 31.9, 25.9 9.0, 8.19. 2.05. 1,48 
3 38.0 (2) 2.05 (m) 56.4,25.9 1.48. 0.94 
1.48 (m) 25.9, 56.4 5.28 
4 25.9 (I) 1.48 (m) 24.1 3.19,2.05,0.94 
5 10.7 (3) 0.94 38.0. 25.9, 24.1 5.28, 3.19, 2.05. 1,48 
6 21.4 (3) 1.06 38.0,25.9 2.05 
NCH" 31.9 (3) 3.19(8) 174.4, 56.4 5.03. 2.01. 1.48.0.98, 0.94 
L-Thr (3) 1 169.2 (0) 
2 53.7 (I) 5.00 (m) 172.8, 169.2, 18.2 7.65, 2.75, 1.31 
3 71.2 (I) 5.47 (dd, 8.7, 6.3) 172.3, 53.7 7.65, 3.53, 2.75, 1.31 
4 18.2 (3) 1.31 (d, 6.3) 71.2, 53.7 5.47, 5.00 
NH 9.00 (d, 6) 5.47. 5.28. 5.00 
N-MepAla (4) I 172.9 (0) 
2 34.7 (2) 2.30 (m) 172.9, 45.4 
2.51 (m) 172.9. 45.4 8.19, 4.58, 2.30 
3 45.4 (2) 2.72 (m) 
4,58 (m) 34.7 2.72, 2.51. 2.30 
NCH, 35.0 (3) 2.75 (s) 169.2,45.4 7.65, 5.47, 5.00. 2.51 
D-Val(5) I 174.0 {OJ 
2 55.4 (I) 5,06 (m) 172,9,174.0,31.0,18.3 8.19,3.24,2.06,0,99,0.98 
3 31.0 (1) 2.06 (m) 55.4, 18.3 8.19. 5.06, 3.24. 0.98 
4 18.3 (3) 0.98 31.0 8.19, 5.06, 2.06 
5 19.7 (3) 0.99 31.0 
NH 8.19 (d, 8.7) 172.9,55.4 5.28. 5.06. 2.51. 2.06. 0.98 
L-N-Melle (6) 1 170,8 (0) 
2 61.4 (1) 5,22 (m) 174.0, 170.8, 33.1, 31.6, 16.1 7.65, 3.24,2.29, 1.13 
3 33.1 (1) 2,29 (m) 3.24, 1.43, 1.13 
4 16.1 (3) 1.13 (d, 6.3) 61.4, 33.1, 25.3 5.22, 2.29, 1.43 
5 25.3 (2) 1.43 (m) 2.29,0.96 
6 21.8 (3) 0.96 25.3 
NCH"l 31.6 (3) 3.24 (s) 174.0.61.4 5.06, 2.29. 2.06 
p-Ala (7) 1 172.5 (0) 
2 35.9 (2) 2.51 (m) 172.5 8.76, 5.47, 3.53, 1.31 
2.69 (m) 8.76, 3.53 
3 35.8 (2) 3.53 (m) 172.5, 170,8 7.65, 5.47,4.54, 2.51 
4.54 (m) 172.5, 170.8 3.53, 2,69 
NH 7.65 (d 5.4) 170.8 5.47. 5.22, 5.00, 4.54, 3.53, 3.24 
D-a/lo-I1e (8) 1 175.9 (0) 
2 53.6 (I) 5.38 (m) 175.9, 172.5, 38.8, 15.5 8.76, 3.33, 1.75, 1.55, 0.98 
3 38.8 (I) 1.75 (m) 53.6, 26.9, 15.5, 12.4 5.38, 3.33, 1.04, 0.98 
4 15.5 (3) 0.98 
5 26.9 (2) 1.22 (m) 53.6, 38,8, 15,5, 12.4 1.55 
1.55 (m) 53,6, 38.8, 12.4 5.58, 1.22, 1.04 
6 12.4 (3) 1.04 
NH 8,76 (d, 9.3) 172.5 5.38. 2.69, 2.5 r. 0.98 
L-N-MeIle (9) 1 172.7 (0) 
2 55.5 (1) 5.18 (m) 175.9, 172.7,33.8,31.7,29.7 3.33,2.69 
3 33.8 (I) 2.28 (m) 3.33, 0,78 
4 15.8 (3) 0.78 (d, 12) 55.5, 33.8, 25,6 2.69, 2.28, 1.42, 
5 25.6 (2) 1.42 (m) 15.8 0.82 
6 9.8 (3) 0.8~ ~~~' 9.6, 6.3) 33.8,25.6 2.28, 1.42 
NCH" 31.7 (3) 3.33 s 175,9,55,5 5.38, 5.18. 2,28, 1.75, 1.42 
L-N-MeAla (10) I 171.1 (0) 
2 57.5 (1) 5.20 (m) 172.7, 171.7,29.7, 15.0 2.69, 1.44 
3 15.0 (3) 1.44 (d, 6.9) 171.1,57.5 5.20,2.69 
NC!'t~ 29.7 (3) 2.69 (s) 172.7,57.5 5.20 5.18, 1.44. 0.78 
I.-Ala (I I) I 174.7 (0) 
2 52.3 (1) 4.51 em) 174.7, 17.9 1.29 
3 17.9 (3) 1.29 (d, 7.5) 174.7, 52.3 7.39,4,51 
NH 7.39 (d. 6.3) 171.1.52.3. 17.9 8.43 4.51. 2,69, 1.29 
D-Leu (12) I 174.9 (0) 
2 48.8 (I) 5.15 (m) 174.9,40.8 8.43, 3.30, 1.87 
3 40.8 (2) 1.34 (m) 1.87. 0.98 
1.87 (m) 174.9,48.8, 25.4 8.43, 5.15. 1.34 
4 25.4 (1) 1.87 (m) 21.3 1.04,0.98 
5 21.3 (3) 1.04 40.8, 25.4, 23,9 1.87 
6 23.9 (3) 0.98 40.8, 25.4, 21.3 
NH 8.43 (d, 8.4) 174.7,48.8 7.39, 5.15, 1.87, 1.34 
D-N-MeLeu (13) I 172.3 (0) 
2 63.0(1) 3.74 (m) 3.30, 2,05, 1.06 
3 38.3 (2) 2.05 (m) 172.3, 63.0, 25.6. 23Jt 22.5 3.74, 1.06, 0.98 
4 25.6(1) 1.66 (m) 38.3, 23.8 3.30 
5 23,8 (3) 0.98 38,3 
6 22.5 (3) 1.06 38.3, 25.6 3.74, 2.05, 1.66 
NCH1 38.8 (3) 3.30 (s) 174.9, 63.0 5.15, 3.74, 1.66 
MeOCH2CO I 170.4 (0) 
2 72.1 (2) 3.86 (8) 170.4, 59.0 7.45,3.16 
OCH3 59.0 (4) 3.16 (8) 72.1 3.86 
{/ Referenced to residual solvent C6D6 OH=7,27, oc=128.4. b l3C spectra recorded on a Varian XL300 at 
75 MHz. Number of attached H detennined by DEPT, C IH spectra recorded on a Varian UNITY 300 at 300 
MHz. d Jnxh = 8,3, 5.0 arrayed mixing times. e A mixing time of 0.155 was used, 
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